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Functions of two novel human lectins in glycoprotein clearance and  
cell migration in the immune system 
 
Potential biological roles for two novel human glycan-binding proteins have been 
investigated.   
In the first part of the work, analysis of the scavenger receptor C-type lectin 
(SRCL) leads to the proposal that the primary function of this receptor is to clear 
glycoproteins released from neutrophils.  The expression of SRCL was characterized by 
screening of cDNA libraries and by immunostaining of tissues.  These results confirm and 
extend earlier reports that SRCL is found in a range of tissues and is expressed by 
cultured umbilical vein endothelial cells, and demonstrated that SRCL is localized 
primarily in endothelial cells.  SRCL is thus positioned to interact with circulating 
glycoproteins and cells.  Potential ligands were isolated from neutrophils by affinity 
chromatography and shown by mass spectrometry to comprise lactoferrin and other 
soluble granule proteins.  The interaction between SRCL and lactoferrin was found to be 
dependent on fucose residues and analysis of lactoferrin N-glycans by mass spectrometry 
revealed multiple Lewisx epitopes borne on unsialylated triantennary glycans, consistent 
with selective binding of SRCL to the Lewisx trisaccharide.  Transfected cells expressing 
SRCL were shown to internalize fluorescein-labelled lactoferrin.  Taken together, these 
results provide support for the hypothesis that soluble glycoproteins in neutrophil 
secondary granules are tagged with the Lewisx epitope to direct their clearance by SRCL 
after release at sites of inflammation. 
Prolectin, a novel C-type lectin, was identified by screening of the human genome.  
Screening of cDNA libraries and immunostaining were used to ascertain that prolectin 
expression is restricted to dividing B cells in and around germinal centres of lymphoid 
tissues.  This expression pattern, together with the presence of motifs in the cytoplasmic 
tail of prolectin that may interact with intracellular signalling molecules, leads to the 
suggestion that prolectin may have a role in the migration of B cells during the adaptive 
immune response. 
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Chapter 1 
Introduction 
 
1.1 Glycan-binding proteins 
The majority of eukaryotic cell surface and secreted proteins are modified by the addition 
of complex carbohydrate moieties known as glycans.  The addition of these bulky, 
hydrophilic oligosaccharides can have a direct effect on protein properties or serve a 
structural role, but many well-characterized functions of glycans involve specific 
recognition of structures within the glycan by glycan-binding proteins, often referred to as 
lectins, which mediate varied biological outcomes in response to glycan binding (Lis and 
Sharon, 1993; Drickamer and Taylor, 1998).  Glycans and glycan-binding proteins appear 
to be present in all organisms, and the recognition of glycans by glycan-binding proteins is 
also an important part of host-pathogen interactions.   
Several different ways to link carbohydrates to proteins have been documented, 
some of which are very rare.  In considering the glycans recognized by glycan-binding 
proteins, two very common forms of glycosylation are the most significant: N-linked 
glycosylation and mucin-type O-linked glycosylation (Kornfeld and Kornfeld, 1985; Van 
den Steen et al., 1998).  The synthesis of these two glycan classes is a central function of 
the endoplasmic reticulum and Golgi apparatus, which house an array of proteins involved 
in glycan biosynthesis that represents up to 5% of the total proteome.  The glycosylation 
machinery includes glycosyltransferases, which form glycosidic bonds between 
monosaccharides, glycosidases, which hydrolyse such bonds, glycan-modifying enzymes 
such as sulfotransferases, and transporters for the nucleotide sugars used in 
biosynthesis.  Enzymes found early in the biosynthetic pathway tend to be common to all 
cells and add a universal glycan core to proteins, whereas enzymes found later in the 
pathway tend to be expressed by only a subset of cells and are responsible for generating 
the structural diversity of glycans which is central to protein-carbohydrate interactions.   
Many of the key features of glycan biosynthesis are exemplified by the synthesis of 
N-linked glycans (Figure 1.1) (Kornfeld and Kornfeld, 1985).  The initial stages of N-glycan 
synthesis are largely conserved in eukaryotes and begin with the transfer of a pre-formed 
14-sugar oligosaccharide from the lipid carrier dolichol onto a nascent polypeptide.  Most 
secreted and membrane proteins carry at least one N-glycan.  The precursor 
oligosaccharide is added to the side chain of the asparagine residue within an Asn-X-
Ser/Thr sequon, where X is any amino acid except proline, providing the polypeptide is 
accessible to the oligosaccharyltransferase enzyme complex of the endoplasmic reticulum 
lumen.  Some of the outer residues of this precursor are then trimmed off by processing 
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Figure 1.1: Overview of N-linked glycan biosynthesis
The common core structure is boxed.  The modifications shown are those common in 
mammalian cells.  Multiple types of modification - for example, addition of core fucose and 
addition of extra branches - can be made to the same glycan molecule.
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glycosidases.  Minimal trimming produces a high-mannose glycan as the final structure, 
while more extensive trimming allows glycosyltransferases to add new monosaccharides 
to the glycan and generate hybrid and complex-type glycans.  Although N-linked glycans 
are traditionally divided into these three classes, it is the complex-type glycans which are 
the most diverse and most important when considering the interaction of mature 
glycoproteins with extracellular glycan-binding proteins.   
Within the defined biosynthetic pathways there is room for considerable diversity in 
the structure of the final glycans.  All mature N-glycans retain a core with the structure 
Manα1–6(Manα1–3)Manβ1–4GlcNAcβ1–4GlcNAcβ1-Asn, but the later stages of 
processing, in which additional residues are added to the basic core, are often specific to 
certain groups of organisms, and within an organism are subject to variation according to 
cell type, developmental stage and disease states due to differences in expression of 
genes encoding glycan-processing enzymes.  In some cases signals within the substrate 
protein, and the rate of protein transit through the secretory pathway, also influence the 
final structure of a glycan at a particular glycosylation site (Miller et al., 2008).  Because 
the final structure of a glycan depends on the interplay between a number of different 
enzymes, and there is no template for glycan biosynthesis, it is common for different 
copies of a protein to be modified with different glycans.  It is not clear if this heterogeneity 
is in itself of functional importance, perhaps in minimizing the binding of viruses to glycans 
(Varki, 1993).  Heterogeneity need not affect interactions with glycan-binding proteins, 
because generally only a small structural feature, which may be found in a range of 
glycans, is recognized (Weis and Drickamer, 1996). 
The common modifications of N-linked glycans in mammals include addition of 
extra residues to the core, addition of extra branches to the basic biantennary glycan to 
create tri- and tetra-antennary structures, and extension of individual antennae with N-
acetyllactosamine units (Figure 1.1) (Kornfeld and Kornfeld, 1985).  The most important 
type of modification with respect to recognition of glycans by glycan-binding proteins is the 
addition of terminal elaborations or capping structures to antennae, because glycan-
binding proteins often recognize only the terminal residues of a glycan.  Examples of 
terminal structures and the biological outcomes of their recognition by glycan-binding 
proteins are shown in Figure 1.2 and are discussed in Sections 1.2, 1.3 and 1.4 below.   
Mucin-type O-linked glycosylation is also common in secreted and cell surface 
proteins, and is initiated by the addition of a GalNAc residue to the side chain of a serine 
or threonine residue (Van den Steen et al., 1998).  Different core structures are built on 
this starting residue, such as the core 2 glycan, GlcNAcβ1-6(Galβ1-3)GalNAcα1-Ser/Thr.  
Similar terminal elaborations to those found on N-glycans are often presented on a poly-
N-acetyllactosamine extension on the GlcNAc arm of a core 2 O-glycan.  O-glycans 
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Figure 1.2: Terminal glycan structures recognized by glycan-binding proteins
Parts of the glycan which are recognized by the glycan-binding protein are outlined in red.  
The examples of recognition of extracellular glycans are discussed in the text.
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therefore resemble the antennae of N-glycans, and glycan-binding proteins may interact 
with a range of different molecules through a shared carbohydrate recognition motif 
presented on different glycans. 
The capacity of protein-carbohydrate interactions to direct biological outcomes 
rests on the specific recognition of individual glycan structures by glycan-binding proteins, 
and represents the decoding of information encoded in the glycan structure by the cell of 
origin.  Testament to the utility of glycan-recognition events in biological systems is the 
fact that sugar-binding activity has evolved independently in multiple types of protein 
module, known as a carbohydrate-recognition domains (CRDs) (Sharon and Lis, 2004).  
Each class of CRD has a distinct evolutionary history, protein fold and mechanism of 
sugar binding, and is sometimes associated with recognition of a certain type of glycan, 
though related proteins may also recognize diverse glycan structures.  Novel classes of 
CRD continue to be defined as sugar-binding activity is discovered in additional protein 
families.  In mammals, the well-established families of glycan-binding proteins can be 
divided into those which are found intracellularly, in luminal compartments that are 
topologically equivalent to the extracellular space, and those that are found at the cell 
surface or secreted.  The intracellular lectins are those of the calnexin, M-type, L-type and 
P-type classes.  They have important roles in the trafficking of glycoproteins through the 
secretory pathway, such as in promoting protein folding, removing misfolded proteins, and 
targeting degradative enzymes to the lysosome (Munier-Lehmann et al., 1996; Helenius 
and Aebi, 2001).   
The extracellular CRDs are those of the C-type, R-type, siglec and galectin 
classes (though some galectins are also found in the cytosol and the nucleus) (Drickamer, 
1999; East and Isacke, 2002; Crocker et al., 2007; Liu and Rabinovich, 2010).  Lectins in 
these families may be involved in the recognition of endogenous ‘self’ glycoconjugates, or 
of pathogen-associated ‘non-self’ glycoconjugates.  The recognition of pathogen-
associated glycans is the central function of the collectin family of C-type lectins, which 
includes mannose-binding protein, a serum lectin that recognizes pathogen surfaces and 
initiates the lectin branch of the complement system (Turner and Hamvas, 2000).  In 
addition, mannose-specific C-type lectins on macrophages and dendritic cells, such as the 
mannose receptor, langerin and DC-SIGN, mediate phagocytosis of pathogens and may 
contribute to antigen presentation (Engering et al., 1997; Idoyaga et al., 2008; Singh et al., 
2009).  Glycan-binding proteins that recognize endogenous glycans can also be exploited 
by viruses presenting self-like glycans, as in the enhancement of HIV infection of T cells 
that results from virus binding to dendritic cell DC-SIGN (Geijtenbeek and van Kooyk, 
2003).  Similarly, the changes in glycosylation that accompany malignant transformation 
of cells can lead to novel interactions with glycan-binding proteins that promote tumour 
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growth and metastasis (Kannagi et al., 2004).  However, the primary function of many 
mammalian lectins is probably in the recognition of endogenous glycoconjugates.  Three 
key functions for the recognition of endogenous glycoconjugates by glycan-binding 
proteins in protein clearance, cell adhesion and cell signalling are discussed below. 
 
1.2 Glycan recognition in protein clearance 
A number of cell surface glycan-binding proteins can act as endocytic receptors.  
Endocytosis is employed to remove glycoproteins from the extracellular space, particularly 
from circulation, and thus regulate levels of these glycoproteins.  In antigen-presenting 
cells, endocytosis of glycoconjugates by glycan-binding proteins is also employed to 
supply peptide antigens for display on MHC Class II molecules.  Many details of receptor-
mediated endocytosis, which is employed by most cell types, have been elucidated by 
studies with the asialoglycoprotein receptor (Spiess, 1990) and are illustrated in Figure 
1.3.  The mechanism for intracellular ligand release by recycling endocytic C-type lectins 
involves protonation of certain amino acid side chains at low pH, which causes the 
dissociation of bound Ca2+ and overall destabilization of the binding site leading to 
dissociation of glycoprotein ligands (Loeb and Drickamer 1988, Wragg and Drickamer 
1999).   
The mannose receptor is the best-characterized example of a glycan-binding 
protein that mediates glycoprotein clearance (Figure 1.3).  The extracellular domain of the 
mannose receptor contains two types of CRD: a single R-type CRD at the membrane-
distal N-terminus, and eight C-type lectin-like domains, of which two or three are 
responsible for sugar binding (Taylor, 2001).  The two types of CRD are involved in the 
clearance of different types of glycoprotein.  The receptor is expressed by endothelial cells 
and Kupffer cells in the liver, and also by macrophages in other tissues (Allavena et al., 
2004).   
 One role of the mannose receptor is in regulating circulating levels of pituitary 
hormones (Figure 1.3).  An episodic rise and fall in circulating levels of the pituitary 
hormone lutropin (luteinizing hormone) is required to activate the hormone receptor and 
trigger ovulation (Rahman and Rao, 2009).  Clearance of lutrophin was known to be 
mediated by an endothelial receptor recognizing the unusual N-linked glycans of lutropin, 
which are terminated with 4-O-sulfated GalNAc residues instead of the more usual 
sialylated galactose residues (Fiete et al., 1991; Baenziger et al., 1992).  This 4-O-
sulfated GalNAc receptor was identified as the previously-characterized mannose 
receptor, and the novel binding activity localized to the R-type CRD using deletion 
mutants (Fiete et al., 1997; Fiete et al., 1998).  Lutropin and the related hormone 
thyrotropin, as well as some additional unrelated proteins, are selected for modification 
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Figure 1.3: Endocytic lectins in glycoprotein clearance
Facing page, top: Domain organization in endocytic lectins.  Facing page, bottom: Stages in 
receptor-mediated endocytosis.  The cytoplasmic tail sequence shown is that of the human 
asialoglycoprotein receptor major subunit.  This page: Tagging of pituitary glycoprotein 
hormones with 4-O-sulfated GalNAc for clearance by the mannose receptor.
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with the 4-O-sulfated GalNAc recognition tag by two GalNAc-transferases which 
recognize a sequence motif in the polypeptide (Miller et al., 2008).  The GalNAc residue is 
modified with sulfate primarily by the sulfotransferase GalNAc-4-ST1 (an additional 
sulfotransferase, GalNAc-4-ST2, is also present in pituitary), and mice lacking this 
enzyme exhibit raised levels of lutropin, resulting in accelerated sexual development in 
both males and females and increased fertility rate in females (Boregowda et al., 2005; Mi 
et al., 2008).  Both the mannose receptor and the 4-O-sulfated GalNAc modification of 
hormones are conserved in vertebrates, suggesting a conserved clearance mechanism 
for regulating hormone function (Manzella et al., 1995).   
  A second clearance function of the mannose receptor is associated with the C-
type CRDs of the receptor.  Wild-type mice rapidly clear BSA tagged with mannose or N-
acetylglucoamine from serum into the liver and spleen, whereas clearance of these 
neoglycoproteins is substantially delayed in mannose receptor-deficient mice and no 
accumulation in liver and spleen is observed (Lee et al., 2002).  Regarding physiological 
ligands cleared by the mannose receptor, proteins with high-mannose glycans, such as 
lysosomal enzymes, are not usually found outside the cell, but can be released when 
tissue is damaged, and are efficiently cleared from circulation in a carbohydrate-
dependent manner (Schlesinger et al., 1978).  In mannose receptor-deficient mice, eight 
out of nine degradative lysosomal enzymes investigated were elevated in serum (Lee et 
al., 2002).  Furthermore, in a proteomic screen for proteins found at raised levels in the 
receptor-deficient mouse, three species of collagen propeptide were identified and all 
carried high-mannose glycans.  These propeptides were elevated in serum following 
wound healing and clearance of exogenous collagen propeptide was delayed in receptor-
deficient mice.  These results suggest that the mannose receptor clears proteins released 
into serum as a result of injury or infection.  In the case of the lysosomal enzymes, 
clearance may be particularly important to avoid additional tissue damage.  Similarly, 
myeloperoxidase, which is found within the lysosome-like primary granules of neutrophils 
and is a key mechanism for killing of engulfed pathogens, is cleared by macrophages 
through interaction of high-mannose glycans with the mannose receptor (Shepherd and 
Hoidal, 1990), thus abrogating any damaging effects of the enzyme. 
The hepatic asialoglycoprotein receptor also mediates glycoprotein clearance.  
The receptor was first identified in studies of clearance of the serum protein 
ceruloplasmin, which normally has a long half-life in circulation, but is rapidly cleared 
when the terminal sialic acid residues are enzymatically removed, due to the exposure of 
sub-terminal galactose residues (Van Den Hamer et al., 1970).  The receptor is an 
oligomer of two closely-related type II transmembrane polypeptides, is found on 
hepatocytes, and recognizes glycans with terminal galactose or GalNAc residues 
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(McPhaul and Berg, 1987; Spiess, 1990).  Mice lacking either subunit of the receptor do 
not accumulate endogenous galactose-terminated glycans in serum, even though they fail 
to clear exogenous glycoproteins, indicating that desialylated serum glycoproteins are not 
the natural ligands for the receptor, as had been speculated  (Braun et al., 1996; Tozawa 
et al., 2001).  More recently, asialoglycoprotein receptor-deficient mice and direct binding 
studies were used to demonstrate that the receptor can clear neoglycoproteins bearing 
sialic acid in an α2,6-linkage to galactose or GalNAc, but not those bearing siaIic acid in 
the alternative α2,3-linkage (Park et al., 2003; Park et al., 2005).  Serum proteins carrying 
α2,6-linked sialic acid, such as haptoglobin, serum amyloid protein and carboxylesterase, 
are elevated in the serum of mice lacking the asialoglycoprotein receptor, suggesting a 
role for the receptor in regulating circulating levels of these proteins (Steirer et al., 2009). 
 
1.3 Glycan recognition in cell adhesion 
In the classical model of glycan recognition in cell adhesion, a transmembrane glycan-
binding protein on one cell engages a cell surface glycoprotein from another cell (Taylor 
and Drickamer, 2007).  The role of glycan-binding proteins in cell adhesion has been well 
characterized for the selectins, a family of three C-type lectins (Figure 1.4), and there is 
evidence that other glycan-binding proteins may also function in cell adhesion.  Studies of 
the selectins indicate that the flexible neck domains of the receptors and fast rates of 
ligand binding and release by the CRDs are crucial to bringing about the characteristic 
rolling of leukocytes on the surface of the vascular endothelium (van der Merwe, 1999), 
suggesting that protein-carbohydrate interactions may confer particular adhesive 
properties which provide an advantage over protein-protein interactions in certain 
situations.  Identification of the ligands for the selectins has revealed that adhesion 
involving protein-carbohydrate interactions can be achieved through recognition of rare 
glycan structures on a very small number of proteins, even though protein glycosylation 
provides the opportunity to add a common recognition tag to a wide range of proteins in a 
given cell. 
The selectins are involved in adhesion events between leukocytes and endothelial 
cells in two distinct contexts of leukocyte trafficking (Sperandio et al., 2009).  The first is 
the recruitment of leukocytes, primarily neutrophils, to inflamed tissues in order to provide 
a first line of innate immune defense against invading microorganisms.  Neutrophils are 
captured from bulk circulation and induced to roll slowly along the endothelium by the 
binding of endothelial E- and P-selectin to neutrophil cell surface glycoproteins.  
Neutrophil recruitment is regulated by the cell surface expression of these selectins: P-
selectin is stored in Weibel-Palade bodies of endothelial cells and mobilized to the cell 
surface by inflammatory signals, while transcription of E-selectin is induced by the same 
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signals (Smith, 1993).  L-selectin also plays a role in neutrophil recruitment through 
‘secondary tethering’ – leukocytes bound to the endothelium through P- and E-selectin 
carry L-selectin, which can bind L-selectin ligands on further leukocytes (Arbones et al., 
1994).  The second leukocyte trafficking function for the selectins is in the homing of 
lymphocytes to secondary lymphoid tissues, which is essential for the recirculation of 
lymphocytes that provides immune surveillance of the whole organism.  Lymphocyte 
homing involves the binding of lymphocyte cell surface L-selectin to ligands expressed 
exclusively on the specialized high endothelial venules of these tissues (Uchimura et al., 
2005).  In both of these examples of leukocyte trafficking, the selectins mediate an initial 
stage of leukocyte adhesion which enables a transition to firm, integrin-mediated adhesion 
and subsequent leukocyte extravasation.   
In vivo experiments using knockout mice have been instrumental in demonstrating 
the functions of the selectins and in identifying physiologically relevant selectin ligands 
(Jung and Ley, 1999).  Three categories of protein have been targeted by gene 
knockouts: the selectins themselves, the proteins which carry glycans recognized by the 
selectins, and the enzymes required for synthesis of these glycans.  For all three 
selectins, the sialyl-Lewisx glycan epitope is the essential determinant of binding, and 
mice deficient in the two leukocyte fucosyltransferases involved in sialyl-Lewisx synthesis, 
FUT7 and FUT4, exhibit complete loss of selectin-mediated leukocyte rolling (Homeister 
et al., 2001).  FUT7 is the enzyme primarily responsible for synthesis of selectin ligands 
and mice lacking only this fucosyltransferase have pronounced defects in neutrophil 
recruitment and lymphocyte homing (Maly et al., 1996). 
Gene knockouts of the selectins have shown that multiple members of the family 
contribute to leukocyte adhesion.  Leukocyte rolling on acutely inflamed endothelium is 
almost completely absent in P-selectin-deficient mice, whereas leukocyte trafficking in E-
selectin-deficient mice is not impaired, indicating that P-selectin is the receptor 
predominantly responsible for leukocyte rolling in inflammation (Mayadas et al., 1993; 
Labow et al., 1994).  However it is only in the absence of both of these selectins that mice 
become susceptible to spontaneous infections due to failure of leukocyte recruitment 
(Jung and Ley, 1999).  The major physiological ligand involved in leukocyte capture by 
both P- and E-selectin is PSGL-1 (Yang et al., 1999; Xia et al., 2002).  PSGL-1 carries the 
sialyl-Lewisx epitope on a single extended O-linked glycan and, in the case of P-selectin, 
sulfation of nearby tyrosine residues is important for binding (Liu et al., 1998; Moore, 
2003).  The additional E-selectin ligands ESL-1 and CD44 are required for E-selectin 
dependent transition to firm adhesion (Hidalgo et al., 2007).  Other proteins have been 
identified which bind to the selectins in vitro, but only these three have been demonstrated 
to contribute to selectin-mediated leukocyte adhesion in vivo. 
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Mice deficient in L-selectin show impaired neutrophil recruitment and also 
complete loss of lymphocyte binding to high endothelial venules, with a major defect in 
lymphocyte homing to secondary lymphoid tissues (Arbones et al., 1994).  PSGL-1 is also 
the principal, and possibly only, ligand for L-selectin in the context of circulating 
leukocytes binding to adherent leukocytes at sites of inflammation (Sperandio et al., 
2003).  Different ligands for L-selectin are present on high endothelial venules.  These 
ligands consist mainly of peripheral node addressins – a protein group which includes 
GlyCAM-1 and CD34 among others, and is defined by recognition by the function-blocking 
monoclonal antibody MECA-79 (Streeter et al., 1988).  Knockout of individual addressins 
such as CD34 does not abrogate binding to high endothelial venules (Suzuki et al., 1996).  
However, all the addressins feature sulfation of sialyl-Lewisx groups as an important 
determinant of L-selectin binding, and knockout of the two relevant sulfotransferases 
affects all the addressins and causes dramatically reduced homing of lymphocytes and 
adhesion of lymphocytes to high endothelial venules (Uchimura et al., 2005). 
Roles in cell adhesion have also been proposed for DC-SIGN, a human cell 
surface C-type lectin of immature dendritic cells that recognizes high-mannose glycans 
and glycans containing terminal fucose, such as the Lewis epitopes (Guo et al., 2004).  
DC-SIGN was originally identified as the receptor responsible for an integrin-independent, 
Ca2+-dependent binding of dendritic cells to ICAM-3 (Geijtenbeek et al., 2000b).  
Antibodies raised against dendritic cells that could block this interaction were found to be 
specific for a single protein, which has subsequently been referred to as DC-SIGN 
(dendritic cell-specific ICAM-3-grabbing non-integrin).  Cells transfected with DC-SIGN 
bound ICAM-3, and binding was inhibited by mannose and mannan, indicating a 
carbohydrate-mediated interaction.  Because ICAM-3 is expressed at high levels on T 
cells, the binding of DC-SIGN to ICAM-3 was proposed to mediate adhesion of dendritic 
cells and T cells, and thus promote the screening of dendritic cells in secondary lymphoid 
tissues for antigens presented on MHC molecules recognized by T cell receptors 
(Geijtenbeek et al., 2000b).  However the adhesion assay used in these experiments 
employed recombinant ICAM-3 and it has since been found that DC-SIGN does not 
recognize native ICAM-3 isolated from T cells (Bogoevska et al., 2007).  This highlights 
the importance of considering cell type-specific glycosylation when investigating 
interactions of glycan-binding proteins. 
Unlike ICAM-3 from T cells, ICAM-3 isolated from neutrophils is a ligand for DC-
SIGN (Bogoevska et al., 2007).  Along with two other cell surface proteins, CEACAM-1 
and integrin αMβ2 (Mac-1), ICAM-3 carries glycans with the Lewisx structure in neutrophils, 
but not in other leukocytes, due to neutrophil-specific expression of the α1,3-
fucosyltransferase FUT9, and is recognized by DC-SIGN in a Lewisx-dependent manner 
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(van Gisbergen et al., 2005b; Bogoevska et al., 2006; Bogoevska et al., 2007).  It has 
been suggested that interaction of these neutrophil surface glycoproteins with DC-SIGN 
may form a synapse that allows the neutrophil to influence dendritic cell maturation and 
the subsequent T cell response, perhaps through secretion of TNFα (van Gisbergen et al., 
2005a).  However the molecular consequences of DC-SIGN-mediated adhesion have not 
been delineated and the significance of neutrophil-dendritic cell interactions in vivo is not 
well established. 
DC-SIGN may also function as an adhesion receptor in the migration of circulating 
dendritic cell precursors across endothelia and into peripheral tissues.  DC-SIGN was 
found to mediate migration of transfected cells across a layer of cultured endothelial cells 
(Geijtenbeek et al., 2000a).  Subsequently, a small number of protein ligands for DC-SIGN 
were detected in human umbilical vein endothelial cells, and the major protein was 
identified as ICAM-2 (Garcia-Vallejo et al., 2008).  DC-SIGN only bound ICAM-2 when the 
molecule carried glycans recognized by DC-SIGN, indicating a carbohydrate-dependent 
interaction, and examination of glycosylation pathways in the endothelial cells indicated 
that the relevant glycan structure on native endothelial ICAM-2 was Lewisy.  Knock-down 
of the α1,2-fucosyltransferase FUT1 required for Lewisy synthesis in endothelial cells 
resulted in decreased adhesion and increased rolling velocity of dendritic cell precursors. 
(Garcia-Vallejo et al., 2008)  Thus DC-SIGN, like the selectins, may play a specific role in 
leukocyte trafficking.  However, investigation of the importance of DC-SIGN-mediated 
adhesion events in vivo is complicated by the fact that there are seven orthologous 
proteins in mouse (Powlesland et al., 2006).  As a result, experiments with knockout mice, 
which have provided key evidence for the roles of the selectins in cell adhesion, cannot be 
employed in the study of DC-SIGN.  
Additional glycan-binding proteins that may have roles in cell adhesion include 
sialoadhesin, a member of the siglec family of sialic acid-binding lectins, which is found on 
macrophages and is well suited to mediate cell adhesion because of its extended neck 
and the requirement for receptor and ligand clustering in order to achieve high avidity 
interaction (Crocker and Redelinghuys, 2008).  CD43 and PSGL-1 have been identified as 
potential sialoadhesin ligands on T cells, and sialoadhesin-deficient mice exhibit 
alterations in T cell immune responses, but a clear physiological role for sialoadhesin-
mediated adhesion remains to be established (van den Berg et al., 2001; Oetke et al., 
2006).   
 
1.4 Glycan recognition in cell signalling 
Transmembrane glycan-binding receptors may act in a similar way to receptors for 
hormones and growth factors in initiating intracellular signalling in response to binding an 
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extracellular ligand.  Glycan-binding proteins may also modulate signalling in cells 
expressing glycoprotein ligands, particularly in the case of soluble glycan-binding proteins 
such as galectin-1, which can induce apoptosis in T cells by cross-linking of CD45 
molecules on the T cell surface (Earl et al., 2010).  In addition, ligand binding by glycan-
binding proteins may be subject to regulation in reponse to signals arising from elsewhere 
in the cell, for example through alteration of subcellular localization, through receptor 
oligomerization or clustering, and through changes in the association of the receptor with 
the cytoskeleton. 
Two common routes taken by glycan-binding proteins to initiate signalling are 
through immunoreceptor tyrosine-containing inhibitory motifs (ITIMs) and activating motifs 
(ITAMs) (Figure 1.5).  When receptors which have ITIMs in their cytoplasmic tails are 
activated by ligand binding, they attract phosphorylation by Src family tyrosine kinases to 
create docking sites for SH2 domain-containing proteins such as the protein tyrosine 
phosphatases SHP-1 and SHP-2, which exert an inhibitory effect on other signalling 
molecules (Ravetch and Lanier, 2000).  Unlike ITIMs, ITAMs are not contained in the 
cytoplasmic tails of glycan-binding receptors, but are present in the cytoplasmic regions of 
transmembrane adaptor molecules such as DAP-12 and FcRγ, which associate with 
receptors that contain a positively-charged residue in the transmembrane domain 
(Hamerman et al., 2009).  Ligation of an associated receptor triggers phosphorylation of 
ITAMs by Src family tyrosine kinases, leading to the recruitment of Syk family tyrosine 
kinases that initiate downstream signalling, which often stimulates cellular responses 
(Hamerman et al., 2009). 
The siglec family glycan-binding protein CD22 is one of a range of co-receptors 
that regulate signalling by the B cell receptor and determine whether it is appropriate for 
the B cell to be activated in reponse to B cell receptor ligation based on signals from the 
local environment (Grimaldi et al., 2005).  The intracellular region of CD22 contains six 
tyrosine residues, three of which occur within ITIMs, and the receptor has an inhibitory 
effect on B cell receptor signalling.  CD22 molecules that are associated with the B cell 
receptor are phosphorylated by the Src family kinase Lyn upon B cell receptor cross-
linking (Smith et al., 1998a).  Phosphorylation attracts SHP-1, which acts on downstream 
elements of the B cell receptor signalling pathway to inhibit signalling (Doody et al., 1995).  
Mice lacking CD22 show increased responses to B cell receptor stimulation in the form of 
elevated Ca2+ mobilization  (O'Keefe et al., 1996). 
CD22 recognizes glycoproteins containing α2,6-linked sialic acid through the most 
distal of the seven immunoglobulin domains which constitute the receptor extracellular 
domain (Powell et al., 1993).  Because α2,6-linked sialic acid is abundant on mammalian 
glycans, including on the surface of B cells, CD22 is thought to bind to sialic acid-
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containing glycoproteins in cis.  Accordingly, CD22 on B cells is generally unable to bind 
exogenous ligands, but may become ‘unmasked’ upon cell activation or in certain cell 
subsets (Razi and Varki, 1998).  Interactions of CD22 with other B cell proteins have thus 
far been found to involve only protein-protein contacts, but cells expressing mutant forms 
of CD22 without the CRD are hyperresponsive to B cell receptor stimulation, suggesting a 
role for carbohydrate binding in the inhibitory function of CD22 (Jin et al., 2002).   
The CD33-related siglecs are receptors with ITIMs that have inhibitory effects on 
leukocyte function (Cao and Crocker, 2010).  It was postulated that recognition of 
endogenous sialic acid by these receptors suppresses unwanted immune cell responses 
(Crocker and Varki, 2001).  Subsequently, additional CD33-related siglecs were 
discovered which lack ITIMs and instead associate with the ITAM-containing adaptor 
DAP-12 (Angata et al., 2006; Blasius et al., 2006; Angata et al., 2007).  Because some of 
these siglecs are very similar to other ITIM-containing siglecs, there may be pairs of 
siglecs with activating and inhibitory functions, which could prevent sialic acid-containing 
pathogens from targeting inhibitory receptors to evade immune responses (Crocker and 
Redelinghuys, 2008).  Endogenous glycoprotein ligands for the CD33-related siglecs 
remain to be identified, but recent work suggests that binding of the heavily sialylated 
protein CD24 to siglec-10 does indeed suppress immune responses during tissue damage 
in the absence of infection (Chen et al., 2009). 
There is growing evidence for the involvement of C-type lectins in signalling, but 
the role of glycan binding in initiating signalling through these receptors remains unclear.  
Signalling capability has been described for several members of the large NK cell receptor 
family, but these receptors completely lack the residues involved in canonical sugar 
binding by C-type lectins (Ryan and Seaman, 1997).  For proteins with well-characterized 
sugar-binding activity, signalling roles have proved harder to identify and investigation of 
the function of these receptors is often complicated by the differences between the genes 
present in human and mouse.  Signalling in response to endogenous ligands rather than 
pathogen-associated glycans also remains largely unexplored. 
The human type II receptor family C-type lectins DCIR, dectin-2, mincle, BDCA-2 
and MCL are encoded by a gene cluster near the NK cell receptors and were discovered 
primarily through screening of DNA databases for novel C-type lectins (Graham and 
Brown, 2009).  The presence of residues known to mediate sugar binding in a range of 
other C-type lectins in the CRDs of these receptors indicates that they may bind mannose 
and related sugars.  They are found primarily on antigen-presenting cells, and have been 
investigated for roles in initiating signalling in antigen-presenting cells in response to 
recognition of pathogen-associated carbohydrates (Kerrigan and Brown, 2010).   
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Mincle associates with the ITAM-containing adaptor molecule FcRγ to trigger a 
typical FcRγ signalling pathway involving a SYK-CARD9-BCL10-MALT1 complex, which 
is able to induce gene transcription (Yamasaki et al., 2008).  This signalling pathway was 
uncovered following ligation of mincle with the nuclear protein SAP130, which may serve 
to signal the presence of dead cells (Yamasaki et al., 2008), but there is also evidence for 
the interaction of mincle with glycan ligands.  Mincle mediates macrophage activation in 
response to binding the pathogenic fungus Malassezia, and this response is abolished if 
the sugar-binding residues of mincle are mutated (Yamasaki et al., 2009).  The ligand for 
mincle appears to include α-linked mannose residues.  Mincle also signals in response to 
binding the yeast Candida albicans (Wells et al., 2008) but it has not been established if 
recognition of Candida is carbohydrate dependent.  Mincle has been reported to be the 
receptor for trehalose-6-6’-dimycolate, a cell wall glycolipid of Mycobacterium tuberculosis 
with long-established immunostimulatory properties (Ishikawa et al., 2009).  As a 
disaccharide of glucose, trehalose might be bound at the sugar-binding site of mincle, but 
trehalose alone did not activate mincle-expressing cells and also did not block activation 
by trehalose-6-6’-dimycolate, indicating that sugar binding is at least not sufficient to 
mediate glycolipid recognition by mincle, consistent with the fact that mincle did not 
recognize any mannose-containing mycobacterial lipids. 
Dectin-2 binds to mannose and recognizes various pathogens including Candida 
albicans and Mycobacterium tuberculosis (McGreal et al., 2006; Sato et al., 2006).  
Dectin-2 has recently been found to signal through the same pathway as mincle and this 
signalling appears to be important for influencing T cell differentiation in response to fungi 
(Robinson et al., 2009; Bi et al., 2010; Saijo et al., 2010).  Thus both mincle and dectin-2 
may initiate signalling in reponse to glycan recognition, although the examples that have 
been identified are quite specialized rather than indicating a general role in innate 
immunity to broad classes of pathogens. 
Where the other receptors in this gene cluster have very short cytoplasmic tails, 
DCIR has a longer cytoplasmic region that includes an ITIM (Bates et al., 1999; Huang et 
al., 2001).  Ligation of DCIR with antibodies causes recruitment of SHP-1 and SHP-2, 
which initiates an unidentified signalling pathway leading to suppression of Toll-like 
receptor-induced cytokine production (Meyer-Wentrup et al., 2008; Meyer-Wentrup et al., 
2009).  Ligation of BDCA-2 with antibodies also suppresses Toll-like receptor-induced 
gene expression, but through a different signalling pathway involving the adaptor FcRγ, 
which in this case appears to trigger a similar signalling cascade to that induced by B cell 
receptor ligation (Fernandes et al., 2000; Arce et al., 2001; Cao et al., 2007; Jahn et al., 
2010).  Glycan-binding activity has not been confirmed in DCIR or BDCA-2 and the 
natural ligands of the receptors are unknown.   
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Signalling capability in the dendritic cell receptor DC-SIGN has been sought 
because this receptor recognizes a range of mannose-containing pathogens which have 
been suggested to modulate dendritic cell function, but the mechanisms of signal 
transduction remain highly speculative.  A study using large-scale gene expression 
profiling and tyrosine-phosphorylated proteome analysis to characterize DC-SIGN-
mediated signalling in repsonse to receptor ligation with an antibody or with HIV found 
changes in gene expression, involvement of the tyrosine residue in the cytoplasmic tail of 
DC-SIGN, and involvement of the guanine nucleotide exchange factor LARG together with 
the Rho small GTPases (Hodges et al., 2007).  The interaction of DC-SIGN with 
mannosylated lipoarabinomannan (ManLAM) from pathogenic mycobacteria appears to 
prevent dendritic cell maturation, which may promote pathogen survival (Geijtenbeek et 
al., 2003).  The signalling pathway downstream from DC-SIGN after activation by 
ManLAM centres on the activation of the serine/threonine kinase Raf1, since inhibition or 
knock-down of Raf-1 inhibited immunosuppressive IL-10 induction by DC-SIGN (Gringhuis 
et al., 2007).  DC-SIGN signalling induced phosphorylation and acetylation of the 
transcription factor NF-κB, which enables DC-SIGN to modulate Toll-like receptor 
signalling as the two pathways converge on this transcription factor.  It is not clear how 
DC-SIGN activation leads to Raf1 activation, because the tyrosine-containing motif of the 
cytoplasmic tail was not required and no adaptor proteins were identified.  DC-SIGN has 
been reported to associate with the tyrosine kinases Lyn and Syk, pointing to a role for 
these kinases in signal transduction (Caparros et al., 2006).  Ligation with antibodies 
leads to activation of ERK1/2, whereas activation with ManLAM does not, pointing to 
alternative parallel pathways and the potential for glycans to induce signalling distinct from 
simple receptor cross-linking (Caparros et al., 2006; Gringhuis et al., 2007).  Recent 
findings indicate that DC-SIGN forms a complex with the scaffold proteins LSP1, KSR1 
and CNK as well as Raf-1, and that binding of different pathogens can either bring about 
activation of Raf-1 by recruitment of LARG and RhoA, or trigger jettisoning of the complex, 
with different downstream effects (Gringhuis et al., 2009).   
 
1.5 Mechanism of glycan binding by C-type lectins 
Many of the general principles that have been established regarding the mechanism of 
sugar recognition by glycan-binding proteins have been garnered through studies of C-
type lectins, which are the largest group of glycan-binding proteins in mammals 
(Drickamer, 1996; Weis and Drickamer, 1996).  As is the case for most glycan-binding 
proteins, the sugar-binding site in C-type lectins is a shallow indentation in the protein 
surface, which usually accommodates fewer than three monosaccharide residues, 
typically from the extremity of a glycan rather than the core.  The interactions between a 
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glycan-binding protein and bound glycan usually consist of hydrogen bonds to the sugar 
hydroxyl groups, and van der Waals packing of aromatic side chains against the non-polar 
face of monosaccharide rings, both of which are important in C-type lectins (Weis and 
Drickamer, 1996).  Additional interactions between protein and sugar, sometimes 
involving water molecules and divalent cations, have generally been found to enhance 
both the selectivity and affinity of protein-carbohydrate interactions, and in the case of C-
type lectins, a Ca2+ ion is a critical part of the binding site, forming a ternary complex with 
the sugar (Weis and Drickamer, 1996).   
The C-type CRD is a small, compact domain of 110-130 residues with a unique 
fold containing a three-stranded antiparallel β-sheet and two α-helices, and two highly-
conserved disulfide bonds (Drickamer, 1999).  The polypeptide chain enters and leaves 
the domain at the same place.  The sugar-binding site is located at the opposite end of the 
domain to the N- and C-termini, within long loop regions that are stabilized by Ca2+ 
binding.  Sugar binding is mediated by a small number of residues within the binding site 
and involves the 3- and 4-hydroxyl groups of a monosaccharide in complex with a Ca2+ 
ion (Figure 1.6) (Weis et al., 1992; Kolatkar and Weis, 1996).  The tendency for C-type 
CRDs to recognize terminal residues of glycans arises from the requirement that a bound 
monosaccharide residue have free 3- and 4-hydroxyl groups.  Structural and mutagenesis 
studies have revealed that C-type CRDs fall into two general categories of ligand 
specificity, which notably can be distinguished at the primary structure level: CRDs with 
the sequence motif Glu-Pro-Asn (EPN) bind mannose, whereas CRDs in which this motif 
is replaced with Gln-Pro-Asp (QPD) bind galactose (Iobst and Drickamer, 1994; Kolatkar 
and Weis, 1996).  The pertinent difference between mannose and galactose lies in the 
stereochemistry of the 4-hydroxyl group.  While, in the monosaccharides found in 
mammalian glycans, the 3-hydroxyl group is always equatorial, the 4-hydroxyl group is 
equatorial in monosaccharides such as mannose, glucose and GlcNAc, which are 
therefore bound by CRDs with an EPN motif, but axial in galactose and GalNAc, which 
are bound by CRDs with the QPD motif.  Fucose, the only L-sugar found in mammalian 
glycans, has an axial 4-hydroxyl group but is bound by mannose-type CRDs by tipping the 
sugar ring (Somers et al., 2000). 
When bound by a C-type CRD, the 3- and 4-hydroxyl groups of a monosaccharide 
each accept a hydrogen bond from an amide side chain and donate a hydrogen bond to 
an acidic side chain, thus four residues contact the sugar.  Switching the stereochemistry 
of the 4-hydroxyl group alters the relative spatial orientation of the two sugar hydroxyl 
groups involved in binding, and therefore requires a complementary change in the 
positions of some interacting protein groups in order to restore optimum hydrogen bonding 
(Weis et al., 1992; Kolatkar and Weis, 1996).  The switch in the protein sequence motif 
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from EPN (acid-proline-amide) to QPD (amide-proline-acid) alters the positions of two of 
the four key hydrogen bond donors and acceptors and is sufficient to switch the sugar-
binding specificity.  The residues in this motif interact with the equatorial 3-hydroxyl group 
in mannose but the axial 4-hydroxyl group in galactose, such that the orientation of the 
sugars in their respective binding sites is quite different – the sugar ring of galactose is 
rotated around 90° relative to the sugar ring of mannose.  The protein-carbohydrate 
interaction is knitted together by the Ca2+ ion, which receives a total of eight coordination 
ligands: the sugar 3- and 4-hydroxyl groups, the four protein side chains making hydrogen 
bonds to the sugar, and two ligands from an aspartate residue at the base of the binding 
site (Weis et al., 1992).  Galactose-binding CRDs contain additional elements to create 
selectivity for galactose over mannose: typically an aromatic side chain such as 
tryptophan packs against the apolar B face of the galactose ring to increase the 
galactose-binding affinity, while a glycine-rich loop holds the tryptophan residue in place 
and thus blocks mannose from entering the binding site (Kolatkar and Weis, 1996; Weis 
and Drickamer, 1996). 
As is the case with most glycan-binding proteins, the limited number of contacts 
between a C-type CRD and a bound sugar produces only a low-affinity interaction, with KD 
values in the high micromolar to low millimolar range.  Multivalency is frequently employed 
to boost affinity to the level required for biologically significant interaction, and may be 
achieved by receptor oligomerization, by the presence of multiple binding sites in one 
polypeptide, or by clustering of receptors on a cell surface (Weis and Drickamer, 1996).  
Polypeptide oligomerization can also contribute to the selectivity of binding, as has been 
described for mannose-binding protein.  The CRD of mannose-binding protein interacts 
only with terminal monosaccharides and binds indiscriminately to all sugars with 
mannose-like stereochemistry, but the fixed geometry of CRDs created by oligomerization 
is sufficient to enable the protein to distinguish pathogen-associated glycans, which 
feature arrays of similar ligands, from self glycans (Weis and Drickamer, 1994).   
The presence of extended binding sites, which make contacts with additional parts 
of the glycan or with the protein portion of a glycoprotein ligand, is important both for 
enhancing binding affinity and for generating selectivity for more complex glycan 
structures.  The primary binding interaction in a C-type CRD involves only a single residue 
of a glycan and is thus of low selectivity when the diversity of glycan structures presented 
on glycoconjugates is considered.  To enable more complex endogenous glycan 
structures to act as recognition signals that initiate biological events, a CRD must be able 
to recognize additional features of the glycan.  In the case of E-selectin and P-selectin, 
specificity for the sialyl-Lewisx structure is created by an extended binding site that offers 
hydrogen bonding to the galactose and sialic acid residues while the principal interactions 
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are made with the fucose residue (Revelle et al., 1996; Somers et al., 2000).  In addition, 
a positively-charged area adjacent to the sugar-binding site in the CRD of P-selectin 
interacts with sulfated tyrosine residues in the vicinity of the glycan attachment site in the 
glycoprotein ligand PSGL-1 (Somers et al., 2000). 
 
1.6 Identification of novel C-type lectins by screening of DNA databases 
Like all classes of carbohydrate-recognition domain, C-type CRDs have a characteristic 
primary structure that enables novel members of the family to be identified from DNA 
sequence data, for example in databases of expressed sequence tags or genomic 
sequences (Drickamer and Taylor, 2003).  There are also numerous and widespread 
examples of domains which are homologous to the C-type CRD and adopt the same fold, 
but lack the critical sugar-binding residues (Drickamer, 1999).  The term C-type lectin-like 
domain (CTLD) is applied to all domains with the C-type lectin fold, both with and without 
sugar-binding activity.   The C-type lectin fold is found in all metazoa, as well as in some 
bacteria and viruses, and has remarkable plasticity of sequence which has allowed it to be 
adapted for many functions (Zelensky and Gready, 2005).  Massive diversification has 
created CTLDs which interact with non-carbohydrate ligands including proteins, lipids and 
inorganic molecules.  However the existence of carbohydrate-binding CTLDs in all the 
phyla which possess CTLD-containing proteins, together with the conservation of the 
sugar-binding mechanism over large evolutionary distances, suggests that carbohydrate 
binding is the ancestral function of the domain . 
Superficially, CTLDs can often be recognized by the presence of highly-conserved 
cysteine residues which form characteristic disulfide bonds, and of hydrophobic residues 
which form the domain core (Drickamer, 1999).  However, when screening translated 
nucleotide sequences for CTLDs, the most advanced profile recognition programs employ 
position weight matrices, which hold likelihood scores for each amino acid at each position 
in a particular domain, derived from the sequences of a large number of known examples 
of that domain (Pearson and Sierk, 2005).  In genuine CTLDs, certain amino acid 
positions are almost invariant while others, such as those in loop regions, are not rigidly 
defined, and this information is captured in the position weight matrix.  The profile 
recognition program compares the identity of the amino acid at each position of a test 
sequence against the position weight matrix, as well as factoring in gaps in the sequence, 
and determines whether the test sequence matches the CTLD profile based on a 
threshold score.  The detection of CTLDs by this statistical method is highly sensitive, and 
the specificity has also been improved by reducing false positives from cysteine-rich 
sequences (Someya et al., 2010).  While some CTLD-containing proteins have been 
known for some time – often due to their abundance, prominent sugar-binding activity, or 
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involvement in disease – many additional examples have been uncovered using this 
bioinformatics approach.   
Examination of current annotated genomes in the Ensembl database reveals that 
CTLD-containing proteins generally represent a large family in metazoan genomes - over 
1% of the total genes in Caenorhabditis elegans, and around 0.4% in vertebrates.  The 
CTLD family has expanded independently in different evolutionary lineages, such that 
there is little orthology between the CTLD-containing proteins in the lineages represented 
by Caenorhabditis elegans, Drosophila melanogaster and vertebrates (Dodd and 
Drickamer, 2001).  Relatively few changes have occurred within the vertebrate lineage, 
such that most CTLD-containing proteins in mammals have orthologs in non-mammalian 
vertebrates.  However some sub-groups – particularly those with sugar-binding activity – 
are particularly rapidly evolving, resulting in important differences in the repertoire of 
CTLD-containing proteins even between closely-related species such as human and 
mouse. 
The human genome contains more that 80 confirmed CTLD-containing proteins.  
Following recent refinements to the genome sequence and annotation, it is likely that the 
complete set of genes encoding CTLD-containing proteins is now known, though it has 
not yet been verified that all of the predicted genes produce a protein product.  The CTLD-
containing proteins of humans and other mammals can readily be classified into 17 
distinct families (Figure 1.7) (Drickamer and Fadden, 2002; Zelensky and Gready, 2005).  
The same groupings are produced whether division is based on the organization of 
structural elements within the polypeptide chain or on the amino acid sequence of the 
CTLD, and the groupings reflect evolutionary and functional commonalities between the 
members of each family.  CTLDs in a particular family are also characterized by the 
number and positions of disulfide bonds and particularly of exon/intron boundaries 
(Bezouska et al., 1991).  The mammalian protein set illustrates the general finding that 
CTLD-containing proteins exhibit remarkable diversity, ranging from simple single-domain 
soluble proteins to large multi-pass transmembrane proteins containing many types of 
domain, but always with the CTLDs located in the extracellular compartment. 
The existence of sugar-binding activity in a C-type CRD can be postulated based 
on the presence in the primary structure of the five residues which form the sugar/Ca2+ 
binding site, and furthermore the specificity for sugars with mannose-like or galactose-like 
stereochemistry can be deduced based on the presence of the EPN or QPD sequence 
motifs (Drickamer and Fadden, 2002). The evolutionary classification of C-type lectins 
based on sequence analysis has revealed that it is not possible to draw a phylogenetic 
tree which segregates CRDs with EPN motifs from those with QPD motifs, indicating that 
the mechanism to switch between mannose and galactose specificities has been 
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rediscovered on multiple occasions during evolution.  This fact is illustrated particularly 
well by the mammalian C-type lectins langerin and the Kupffer cell receptor.  These type II 
receptors are encoded by tandem genes which arose from a gene duplication event, but 
langerin has a mannose-binding EPN motif whereas the Kupffer cell receptor has a typical 
galactose-binding site with a QPD motif followed by an extra loop containing a tryptophan 
residue.  In contrast to the simplicity and universality of the EPN/QPD mechanism for 
creating the general ligand specificity of the CRD, the residues which fine-tune the glycan 
specificity may be unique to individual proteins, and despite additional structural and 
mutagenesis data on C-type CRDs, it has not proved possible to make more detailed 
predictions about ligand specificity based on primary structure alone.   
In this work, the functions of two novel human C-type lectins discovered by 
screening of DNA databases are investigated.  The scavenger receptor C-type lectin 
(SRCL) was discovered by DNA database screening, and initial characterization of the 
protein showed that it is an endocytic receptor with specificity for the Lewisx trisaccharide 
(Ohtani et al., 2001; Coombs et al., 2005).  The novel CTLD-containing protein prolectin 
was recently identified by genome screening, and represents one of the final human 
CTLD-containing proteins to be described (Graham et al., 2009).  The CTLD of prolectin 
has sugar-binding activity, while the intracellular domain of the molecule is rich in motifs 
likely to interact with signalling molecules. 
 
1.7 The scavenger receptor C-type lectin 
SRCL is a trimeric type II transmembrane protein in which a cluster of C-type CRDs is 
projected from the membrane by a long neck consisting of a section of collagen-like triple 
helix and a section of α-helical coiled-coil (Figure 1.8) (Nakamura et al., 2001a; Ohtani et 
al., 2001).  This unique arrangement of domains represents a natural chimera: the 
majority of the protein, including the transmembrane domain and the elongated neck 
region, is homologous to the class A scavenger receptor SCARA3, while the C-type CRD 
is related to CRDs from the type II receptor family of CTLD-containing proteins.  The 
cloning of SRCL was reported independently by two groups (Nakamura et al., 2001a; 
Ohtani et al., 2001) and the receptor is also known as Collectin Placenta-1 (CL-P1), but 
the designation SRCL is used here since it more accurately reflects the organization and 
evolution of the protein. 
The presence of homologous regions in SRCL and SCARA3 is the result of a gene 
duplication event which occurred in a common ancestor of vertebrates.  The homologous 
region consists of four exons, each of which encodes a discrete element of the protein 
structure (Figure 1.9).  Additional exons encode the unique N- and C-terminal regions of 
each protein, including the C-type CRD of SRCL.  Even though the protein sequence of 
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diagram of the evolution of the SCARA3 and SRCL genes.  Two SRCL genes are present in 
the genomes of the fish species fugu, tetraodon, medaka and stickleback.  Only one of these 
genes (SRCL2) appears to remain in the zebrafish genome.
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the neck region is constrained by the need to maintain helical repeats, there is only 34% 
amino acid identity between the homologous regions of human SRCL and SCARA3, 
reflecting the long time period since gene duplication (vertebrates arose ~500 million 
years ago (Holland and Chen, 2001)).  Genome sequencing projects have revealed that 
both SCARA3 and SRCL are conserved across vertebrate phyla, and that the SRCL gene 
was affected by the genome duplication event which occurred ~350 million years ago in 
the fish lineage (Meyer and Van de Peer, 2005).  There is around 50% sequence identity 
between human and fish SRCL proteins.  The duplication that created SRCL extended to 
the adjacent gene, clusterin, creating a clusterin homolog, clusterin-like 1, adjacent to 
SRCL.  Together with SRCL, clusterin-like 1 was duplicated again in the fish lineage.  One 
of the two resulting gene pairs has been lost in zebrafish, as has been noted for other 
duplicated genes in this organism (Alsop and Vijayan, 2009). 
The majority of the SRCL polypeptide therefore resembles the class A scavenger 
receptor SCARA3.  Scavenger receptors, which are characterized by their ability to bind 
low-density lipoprotein, are divided into several unrelated structural classes (Pluddemann 
et al., 2007), and those in class A are trimeric transmembrane receptors with C-terminal 
disulfide-rich domains (Figure 1.10) (Platt et al., 2002; Arredouani and Kobzik, 2004; 
Sarrias et al., 2004).  The SCARA3-like neck region of SRCL mediates trimerization of the 
receptor: sedimentation equilibrium analytical ultracentrifugation has been used to 
demonstrate that the extracellular domain of SRCL forms a stable trimer, whereas the 
isolated CRD is monomeric (Coombs et al., 2005).  SRCL trimers are presumably 
stabilized by the formation of lengths of triple helix in the extracellular domain.  The neck 
region of the SRCL polypeptide contains two kinds of helix-forming repeat: adjacent to the 
CRD there are idealized proline-rich Gly-X-Y repeats like those found in collagen, while in 
the membrane-proximal part of the neck there are heptad repeats, which do not have 
perfect repetition of hydrophobic residues, but are nonetheless expected to form a coiled-
coil of α-helices.   
The two helical sections in the neck of SRCL have different structural properties, 
for examples the coiled-coil is a left-handed helix while the collagen helix is right-handed 
(Beck and Brodsky, 1998).  Notably, the three polypeptides are in register in the coiled-
coil but staggered in the collagen-like region, which means that the receptor cannot have 
simple rotational symmetry and points to a degree of conformational disorder at the 
transition between the two helix types.  This local flexibility could create a hinge between 
the two rigid helical sections of the neck, similar to that observed in the class A scavenger 
receptor SR-A in electron microscopy experiments, which indicated that the angle 
between the coiled-coil and collagen-like domains can vary between 20° and 180° (Figure 
1.11) (Resnick et al., 1996).  The shorter length of the collagen-like domain in SRCL 
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 Cytoplasmic tail                        
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              Extracellular domain 
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 Coiled-coil region 
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                      CRD 
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Figure 1.10: Comparison of SRCL and the class A scavenger receptor proteins
This page: Domain organization in class A scavenger receptors.  Systematic protein names 
are shown, and where alternative names are generally used these are indicated in bold.  Not 
to scale. SRCL drawing adapted from P Coombs, PhD thesis, 2007.
Facing page: Amino acid sequence alignment of SRCL and SCARA3.  Exons are indicated 
with alternative black and blue type.  The SRCL sequence is truncated to the start of the CRD.
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Figure 1.11: A potentially flexible hinge region in the extracellular domain of SRCL
Top: Flexibility in the neck of SRCL inferred from studies of macrophage scavenger receptor 
SR-A.  Bottom: Alignment of the putative hinge region in human class A scavenger receptors 
and in SRCL proteins from different species.  Identical conserved residues are shown in 
blue.  A conserved potential N-glycosylation site is shown in red.  The start of the collagen-
like region is indicated.  SRCL drawing adapted from P Coombs, PhD thesis, 2007.
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compared to the coiled-coil domain would permit the top portion of the molecule to fold 
back on the bottom portion at a hinge between the two helices.  The junctional region 
between the two helix types is a particularly well conserved region in the class A 
scavenger receptors, including SRCL, and has a potential N-glycosylation site, occupancy 
of which might affect protein flexibility.  The junctional region is also strikingly well 
conserved between SRCL proteins from different species. 
 
1.8 Expression of SRCL 
The expression of SRCL has been investigated in a small number of studies with some 
conflicting results.  The two initial reports of human SRCL cloning both included surveys of 
SRCL mRNA expression in different tissues, with broadly consistent results (Nakamura et 
al., 2001a; Ohtani et al., 2001).  In one study, high expression was detected by northern 
blot analysis in placenta, heart, lung and small intestine, with lower expression in brain, 
skeletal muscle, colon, thymus and kidney and no expression in spleen, liver and 
leukocytes (Nakamura et al., 2001a).  In the second study, expression was detected by 
northern blot analysis in placenta, heart and lung and by reverse-transcription PCR in a 
wide range of tissues, with notably low expression in liver and spleen (Ohtani et al., 2001).  
A later analysis by real-time reverse-transcription PCR found mRNA expression in a range 
of tissues, including very high levels in placenta and retina, and moderate levels in heart 
and skeletal muscle (Selman et al., 2008).  In rodents, SRCL has been found by northern 
blot analysis to be expressed in a range of tissues, with particularly high levels in lung 
(Nakamura et al., 2001b; Nakamura et al., 2006).  SRCL expression thus appears to have 
a broad tissue distribution, with particularly high levels in placenta, heart and lung 
constrasting with little expression in liver. 
The question of which specific cell types express SRCL has been addressed with 
reference to its relationship to scavenger receptors.  Scavenger receptors are frequently 
expressed by macrophages, since these cells specialize in the uptake of molecules from 
the environment (Platt et al., 2002; Arredouani and Kobzik, 2004).  However, one study 
reported no expression of SRCL in human macrophages, monocytes, Kupffer cells or in 
LPS-stimulated monocytic cell lines THP-1, U937 and HL-60 (Ohtani et al., 2001).  The 
situation may be different in rodents, with SRCL mRNA and protein having been detected 
in the murine macrophage cell line J774A.1 by northern blotting and immunoblotting 
respectively, and SRCL mRNA having been detected in murine neonatal astrocytes and 
rat neonatal microglia by RT-PCR (Nakamura et al., 2001b; Nakamura et al., 2006).   
Scavenger receptors are also expressed by vascular endothelial cells (Adachi and 
Tsujimoto, 2006), which constitute the innermost lining of blood vessels.  Expression of 
SRCL has been detected in human umbilical vein endothelial cells (HUVECs) by flow 
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cytometry and western blot, in umbilical artery endothelial cells (HUAEC) by flow 
cytometry, and in endothelial cells in murine and human heart sections by 
immunofluorescence (Ohtani et al., 2001).  However, a later analysis suggests that SRCL 
is generally not expressed by endothelial cells (Selman et al., 2008).  In this study, real-
time RT-PCR did show expression of SRCL mRNA in HUVECs and HUAECs, but SRCL 
could not be detected on HUVECs or the endothelial cell line HPMEC ST1.6R by flow 
cytometry, and immunocytochemical analysis revealed the protein to be intracellular in 
these cell types.  Among other endothelial cell types, SRCL expression was detected by 
real-time RT-PCR in the cell lines AS-M.5 and HPMEC ST1.6R, though at a lower level 
than in HUVECs and HUAECs, but not in HMEC-1 and EA.hy926.  In 
immunohistochemical staining of tissue sections, SRCL was not detected in any vascular 
endothelial cells with the exception of those of the umbilical vein, with expression instead 
restricted to trophoblasts of the placenta, alveolar macrophages in lung, and some very 
minor cell populations in tonsil. 
 
1.9 SRCL as a scavenger receptor 
The work presented in Chapters 2 and 3 will focus on the biological role of sugar binding 
by SRCL.  However the receptor is likely to be a multi-functional protein with additional 
roles that are independent of the CRDs, but related to the homology of SRCL and class A 
scavenger receptors.  SRCL expression has been reported in endothelial cells (Ohtani et 
al., 2001), which are one of the main cell types expressing scavenger receptors, and the 
receptor also has clusters of basic residues in the collagen-like domain, which in other 
class A scavenger receptors create positively-charged patches which mediate binding and 
internalization of a variety of polyanionic ligands.  Class A scavenger receptor ligands 
include advanced glycation end products, β-amyloid fibrils, bacterial lipopolysaccharide 
and lipoteichoic acid, and whole bacteria, in addition to acetylated or oxidized low-density 
lipoprotein (Mukhopadhyay and Gordon, 2004; Pluddemann et al., 2007).   
A key role of scavenger receptors is in phagocytosis – the receptor-dependent 
internalization of micrometer-sized particles, such as whole bacteria, into a phagosome, 
which usually fuses with the lysosome (Mukhopadhyay and Gordon, 2004).  In 
‘professional’ phagocytes, such as macrophages, dendritic cells and granulocytes, 
phagocytosis is employed to eliminate microorganisms and generate antigens for 
presentation to T cells.  Phagocytosis is not a major function of endothelial cells, but these 
cells are able to present antigens (Marelli-Berg and Jarmin, 2004).   
Consistent with a role for SRCL in phagocytosis, Chinese hamster ovary cells 
transfected with SRCL are reported to bind and phagocytose the Gram-negative 
bacterium Escherichia coli, the Gram-positive bacterium Staphylococcus aureus, and the 
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yeast Saccharomyces cerevisiae.  These binding activities appear to be associated with 
the clusters of positively-charges residues in the collagen-like region, since SRCL 
constructs both with and without CRDs bind bacteria, and binding activities are inhibited 
by polyanionic molecules (Nakamura et al., 2001a; Ohtani et al., 2001).  It has recently 
been reported that SRCL is the primary receptor on human umbilical vein endothelial cells 
for phagocytosis of zymosan, a yeast cell wall polymer of β1,3-linked glucose which 
produces a severe inflammatory response (Jang et al., 2009).  The interaction between 
SRCL and zymosan was described as electrostatic and probably does not involve the 
CRDs.  Thus SRCL may have a role in the phagocytosis of microorganisms, but this 
function does not require sugar recognition, even though the cell walls of microorganisms 
often contain complex carbohydrates that are recognized by mammalian glycan-binding 
proteins. 
The uptake of acetylated or oxidized low-density lipoprotein by scavenger 
receptors on macrophages is linked to the formation of foam cells, a major component of 
atherosclerotic plaques in vascular disease.  SRCL may contribute to atherogenesis, as 
Chinese hamster ovary cells transfected with SRCL bind oxidized low-density lipoprotein, 
though not unmodified or acetylated low-density lipoprotein (Ohtani et al., 2001).  It has 
been suggested that scavenger receptors bind and clear β-amyloid in Alzheimer’s 
disease.  A similar role was proposed for SRCL, since SRCL protein expression was 
found to be induced in β-amyloid-positive astrocytes and vascular or perivascular cells in 
a transgenic mouse model of Alzheimer’s disease, the receptor was detected in the brains 
of Alzheimer’s disease patients, and SRCL-transfected mammalian cells could bind β-
amyloid fibrils (Nakamura et al., 2006).   
Little is known about the specific function of SCARA3, the class A scavenger 
receptor that is most similar to SRCL.  Unusually for a transmembrane protein, SCARA3 
has neither extracellular globular domains nor a substantial cytoplasmic domain, but its 
conservation in vertebrates points to useful functionality.  It has been suggested that 
SCARA3 exerts a protective effect against cellular damage caused by ultra-violet 
irradiation and oxidative stress by scavenging reactive oxygen species, reportedly 
relocating from the secretory pathway to the cytoplasm during oxidative stress (Han et al., 
1998).  SCARA3 has also been identified as a potential tumour suppressor gene, since 
downregulation or methylation of the gene was observed in many prostate cancer 
samples and was associated with a high rate of metastasis (Yu et al., 2006).  A 
mechanism for SCARA3-induced cell death through inhibition of mRNA polyadenylation 
has been proposed (Zhu et al., 2009). 
The low level of sequence identity between SRCL and SCARA3 indicates that 
functions of SCARA3 will not necessarily be mirrored in SRCL and the duplication of the 
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ancestral SCARA3-like gene may have served to create two receptors with divergent 
functions.  Though a SCARA3-like isoform of SRCL in which the CRD exons are omitted 
has been reported (Nakamura et al., 2001a), this variant has not been verified, and the 
principal form of the protein includes the CRD.  The conservation of SRCL in vertebrates 
suggests that the combination of an extended helical neck with C-type CRDs is of unique 
and particular value.  The creation of new proteins with novel domain combinations like 
SRCL has emerged as an important theme in the origin of complexity in genomic studies 
of eukaryotic evolution (Chothia and Gough, 2009).   
 
1.10 Glycan recognition by SRCL 
Analysis of the amino acid sequence of the CRD of SRCL places the receptor in the type 
II receptor family of CTLD-containing proteins (Figures 1.7 and 1.12).  The CRD has a 
QPD motif and a glycine-rich loop and is therefore of the galactose-binding type.  It has 
40-45% sequence identity with the other galactose-binding receptors of the type II 
receptor family, and ~35% identity with the mannose-binding receptors.  This degree of 
similarity contrasts with the 25-30% identity found with CRDs from most other families of 
mammalian CTLD-containing receptors, though there is a higher level of identity with the 
CRDs of the proteoglycan family (~35%) due to the overall similarity of proteoglycan and 
type II receptor CRDs, and the presence of galactose-type binding sites in the 
proteoglycans.  The positions of cysteine residues involved in disulfide bonding and of the 
exon boundaries within the CRD also confirm the homology of SRCL with other type II 
receptors.  The relatively low level of sequence identity between the CRD of SRCL and 
the most similar CRD from another human protein (the macrophage galactose lectin, 45% 
identity) reflects the evolutionary age of the SRCL gene and the sequence plasticity that is 
a feature of the C-type lectin domain fold. 
SRCL also resembles other members of the type II receptor family in overall 
structural organization, having a short N-terminal cytoplasmic domain and an oligomeric 
neck region, even though these regions of SRCL are not homologous to other proteins in 
the group.  SRCL is however the only member of the type II receptor family that has a 
collagen-like region in the neck, and the neck overall is much longer than in other 
proteins.  Notably, SRCL is the only member of the rapidly-evolving type II receptor family 
that is clearly conserved across vertebrate species as a single ortholog (with the 
exception of the gene duplication in fish), other members of this family having undergone 
lineage-specific duplication and diversification or suffered gene loss.  
Typically for a C-type lectin, the CRD of SRCL binds galactose with low affinity, but 
the clustering of CRDs brought about by receptor trimerization produces a substantial 
increase in affinity (Coombs et al., 2005).  The sugar-binding specificity of trimeric SRCL 
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1st exon 
 
                1          1                2 
SRCL            CPPHWKNFTDKCYYFSVEKEIFEDAKLFCEDKSSHLVFINTREEQ 
 
MGL       STEGTCCPVNWVEHQDSCYWFSHSGMSWAEAEKYCQLKNAHLVVINSREEQ 
ASGR1      SERTCCPVNWVEHERSCYWFSRSGKAWADADNYCRLEDAHLVVVTSWEEQ 
ASGR2      SQRTCCPVNWVEHQGSCYWFSHSGKAWAEAEKYCQLENAHLVVINSWEEQ 
 
DCIR       TAWSCCPKNWKSFSSNCYFISTESASWQDSEKDCARMEAHLLVINTQEEQ 
BDCA-2       WSCCPTPWTSFQSSCYFISTGMQSWTKSQKNCSVMGADLVVINTREEQ 
Dectin-2     WGCCPASWKSFGSSCYFISSEEKVWSKSEQNCVEMGAHLVVFNTEAEQ 
Clec4D     STWNCCPIDWRAFQSNCYFPLTDNKTWAESERNCSGMGAHLMTISTEAEQ 
Mincle     SVKNCCPLNWEYFQSSCYFFSTDTISWALSLKNCSAMGAHLVVINSQEEQ 
 
CD23       FVCNTCPEKWINFQRKCYYFGKGTKQWVHARYACDDMEGQLVSIHSPEEQ 
LSECtin     SCEPCPTSWLSFEGSCYFFSVPKTTWAAAQDHCADASAHLVIVGGLDEQ 
DCSIGN     RLCHPCPWEWTFFQGNCYFMSNSQRNWHDSITACKEVGAQLVVIKSAEEQ 
DCSIGNR    RLCRHCPKDWTFFQGNCYFMSNSQRNWHDSVTACQEVRAQLVVIKTAEEQ 
 
Prolectin DCRRITCPEGWLPFEGKCYYFSPSTKSWDEARMFCQENYSHLVIINSFAEH 
 
Langerin   DILQVVSQGWKYFKGNFYYFSLIPKTWYSAEQFCVSRNSHLTSVTSESEQ 
 
 
2nd exon 
 
SRCL         QWIKKQMVGRESH-WIGLTDSERENE---WKWLDGTSPDYK 
 
MGL          NFVQKYLGSAYT--WMGLSDPEGA-----WKWVDGTDYATGFQ 
ASGR1        KFVQHHIGPVNT--WMGLHDQNGP-----WKWVDGTDYETGFK 
ASGR2        KFIVQHTNPFNT--WIGLTDSDGS-----WKWVDGTDYRHNYK 
 
DCIR         DFIFQNLQEESAY-FVGLSDPEGQRH---WQWVDQTPYNESST 
BDCA-2       DFIIQNLKRNSSY-FLGLSDPGGRRH---WQWVDQTPYNENVT 
Dectin-2     NFIVQQLNESFSY-FLGLSDPQGNNN---WQWIDKTPYEKNVR 
Clec4D       NFIIQFLDRRLSY-FLGLRDENAKGQ---WRWVDQTPFNPRRV 
Mincle       EFLSYKKPKMREF-FIGLSDQVVEGQ---WQWVDGTPLTKSLS 
 
CD23         DFLTKHASHTGS--WIGLRNLDLKGE---FIWVDGSHVDYS 
LSECtin      GFLTRNTRGRGY--WLGLRAVRHLGKVQGYQWVDGVSLSFS 
DCSIGN       NFLQLQSSRSNRFTWMGLSDLNQEGT---WQWVDGSPLLPS 
DCSIGNR      NFLQLQTSRSNRFSWMGLSDLNQEGT---WQWVDGSPLSPS 
 
Prolectin    NFVAKAHGSPRVY-WLGLNDRAQEGD---WRWLDGSPVTLS 
 
Langerin     EFLYKTAGGLIY--WIGLTKAGMEGD---WSWVDDTPFNKVQSVR 
 
 
3rd exon 
 
                      Gly-loop   3                  3        2 
SRCL         NWKAGQPDNW-GHGHGPGEDCAGLIYAGQ-----WNDFQCEDVNN-FICEKDRET 
 
MGL          NWKPGQPDDWQGHGLGGGEDCAHFHPDGR-----WNDDVCQRPYH-WVCEAGLGQTSQE 
ASGR1        NWRPEQPDDWYGHGLGGGEDCAHFTDDGR-----WNDDVCQRPYR-WVCETELDKASQE 
ASGR2        NWAVTQPDNWHGHELGGSEDCVEVQPDGR-----WNDDFCLQVYR-WVCEKRRNATGEV 
 
DCIR         FWHPREPSDP-------NERCVVLNFRKSPKRWGWNDVNCLGPQR-SVCEMMKIHL 
BDCA-2       FWHSGEPNNL-------DERCAIINFRSS-EEWGWNDIHCHVPQK-SICKMKKIYI 
Dectin-2     FWHLGEPNHS-------AEQCASIVFWKP-TGWGWNDVICETRRN-SICEMNKIYL 
Clec4D       FWHKNEPDNSQ------GENCVVLVYNQD--KWAWNDVPCNFEAS-RICKIPGTTLN 
Mincle       FWDVGEPNNIAT-----LEDCATMRDSSN-PRQNWNDVTCFLNYF-RICEMVGINPLNK 
 
CD23         NWAPGEPTSRSQ-----GEDCVMMRGSGR-----WNDAFCDRKLGAWVCDRLAT-CTPP 
LSECtin      HWNQGEPNDAWG-----RENCVMMLHTGL-----WNDAPCDSEKDGWICEKRHN-C 
DCSIGN    FKQYWNRGEPNNVGE------EDCAEFSGNG------WNDDKCNLAKF-WICKKSAASCSRD 
DCSIGNR   FQRYWNSGEPNNSGN------EDCAEFSGSG------WNDNRCDVDNY-WICKKPAA-CFRD 
 
Prolectin    FWEPEEPNNIH------DEDCATMNKGGT-----WNDLSCYKTTY-WICERK-CSC 
 
Langerin     FWIPGEPNNAGN-----NEHCGNIKAPSLQA---WNDAPCDKTFL-FICKRPYVPSEP 
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Figure 1.12:  Comparison of SRCL and other C-type lectins of the type II receptor family
This page: Scale comparison of selected type II receptors.  Receptor drawings adapted from 
P Coombs, PhD thesis, 2007.  Facing page: Amino acid sequence alignment of CRDs from 
human type II receptor C-type lectins.  Aligned sequences are arranged in evolutionary sub-
2+
groups.  Residues at the sugar/Ca  binding site are highlighted in green.  Cysteine residues 
are highlighted in yellow and disulfide bond pairings indicated.  Conserved hydrophobic 
residues are highlighted in light grey and other conserved residues in dark grey.  Some CRDs 
have been truncated at the C-terminus.
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was elucidated by screening of a glycan array, which consists of immobilized samples of a 
large and diverse range of biologically relevant oligosaccharides.  Array screening showed 
that SRCL does not bind to galactose-terminated glycans in general, but is unusually 
selective, recognizing only the Lewisx trisaccharide Galβ1-4(Fucα1-3)GlcNAcβ1-, and to a 
lesser extent the Lewisa trisaccharide Galβ1-3(Fucα1-4)GlcNAcβ1- (Coombs et al., 2005) 
(Figure 1.13).    Some binding activity was evident towards a Lewisx-like structure in which 
the terminal galactose is replaced with GalNAc, and to blood group H antigen-like 
structures Fucα1-2Galβ1-3GalNAcβ1- and Fucα1-2Galβ1-3GlcNAcβ1-.  The overall 
picture is that adjacent terminal galactose and fucose residues are required for high-
affinity binding by SRCL.  Mouse SRCL has also been subjected to glycan array 
screening, and exhibits similar specificity for Lewisx and Lewisa, consistent with the very 
high level of sequence identity (92%) between the mouse and human proteins (Feinberg 
et al., 2007).  Selective binding of human SRCL to Lewisx structures as presented on 
glycoconjugates has been confirmed using radiolabelled extracellular domain of the 
receptor to probe immobilized glycoproteins and neoglycolipids bearing different glycan 
structures (Coombs et al., 2005).   
The Lewisx trisaccharide is also a ligand for the human type II transmembrane C-
type lectin DC-SIGN.  The structure of Lewisx bound to DC-SIGN determined by X-ray 
crystallography shows the fucose residue bound at the primary binding site and the 
galactose and GlcNAc portions of Lewisx structure recognized through supplementary 
hydrogen bonds and van der Waals interactions (Guo et al., 2004).  In contrast, the 
structure of Lewisx bound to mouse SRCL reveals a novel mechanism for Lewisx binding, 
in which the galactose residue of Lewisx is bound at the primary binding site, while 
additional interactions are made with fucose to create the selectivity for the Lewisx epitope 
(Feinberg et al., 2007).  The narrower range of glycans bound by SRCL compared to DC-
SIGN indicates that the mode of binding exhibited by SRCL is more selective for Lewisx. 
The galactose residue of Lewisx is bound in canonical fashion by two amide and 
two acid side chains (Gln694, Asp696, Glu706, and Asn718) in mouse SRCL, which 
participate in hydrogen bonds with the 3- and 4-hydroxyl groups of galactose whilst also 
coordinating the Ca2+ ion (Figure 1.14).  The remaining coordination for the Ca2+ ion 
comes from the 3- and 4-hydroxyl groups of galactose and from Asp719.  These central 
interactions are supplemented by hydrophobic packing of the galactose ring against the 
side chain of Trp698, which is unexpectedly rotated 180° relative to its position in the 
structure of GalNAc bound at an asialoglycoprotein receptor-like binding site engineered 
into mannose-binding protein (Kolatkar and Weis, 1996).  Specificity for the Lewisx 
trisaccharide is created by supplementary interactions with the fucose residue: Lys691 
makes hydrogen bonds to the 4-hydroxyl group and ring oxygen, and Ile712 engages in a 
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Figure 1.13: Oligosaccharide ligands for SRCL identified by glycan array screening
An array of immobilized oligosaccharides was probed with fluorescein-labelled extracellular 
x
domain of human SRCL. The level of fluorescence was normalized to glycan 25 (Lewis ).  
Figure adapted from Coombs et al., 2005.
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xFigure 1.14: Mechanism of Lewis  trisaccharide binding in SRCL
x
Top: Schematic representation of the sugar-binding site in mouse SRCL with bound Lewis .  
Bottom: Conservation of the sugar-binding site in SRCL.  Amino acid sequences were 
deduced from genomic DNA sequence in the Ensembl database.  Boxed residues 
correspond to those shown in the top portion of the figure.
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Mammals
Mouse WKAGQPDNWGSGHGP-GEDCAGLIYAGQWNDF
Human WKAGQPDNWGHGHGP-GEDCAGLIYAGQWNDF
Macaque WKAGQPDNWGHGHGP-GEDCAGLIFAGQWNDF
Lemur WKAGQPDNWGHGHGP-GEDCAGLIYAGQWNDF
Dog WKAGQPDDWGHGHGP-GEDCAGLIYAGQWNDF
Horse WKAGQPDNWGHGHGP-GEDCAGLIYAGQWNDF
Elephant WKAGQPDNWGHGHGP-GEDCAGLIYAGQWNDF
Armadillo WKAGQPDNWGHGHGP-GEDCAGLVYAGQWNDF
Opossum WKPGQPDNWGHGHGP-GEDCAGLIYTGQWNDF
Platypus WKNGQPDNWGRGHGP-GEDCAGLIYAGLWNDF
Non-mammals
Chicken WKTGQPDNWNHGHGP-GEDCAGLIYAGLWNDF
Lizard WSAGQPDNWKHGHGP-GEDCAGLIHAGLWNDF
Xenopus WKEGQPDNWSHQTGP-GEDCAGLIYSGLWNDF
Fugu 1 WKPGQPDNWNHGQDISGEDCAGLIHEALWNDF
Medaka 1 WKPGQPDNWGHSHEA-GEDCAGLIHEGLWNDF
Fugu 2 WKPGQPDNWTHGHEE-GEDCAGLIHNAHWNDF
Medaka 2 WKPGQPDNWTHGHED-GEDCAGLIHLAFWNDF
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van der Waals interaction with the exocyclic methyl group.  Ile712 also contacts Asn718 
from the primary binding site, while Phe720 makes contacts with both Ile712 and residues 
from the primary binding site to organize the whole glycan-binding pocket.  The 
significance of these residues in the wider glycan-binding pocket in creating selectivity and 
affinity in Lewisx binding has been examined by mutagenesis (Feinberg et al., 2007).  
Mutating Lys691 to alanine does not abolish preferential binding to Lewisx, indicating that 
the contacts this residue makes to fucose are not the source of the selectivity of SRCL for 
Lewisx.  However mutating Ile712 to valine did result in a loss of selectivity for Lewisx over 
galactose, while substitution with alanine brought about an overall reduction in sugar-
binding activity.  Mutating Phe720 to alanine abolished sugar binding, highlighting the 
importance of this residue in organizing the binding pocket.   
Comparison of SRCL amino acid sequences from over 30 species in the Ensembl 
genome database reveals that the region of the SRCL polypeptide around the sugar-
binding site is very well conserved (alignment of selected sequences shown in Figure 
1.14).  The invariant residues include the four critical residues which bind both sugar and 
Ca2+ at the primary binding site (Gln694, Asp696, Glu706, and Asn718) and the remaining 
Ca2+ coordination ligand Asp719.  The tryptophan side chain that packs against the 
galactose ring (Trp698) is also conserved and a glycine-rich loop (Trp698 to Glu706 in the 
mouse) is present in all proteins.  The three residues involved in the wider glycan-binding 
pocket (Lys691, Ile712, Phe720) are almost completely invariant, with most instances of 
variation occurring in fish species, where the duplication of the SRCL gene may mean that 
sequence drift could have occurred in one of the proteins without deleterious effect.  The 
conservation of residues in the glycan-binding pocket suggests that Lewisx binding by 
SRCL is likely to be conserved in all species.  The fucosyltransferase that appears most 
selective for synthesis of Lewisx over alternative structures (FUT9) (Nishihara et al., 1999) 
shows the same phylogenetic distribution as SRCL, indicating that the recognition of 
Lewisx by SRCL may be evolutionarily ancient, with roles potentially common to all 
vertebrates.   
Although Lewisa was found to be a good ligand for SRCL in glycan array 
screening, it is likely that Lewisx is the key biological ligand for SRCL, since Lewisa does 
not appear to be an essential part of the mammalian glycome (Oulmouden et al., 1997; 
Petit et al., 2006).  Lewisa biosynthesis requires α1,4-fucosyltransferase activity, which is 
exhibited only by FUT3 and FUT5 among human fucosyltransferases (Dupuy et al., 1999) 
(Figure 1.15).  These enzymes are expressed in epithelial cells, but the amount of Lewisa 
in normal (non-cancerous) human tissue is minimal due to the co-expression of α1,2-
fucosyltransferases that result in the synthesis of the alternative Lewisb structure 
(Mollicone et al., 1995).  Furthermore, both the α1,2- and α1,4-fucosyltransferase 
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activities are absent in some individuals due to gene polymorphisms (Koda et al., 2001), 
and it is not clear that non-primates have enzymes with α1,4-fucosyltransferase activity at 
all (Oulmouden et al., 1997).  The structure of mouse SRCL in complex with Lewisx 
suggests that Lewisa can be accommodated in the binding site, with the terminal 
galactose and fucose residues making identical contacts to the protein as in Lewisx 
binding, simply by flipping the underlying GlcNAc residue, which does not make any 
contacts to the protein (Feinberg et al., 2007).  Lewisa binding by SRCL may therefore be 
an unintended but functionally neutral consequence of Lewisx binding. 
 
1.11 Potential functions of glycan recognition by SRCL 
The physiological role of SRCL as a glycan-binding protein is not known.  The superficial 
similarity of SRCL to the collectins has led to suggestions that SRCL may have a role in 
the innate immune system in the recognition and clearance of pathogens (Nakamura et 
al., 2001a; Ohtani et al., 2001).  The combination of a C-type CRD with coiled-coil and 
collagen-like regions that is found in SRCL is indeed also characteristic of the collectins, 
and this fact has been reflected in the alternative protein name Collectin Placenta-1 (CL-
P1) and the designated gene name Collectin Sub-family Member 12 (COLEC12).  
However, the coiled-coil and collagen-like regions of SRCL are not homologous to those 
in the collectins, and are considerably longer as well as being arranged in the opposite 
order in the polypeptide chain.  SRCL cannot function analogously to the collectins in the 
neutralization and opsonization of pathogens because it is a membrane-bound receptor 
rather than a soluble protein.  The CRD of SRCL is of the galactose-binding type, which is 
generally associated with recognition of self glycans, and is not closely related to the 
CRDs of the collectins, which have mannose-type specificity appropriate for recognizing 
pathogen-associated glycoconjugates.  The Lewisx epitope recognized by SRCL is not 
associated with pathogens, with certain exceptions such as Helicobacter pylori and 
schistosomes (Srivatsan et al., 1992; Sherburne and Taylor, 1995).  Roles of SRCL 
similar to class A scavenger receptors in the binding and uptake of pathogens do not 
involve sugar recognition (Nakamura et al., 2001a; Ohtani et al., 2001).  For these 
reasons, this work will consider the role of SRCL in the recognition exclusively of 
endogenous glycoconjugates. 
SRCL is an endocytic receptor that can mediate uptake of glycoconjugate ligands, 
as demonstrated using rat fibroblasts transfected with SRCL to internalize and degrade a 
Lewisx-conjugated neoglycoprotein (Coombs et al., 2005).  Strikingly, a fully-extended 
SRCL molecule, at 100 nm in length, would span the width of an endocytic vesicle, which 
is typically less than 100 nm in diameter (Robinson et al., 1998).  The short cytoplasmic 
tail of SRCL is particularly well conserved between species and consists of a membrane-
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proximal portion homologous to SCARA3 and a unique SRCL-specific N-terminal portion.  
The exons encoding the two portions are separated by an intron of over 100 kilobases, 
among the largest in the human genome.  The SRCL-specific portion contains an 
endocytosis signal motif of the form YXXφ, specifically YKRF, which is absolutely 
conserved between species.  Such motifs are not found in other class A scavenger 
receptors but are present in several endocytic C-type lectins (Spiess, 1990).  The pH-
dependence of ligand binding in SRCL is comparable to other C-type lectins, with binding 
maximal above pH 7, and abolished below pH 6, with a mid-point around pH 6.5 (Coombs 
et al., 2005).  SRCL can therefore bind ligands in the extracellular space and release them 
into endosomal compartments.  It has been proposed that the pH sensor in SRCL is a 
histidine residue (His702 in the mouse protein) that is located in the glycine-rich loop that 
follows the QPD motif, such that pH-dependent changes in the structure of the loop might 
disrupt the sugar-binding site and trigger ligand release (Feinberg et al., 2007).  SRCL 
may therefore have a role in clearing endogenous glycoproteins from the circulation or 
other extracellular fluid, analagous to the functions of the asialoglycoprotein receptor and 
mannose receptor.   
SRCL could also have a role in cell adhesion, analagous to the role of the 
selectins.  Both the sialyl-Lewisx epitope recognized by the selectins and the Lewisx 
epitope recognized by SRCL are found on leukocytes, such that SRCL might also mediate 
binding of leukocytes to the endothelium.  In addition, the binding of selectins to sialyl-
Lewisx epitopes on cancer cells contributes to metastasis, and a similar outcome has 
been proposed for SRCL binding to tumour cell-associated Lewisx-containing glycans 
(Elola et al., 2007; Powlesland et al., 2009).  Though SRCL and the selectins bind 
fucosylated structures in fundamentally different ways, both exhibit high selectivity in 
ligand binding, and while the selectin neck is monomeric, shorter and more flexible than 
that of SRCL, in both instances the neck may serve to lift the CRDs away from the cell 
membrane to enhance ligand binding.   
The physiological ligands of SRCL may therefore be cell surface glycoproteins 
involved in cell adhesion, or soluble proteins secreted from cells.  The key enzyme 
involved in the synthesis of the SRCL ligand Lewisx is the fucosyltransferase FUT9, which, 
compared to the other mammalian fucosyltransferases, has a marked propensity for the 
synthesis of Lewisx over alternative structures such as Lewisa, sialyl-Lewisx, and the VIM-
2 epitope (Nishihara et al., 1999) (Figure 1.15).  FUT9 is responsible for the abundant 
Lewisx expression in neutrophils and in neurons of the central nervous system (Nakayama 
et al., 2001; Nishihara et al., 2003).  The small amount of Lewisx found in monocytes is 
instead synthesized by FUT4 (Nakayama et al., 2001).  FUT9 and FUT4 are the only α1-
3/4 fucosyltransferases expressed during early embyogenesis, and consistent with this 
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expression, Lewisx is found in early embryonic cells and primordial germ cells across 
vertebrate species (Cailleau-Thomas et al., 2000; Muramatsu and Muramatsu, 2004).  
Lewisx is also occasionally found on normal and cancerous epithelial cells and some 
lymphomas (Sanders et al., 1988; Rudiger et al., 1998; Croce et al., 2007).  The presence 
of FUT6 in liver and plasma means that Lewisx-containing glycoproteins could be secreted 
directly into the bloodstream, or could be created in the bloodstream by fucosylation of 
secreted non-sialylated proteins, though Lewisx-containing glycoproteins in serum have 
not been documented. 
The specific functions of the Lewisx structure are unclear despite the epitope 
having been recognized for many years.  FUT9-deficient mice displaying loss of Lewisx 
from brain and during early embyogenesis exhibited anxiety-like behaviours (Kudo et al., 
2007), and the very rare human fucose transporter causing leukocyte adhesion deficiency 
II, which eliminates expression of fucosylated glycans including Lewisx, is characterized 
by immunological and neurological defects (Yakubenia and Wild, 2006).  However the role 
of Lewisx in these phenotypes is known.  Illumination of the role of SRCL may therefore 
also shed light on the function of the Lewisx structure.   
 
1.12 Work presented in this thesis 
The aims of the work presented in this thesis were to propose physiological roles for two 
novel human C-type lectins which were discovered by screening of DNA databases, 
through investigation of the tissue localization of the receptors and identification of 
endogenous glycoprotein ligands. 
Chapter 2 describes the characterization of SRCL expression.  This work confirms that 
SRCL is expressed primarily in endothelial cells, consistent with roles for the receptor in 
leukocyte adhesion or glycoprotein clearance, and includes a broad tissue screen that 
identifies additional sites of SRCL expression. 
Chapter 3 describes the identification of endogenous, Lewisx-containing glycoprotein 
ligands for SRCL from neutrophils.  These ligands were found to consist predominantly of 
soluble granule glycoproteins, indicating a role for SRCL in the clearance of neutrophil 
proteins released at sites of inflammation. 
Chapter 4 describes the identification of prolectin, a novel C-type lectin with unique 
signalling potential, by screening of the human genome.  The characterization of prolectin 
expression is also described, and leads to the hypothesis that prolectin is involved in the 
migration of activated and effector B cells during the adaptive immune response.   
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Characterization of expression of the scavenger receptor 
C-type lectin in endothelial cells and other cell types 
 
2.1 Introduction 
This chapter describes the characterization of expression of the scavenger receptor C-
type lectin (SRCL).  Previous reports of SRCL expression indicate that mRNA for SRCL is 
found in a wide range of tissues, but there are conflicting data regarding the expression of 
SRCL protein in tissues and cell lines, particularly regarding potential expression of SRCL 
in endothelial cells (Ohtani et al., 2001; Selman et al., 2008).  The detection of novel 
proteins such as SRCL in cultured cells and tissue sections is often problematic because 
antibodies to novel antigens are not well characterized in terms of their sensitivity to 
fixation and antigen retrieval procedures.  In the absence of established positive control 
cells and tissues it is also difficult to validate staining results.  Furthermore the expression 
level of a novel protein is unknown, and in particular may be much lower for proteins 
which have been discovered through genomic screening rather than biochemical 
approaches.   
Establishing which cell types express SRCL is a vital step in investigating the 
function of the receptor.  This work aims to clarify the situation regarding expression of 
SRCL in endothelial cells.  In addition, because previous investigations into SRCL 
expression have concentrated on macrophages and endothelial cells due to the 
relationship of SRCL to scavenger receptors, this work employed unbiased screening 
approaches to enable detection of SRCL expression across a range of cell types. 
 
2.2 Materials and Methods  
General 
Buffers are defined as follows: 
Loading buffer   25 mM Tris, pH 7.8, 0.5 M NaCl, 25 mM CaCl2. 
Eluting buffer   25 mM Tris, pH 7.8, 0.5 M NaCl, 2.5 mM EDTA. 
Low-salt loading buffer 25 mM Tris, pH 7.8, 150 mM NaCl, 25 mM CaCl2. 
Low-salt eluting buffer 25 mM Tris, pH 7.8, 150 mM NaCl, 2.5 mM EDTA. 
TBS     10 mM Tris, pH 7.4, 150 mM NaCl. 
PBS     10 mM phosphate, pH 7.4, 150 mM NaCl. 
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All cell culture media and reagents were obtained from Invitrogen unless specified 
otherwise.  Cell culture media were supplemented with 50 U/mL of penicillin and 50 μg/mL 
of streptomycin.  Dulbecco’s phosphate-buffered saline (DPBS) was from Sigma.  Cells 
were maintained in a humidified incubator at 37°C with an atmosphere of 5% CO2.   
Oligonucleotides for cloning and PCR were synthesized by Invitrogen.   
 
Cloning 
Restriction endonucleases, DNA ligase, and T4 polymerase were obtained from New 
England BioLabs. PCR was performed using the Advantage 2 Polymerase kit (TaKaRa).  
The final reaction volume was 50 μL, containing 5 μL of 10x polymerase buffer, 1 μL of 
deoxyribonucleotide triphosphate solution (final concentration 200 μM), 2 μl of each 10 μM 
primer solution (final concentration 0.4 μM), 1 μL of PCR-ready first-strand cDNA 
preparation and 1 μL of polymerase.  After an initial incubation at 95°C for 1 min, 40 
cycles of 30 s at 95°C and 1 min at 65°C were performed.  PCR products were purified by 
agarose gel electrophoresis and cloned into the pCRII-TOPO cloning vector (Invitrogen).  
All final constructs were verified by DNA sequencing. 
 
Cloning and expression of the CRD of SRCL 
The region of the cDNA of SRCL encoding the CRD was amplified from a first-strand 
cDNA preparation from human placenta (Clontech) using the following primers (Figures 
2.1 and 2.2): 
 
                                   FseI 
Forward AAGGCCGGCCGAGGACAATAGCTGCCCGCCTCACTGGAAG 
 
                                   NotI 
Reverse TTGCGGCCGCTTATAATGCAGATGACAGTACTGTCTCCCTGTC 
 
The coding sequence was transferred using the underlined restriction sites into a modified 
pINIIIompA2 expression vector downstream of the ompA signal sequence, which was 
used to target the protein to the bacterial periplasm (Ghrayeb et al., 1984) (Figure 2.3).  
The coding sequence was inserted out-of-frame with the signal sequence and the correct 
reading frame was generated by digestion with FseI followed by trimming of the 3’ 
extension with T4 polymerase and re-ligation of the plasmid.  The expression plasmid was 
transformed into Escherichia coli strain JA221.  Luria-Bertani medium (1 L) containing 50 
mg/L ampicillin was inoculated with 30 mL of an overnight culture and the culture was 
grown by shaking at 30°C.  The culture was induced at OD550 of 0.8 by addition of 10 mg/L 
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SRCL cDNA
Coiled-coil Collagen CRDUTR UTR
1 2 3 4 5 7 8 9 106 Exon
                               
                                                                   
                                                                 
                        Full-length receptor (N-terminal section) cloning –
–
                                                     PCR 3 –
GAGCTCCCCGGCCGGCGGTGCGTCCCCACGGTCACCATGAAAGACGACTTCGCAGAGGAG 239
MetLys 8
GAGGAGGTGCAATCCTTCGGTTACAAGCGGTTTGGTATTCAGGAAGGAACACAATGTACC
28
AAATGTAAAAATAACTGGGCACTGAAGTTTTCTATCATATTATTATACATTTTGTGTGCC
48
TTGCTAACAATCACAGTAGCCATTTTGGGATATAAAGTTGTAGAGAAAATGGACAATGTC 419
68
ACAGGTGGCATGGAAACATCTCGCCAAACCTATGATGACAAGCTCACAGCAGTGGAAAGT 479
88
GACCTGAAAAAATTAGGTGACCAAACTGGGAAGAAAGCTATCAGCACCAACTCAGAACTC 539
108
TCCACCTTCAGATCAGACATTCTAGATCTCCGTCAGCAACTTCGTGAGATTACAGAAAAA 599
128
ACCAGCAAGAACAAGGATACGCTGGAGAAGTTACAGGCGAGCGGGGATGCTCTGGTGGAC 659
148
AGGCAGAGTCAATTGAAAGAAACTTTGGAGAATAACTCTTTCCTCATCACCACTGTAAAC   719
168
AAAACCCTCCAGGCGTATAATGGCTATGTCACGAATCTGCAGCAAGATACCAGCGTGCTC   779
188
                                                                   
                                                                                                      
CAGGGCAATCTGCAGAACCAAATGTATTCTCATAATGTGGTCA ACCTCAACAAC   839
208
CTGAACCTGACCCAGGTGCAGCAGAGGAACCTCATCACGAATCTGCAGCGGTCTGTGGAT   899
228
GACACAAGCCAGGCTATCCAGCGAATCAAGAACGACTTTCAAAATCTGCAGCAGGTTTTT   959
248
CTTCAAGCCAAGAAGGACACGGATTGGCTGAAGGAGAAAGTGCAGAGCTTGCAGACGCTG  1019
268
GCTGCCAACAACTCTGCGTTGGCCAAAGCCAACAACGACACCCTGGAGGATATGAACAGC  1079
288
CAGCTCAACTCATTCACAGGTCAGATGGAGAACATCACCACTATCTCTCAAGCCAACGAG  1139
308
CAGAACCTGAAAGACCTGCAGGACTTACACAAAGATGCAGAGAATAGAACAGCCATCAAG  1199
328
TTCAACCAACTGGAGGAACGCTTCCAGCTCTTTGAGACGGATATTGTGAACATCATTAGC  1259
348
AATATCAGTTACACAGCCCACCACCTGCGGACGCTGACCAGCAATCTAAATGAAGTCAGG  1319
368
   
   
   
                                         
    
    
                                       
    
   
AspAspPheAlaGluGlu
GluGluValGlnSerPheGlyTyrLysArgPhe
• PCR 3
   299
   359
   
   
   
GlyIleGlnGluGlyThrGlnCysThr
LysCysLysAsnAsnTrpAlaLeuLysPheSerIleIleLeuLeuTyrIleLeuCysAla
LeuLeuThrIleThrValAlaIleLeuGlyTyrLys
 Extracellular domain (N-terminal section) cloning –
ValValGluLysMetAspAsnVal
ThrGlyGlyMetGluThrSerArgGlnThrTyrAspAspLysLeuThrAlaValGluSer    
AspLeuLysLysLeuGlyAspGlnThrGlyLysLysAlaIleSerThrAsnSerGluLeu
SerThrPheArgSerAspIleLeuAspLeuArgGlnGlnLeuArgGluIlrThrGluLys   
ThrSerLysAsnLysAspTheLeuGluLysLeuGlnAlaSerGlyAspAlaLeuValAsp   
ArgGlnSerGlnLeuLysGluThrLeuGluAsnAsnSerPheLeuIleThrThrValAsn   
LysThrLeuGlnAlaTyrAsnGlyTyrValThrAsnLeuGlnGlnAspThrSerValLeu   
GlnGlyAsnLeuGlnAsnGlnMetTyrSerHisAsnValValIleMetAsnLeuAsnAsn   
LeuAsnLeuThrGlnValGlnGlnArgAsnLeuIleThrAsnLeuGlnArgSerValAsp   
AspThrSerGlnAlaIleGlnArgIleLysAsnAspPheGlnAsnLeuGlnGlnValPhe   
LeuGlnAlaLysLysAspThrAspTrpLeuLysGluLysValGlnSerLeuGlnThrLeu   
AlaAlaAsnAsnSerAlaLeuAlaLysAlaAsnAsnAspThrLeuGluAspMetAsnSer   
GlnLeuAsnSerPheThrGlyGlnMetGluAsnIleThrThrIleSerGlnAlaAsnGlu   
GlnAsnLeuLysAspLeuGlnAspLeuHisLysAspAlaGluAsnArgThrAlaIleLys   
PheAsnGlnLeuGluGluArgPheGlnLeuPheGlyThrAspIleValAsnIleIleSer   
AsnIleSerTyrThrAlaHisHisLeuArgThrLeuThrSerAsnLeuAsnGluValArg   
Full-length receptor (C-terminal section) cloning 
 BspHI
TCATGA
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Figure 2.2: SRCL cDNA sequence showing positions of primers
Primers labelled PCR were used to screen cDNA preparations from tissues and cells for the 
presence of SRCL cDNA.
               
   
   
                                              
ACCACTTGCACAGATACCCTTACCAAACACACAGATGATCTGACCTCCTTGAATAATACC  1379
388
CTGGCCAACATCCGTTTGGATTCTGTTTCTCTCAGGATGCAACAAGATTTGATGAGGTCG  1439
408
                                                                                                                                        
AGGTTAGACACTGAAGTAGCCAACTTATCAGTGATTATGGAAGAAATGAAGCTA   1499
428
TCCAAGCATGGTCAGCTCATCAAGAATTTTACAATACTACAAGGTCCACCGGGCCCCAGG 1599
448
GGTCCAAGAGGTGACAGAGGATCCCAGGGACCCCCTGGCCCAACTGGCAACAAGGGACAG 1619
468
AAAGGAGAGAAGGGGGAGCCTGGACCACCTGGCCCTGCGGGTGAGAGAGGCCCAATTGGA 1679
488
CCAGCTGGTCCCCCCGGAGAGCGTGGCGGCAAAGGATCTAAAGGCTCCCAGGGCCCCAAA 1739
508
GGCTCCCGTGGTTCCCCTGGGAAGCCCGGCCCTCAGGGCTCCAGTGGGGACCCAGGCCCC 1799
528
CCGGGCCCACCAGGCAAAGAGGGACTCCCCGGCCCTCAGGGCCCTCCTGGCTTCCAGGGA 1859
548
CTTCAGGGCACCGTTGGGGAGCCTGGGGTGCCTGGACCTCGGGGACTGCCAGGCTTGCCT 1919
568
GGGGTACCAGGCATGCCAGGCCCCAAGGGCCCCCCCGGCCCTCCTGGCCCATCAGGAGCG 1979
588
                                                                                                       
    
GTGGTGCCCCTGGCCCTGCAGAATGAGCCAACCCCAGCACCGGAGGACAATGGCTGCCCG 2039
608
CCTCACTGGAAGAACTTCACAGACAAATGCTACTATTTTTCAGTTGAGAAAGAAATTTTT  2099
628
GAGGATGCAAAGCTTTTCTGTGAAGACAAGTCTTCACATCTTGTTTTCATAAACACTAGA  2259
648
GAGGAACAGCAATGGATAAAAAAACAGATGGTAGGGAGAGAGAGCCACTGGATCGGCCTC  2219
668
ACAGACTCAGAGCGTGAAAATGAATGGAAGTGGCTGGATGGGACATCTCCAGACTACAAA  2279
688
AATTGGAAAGCTGGACAGCCGGATAACTGGGGTCATGGCCATGGGCCAGGAGAAGACTGT  2339
708
GCTGGGTTGATTTATGCTGGGCAGTGGAACGATTTCCAATGTGAAGACGTCAATAACTTC  2399
728
                            
ATTTGCGAAAAAGACAGGGAGACAGTACTGTCATCTGCATTATAACGGACTGTGATGGGA  2459
742
TCACATGAGCAAATTTTCAGCTCTCAAAGGCAAAGGACACTCCTTTCTAATTGCATCACC  2519
ThrThrCysThrAspThrLeuThrLysHisThrAspAspLeuThrSerLeuAsnAsnThr   
LeuAlaAsnIleArgLeuAspSerValSerLeuArgMetGlnGlnAspLeuMetArgSer   
ArgLeuAspThrGluValAlaAsnLeuSerValIleMetGluGluMetLysLeuValAsp   
• Extracellular domain (N-terminal section) cloning
SerLysHisGlyGlnLeuIleLysAsnPheThrIleLeuGln
AccI
GTAGAC
• Full-length receptor (N-terminal section) cloning
                              
                             • Full-length receptor (C-terminal section) cloning
 
 
 
 
 
 
 
 
GlyProProGlyProArg
GlyProArgGlyAspArgGlySerGlnGlyProProGlyProThrGlyAsnLysGluGln   
LysGlyGluLysGlyGluProGlyProProGlyProAlaGlyGluArgGlyProIleGly   
ProAlaGlyProProGlyGluArgGlyGlyLysGlySerLysGlySerGlnGlyProLys   
GlySerArgHlySerProGlyLysProGlyProGlnGlySerSerGlyAspProGlyPro   
ProGlyProProGlyLysGluGlyLeuProGlyProGlnGlyProProGlyPheGlnGly   
LeuGlnGlyThrValGlyGluProGlyValProGlyProArgGlyLeuProGlyLeuPro   
GlyValProGlyMetProGlyProLysGlyProProGlyProProGlyProSerGlyAla   
ValValProLeuAlaLeuGlnAsnGluProThrProAlaProGluAspAsn
CRD cloning 
GlyCysPro
ProHisTrpLysAsnPheThrAspLysCysTyrTyrPheSerValGluLysGluIlePhe   
GluAspAlaLysLeuPheCysGluAspLysSerSerHisLeuValPheIleAsnThrArg   
GluGluGlnGlnTryIleLysLysGlnMetValGlyArgGluSerHisTryIleGlyLeu   
ThrAspSerGluArgGluAsnGluTryLysTrpLeuAspGlyThrSerProAspTyrLys   
AsnTrpLysAlaGlyGlnProAspAsnTryGlyHisGlyHisGlyProGlyGluAspCys   
AlaGlyLeuIleTyrAlaGlyGlnTryAsnAspPheGlnCysGluAspValAsnAsnPhe   
• CRD cloning
IleCysGluLysAspArgGluThrValLeuSerSerAlaLeu                     
–
     PCR 2                                                                                PCR 1 
  • PCR 1
                       •PCR 2
– –
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...AATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTAGCGCAGGCCGGCCGA... 
    
FseI
 MetLysLysThrAlaIleAlaIleAlaValAlaLeuAlaGlyPheAlaThrValAlaGlnA    la
Expression vector containing ompA signal sequence
Cloning vector containing cDNA encoding the CRD of SRCL
     
...GGCCGGCCGAGGACAAT ...
           
FseI
GGCTGCCCG
GluAspAsnGlyCysPro...
                                                                 
...AATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTAGCGCAGGCCGGCCGAGGACAAT...
    
FseI
MetLysLysThrAlaIleAlaIleAlaValAlaLeuAlaGlyPheAlaThrValAlaGlnA    laGluAspAsn...
...AATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTAGCGCAGGCCGAGGACAAT...
    MetLysLysThrAlaIleAlaIleAlaValAlaLeuAlaGlyPheAlaThrValAlaGlnAlaGluAspAsn...
ompA signal sequence SRCL CRD
Figure 2.3: Expression of the CRD of SRCL using the ompA signal sequence
The N-terminal methionine residue is boxed.  Further details are given in the text and in 
Figures 2.1 and 2.2.
SRCL CRD cDNA ligated into expression vector
Plasmid cut with FseI and 3’ overhangs removed
Plasmid re-ligated to create correct reading frame
Interruption in reading frame
SRCL CRD
SRCL CRD cDNA fused in-frame
with signal sequence
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isopropyl β-D-1-thiogalactopyranoside (IPTG) and 100 mM CaCl2 and grown overnight at 
30°C.  Cells were harvested by centrifugation at 3,500 rpm for 10 min in a Beckman 
JLA8.1000 rotor.  The cell pellet was resuspended in 25 mL of cold 10 mM Tris, pH 7.8 
and spun at 10,000 rpm for 10 min in a Beckman JA20 rotor.  The pellet was resuspended 
in 25 mL of loading buffer and sonicated with a Branson sonifier to lyse cells and release 
the protein, which is located in the periplasm in the correctly folded state.  Cell debris was 
removed by centrifugation of the lysate at 10,000 rpm for 15 min in a Beckman JA20 rotor 
and re-centrifugation of the supernatant at 35,000 rpm for 1 h in a Beckman 55.2Ti rotor.  
The supernatant was loaded on to a 10-mL column of galactose-Sepharose prepared by 
the divinyl sulfone method (Fornstedt and Porath, 1975).  The column was washed with 
10 x 2 mL aliquots of loading buffer followed by 10 x 2 mL aliquots of eluting buffer. 
 
Cloning and expression of full-length SRCL 
Full-length SRCL was cloned in two sections, which were joined at an AccI site (Figure 
2.2).  Generation of an expression plasmid for full-length SRCL and transfection of this 
plasmid into Rat-6 fibroblasts was performed by P. Coombs (Coombs et al., 2005).  The 
SRCL cDNA was inserted into the retroviral expression vector pVcos (Maddon et al., 
1985).  The neomycin resistance gene, under the control of the herpes virus thymidine 
kinase promoter, was inserted into this vector (Southern and Berg, 1982).  The plasmid 
was transfected into ΨCre packaging cells (Danos and Mulligan, 1988) by the calcium 
phosphate method (Wigler et al., 1979) to produce a virus that was used to infect Rat-6 
fibroblasts.  Fibroblasts were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum, and cells stably expressing SRCL were 
selected using 400 μg/L G418.  Following selection cells were maintained in medium 
containing 100 μg/L G418.  Fibroblasts were also transfected with the same vector 
containing the neomycin resistance gene but no SRCL cDNA, to serve as a control. 
 
Cloning and expression of the extracellular domain of SRCL 
A cDNA encoding a soluble fragment of SRCL including the entire extracellular domain of 
the protein (Figure 2.1) was generated by amplifying the N-terminal region of the 
extracellular domain and ligating this region to the full-length clone of SRCL at a BspHI 
site (Figure 2.2).  It is necessary to express this fragment of SRCL in mammalian cells to 
ensure correct post-translational hydroxylation and glycosylation of the neck region in the 
secretory pathway.  The cDNA for the extracellular domain of SRCL was fused to the dog 
preproinsulin signal sequence to direct secretion of the fragment and this cDNA 
transferred to the vector pED between the adenovirus major late promoter and the 
dihydrofolate reductase gene (Kaufman et al., 1991).  Transfection of DXB11 Chinese 
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hamster ovary (CHO) cells with this vector using the calcium phosphate method was 
performed by P. Coombs (Coombs et al., 2005).  Cells were grown in minimal essential 
medium (MEM)-α medium without nucleosides supplemented with 10% dialysed fetal 
bovine serum.  To amplify protein expression, methotrexate was added to the medium at 
increasing concentration over several weeks up to a final level of 0.5 μM, at which level 
the cells were maintained.  For purification of protein, four harvests of tissue culture 
supernatant (45 mL each) were made on alternate days from confluent cells in 225 cm2 
flasks.  Medium (180 mL) was adjusted to loading buffer composition, and spun at 10,000 
rpm for 15 min in a Beckman JA14 rotor.  Galactose-Sepharose chromatography was 
performed as described for the CRD of SRCL.  Fractions containing protein were dialysed 
extensively against water and lyophilized.  The secreted extracellular domain of SRCL has 
been determined to be trimeric by equilibrium sedimentation analytical ultracentrifugation 
(Coombs et al., 2005).  
 
PCR-based detection of SRCL expression 
The following primers were used in 35 cycles of PCR to amplify regions of the cDNA of 
SRCL (Figure 2.2).  
 
Primer pair 1 (CRD of SRCL, 423 base pairs) 
GAGGACAATAGCTGCCCGCCTCACTGGAAG  (forward) 
TTATAATGCAGATGACAGTCATGTCTCCCTGTC  (reverse)  
 
Primer pair 2 (CRD of SRCL, 492 base pairs) 
GTGCCCCTGGCCCTGCAGAATGAGCCAACC  (forward) 
AATTTGCTCATGTGATCCCATCACAGTCCG   (reverse) 
 
Primer pair 3 (N-terminal region of SRCL, 642 base pairs) 
CCCCACGGTCACCATGAAAGACGACTTCGCAG  (forward) 
CAGGTTCAGGTTGTTGAGGTTCATGATGACCAC (reverse) 
 
PCR Ready First Strand cDNAs for a range of tissues and for common cell lines were 
obtained from Biochain.  First strand cDNA from cultured human umbilical vein endothelial 
cells was purchased from ScienCell.  PCR was performed using the Advantage 2 
Polymerase kit (TaKaRa).  The final reaction volume was 10 μL, containing 1 μL of 10x 
polymerase buffer, 0.2 μL of deoxyribonucleotide triphosphate solution (final concentration 
200 μM), 0.2 μl of each 10 μM primer solution (final concentration 0.2 μM), and 0.2 μL of 
polymerase.  Reactions typically contained 0.2 μL of first-strand cDNA preparation but the 
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volume was adjusted to normalize amounts of cDNA between different preparations.  After 
initial incubation at 95°C for 1 min, 25-35 cycles of 30 s at 95°C and 1 min at 65°C were 
performed.  PCR products were resolved on 1.5% or 2% agarose gels containing SYBR® 
Safe DNA gel stain (Invitrogen) for DNA visualization under ultraviolet light. 
Measures were taken to ensure validity of PCR results.  To ensure the integrity of 
cDNA preparations and provide an approximate normalization of cDNA levels between 
different cDNA preparations, a region of the cDNA of the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified from all samples in 
parallel with amplification of glycan-binding protein cDNA.  Primers to amplify a 983 base 
pair region of GAPDH cDNA were obtained from BD Biosciences and were used in 25 
cycles of PCR.  To prevent contamination of reactions with plasmid DNA which could act 
as a template for DNA amplification, PCR experiments were conducted in a different 
laboratory where no molecular biology work was performed.  Dedicated pipettors, water 
baths and other equipment were kept in this laboratory and primers and other reagents 
were handled only in this laboratory.  Nucleic-acid free reaction tubes and nucleic-acid 
free pipette tips with filters were used.  Laboratory coats and gloves were worn and gloves 
changed regularly.  Control reactions in which cDNA or primers were omitted were run in 
parallel with test reactions.  Some reactions were performed using primers which anneal 
to the cDNA outside of the cloned region to eliminate the possibility of plasmid 
contamination acting as a template in PCR.   
 
Production of polyclonal antibodies to SRCL 
Bacterially-expressed CRD of SRCL (2 mg) was supplied to Eurogentec for production of 
rabbit polyclonal antibodies using an 87-day programme in which two rabbits were given 
four injections of antigen on days 0, 14, 28 and 56, and blood was collected on days 38, 
66 and 87.  Antibodies were validated by immunoblotting against purified CRD of SRCL 
and the second or final bleeds were used for affinity purification of antibodies.  An SRCL 
affinity column was prepared by covalently coupling purified CRD to Affigel-10 resin (Bio-
Rad).  Resin (2 mL) was washed thoroughly with water and incubated with 5 mg of CRD 
in 5 mL of 100 mM HEPES, pH 8.0, 150 mM NaCl, 50 mM CaCl2 in a Bio-Rad mini-
column for 4 h at 4°C with rotary agitation.  The column was drained and washed 
extensively with low-salt loading buffer.  The column was equilibrated with DPBS and a 
sample of immune serum (5 mL) was diluted with an equal volume of DPBS and 
circulated five times over the column.  The column was washed with 10 mL of DPBS 
followed by 10 mL of DPBS containing 0.5 M NaCl.  Antibodies were eluted using 0.5 mL 
fractions of 3 M potassium thiocyanate containing 0.5 M ammonium hydroxide.  Antibody 
elution was monitored by measurement of absorbance at 280 nm, and peak fractions 
66
Chapter 2 
were pooled and immediately dialysed against DPBS.  Antibody concentration was 
determined by comparison with rabbit IgG standards using the Bradford protein assay and 
SDS-polyacrylamide gel electrophoresis.  Affinity-purified antibodies were tested for 
activity by immunoblotting. 
 
Human umbilical vein endothelial cells 
Clonetics endothelial cell system components, including cryopreserved human umbilical 
vein endothelial cells (HUVECs) from pooled donors, culture medium, supplements and 
subculturing reagents, were obtained from Lonza.  HUVECs were cultured in Endothelial 
Basal Medium-2 supplemented with 2% fetal bovine serum, human epidermal growth 
factor, hydrocortisone, gentamicin, amphotericin-B, vascular endothelial growth factor, 
human fibroblast growth factor-B, insulin-like growth factor-1, ascorbic acid and heparin.  
Cells were seeded in 25 cm2 tissue culture flasks at 2500-5000 cells/cm2.  Medium was 
renewed every other day and cells were passaged when cultures reached 70-80% 
confluence using the reagents supplied.  To passage cells, the flask was washed with 
HEPES-buffered saline solution, and incubated for 2 min at room temperature with 2 mL 
of trypsin solution.  Trypsin neutralization solution (5 mL) was added, the cell suspension 
was aspirated, and cells were collected by centrifugation.  The cell pellet was 
resuspended in 5 mL of growth medium and cells dispensed into new flasks.  Experiments 
were performed using cells at passages 1-5 and were repeated at different passage 
numbers to confirm consistency of results. 
 
Immunofluorescence on cultured cells 
SRCL-transfected Rat-6 fibroblasts, control Rat-6 fibroblasts, and HUVECs were grown 
on untreated glass coverslips in normal growth medium.  Coverslips were washed with 
DPBS and fixed in ice-cold methanol for 5-10 min.  All incubations were performed at 
room temperature in a humidified chamber and dilution of reagents and washes were 
performed using PBS unless otherwise stated.  For standard immunofluorescence 
staining, cells were blocked for 30 min with 10% normal goat serum (Vector), incubated 
for 90 min with anti-SRCL antibodies or negative control rabbit IgG (Vector) at 10 μg/mL in 
2% normal goat serum, and incubated for 30 min with Alexa Fluor 488-labelled goat anti-
rabbit IgG (Invitrogen) at 10 μg/mL.  For immunofluorescence staining using tyramide 
signal amplification (TSA), the PerkinElmer TSA biotin kit was used.  Blocking and reagent 
dilution were performed using the supplied blocking reagent.  Rabbit antibodies to SRCL 
or CD31 (Abcam) or control rabbit IgG were used at 1 μg/mL.  Following removal of 
primary antibody and washing, cells were incubated for 30 min with horseradish 
peroxidase-conjugated goat anti-rabbit IgG (Vector) at 1 μg/mL followed by 10 min 
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incubation with biotinyl tyramide diluted 1:50 with the supplied amplification diluent.  
Detection was by 30-min incubation with Alexa Fluor 488-labelled streptavidin (Invitrogen) 
at 2 μg/ml.  In some experiments, cells were doubly stained with anti-SRCL antibodies 
and mouse anti-CD31 (clone JC70A, Dako) at 5 μg/mL.  The mouse antibody was 
detected using Alexa Fluor 594-labelled goat anti-mouse IgG (Invitrogen) at 5 μg/mL, 
applied at the same time as Alexa Fluor 488-labelled streptavidin.  Coverslips were 
mounted with VectaShield aqueous mounting medium containing 4’,6-diamidino-2-
phenylindole (DAPI) (Vector) and sealed. 
 
Binding of oligosaccharide-derivatized polymers to cells 
The multivalent biotinylated polymers Galβ1-4GlcNAcβ-PAA-biotin (N-acetyllactosamine) 
and Galβ1-4(Fucα1-3)GlcNAcβ-PAA-biotin (Lewisx) were purchased from GlycoTech, 
resuspended at 1 mg/mL in 10 mM Tris, pH 7.8, 50% glycerol and stored at -20°C.  
Biotinylated polymers (10 μg) were incubated with 100 μg Alexa Fluor 488-labelled 
streptavidin (Invitrogen) for 30 min at room temperature in a total volume of 80 μl.  The 
mixture was incubated for a further 30 min with 20 μl of 1 mg/mL biotin, then diluted 10-
fold into HEPES-buffered tissue culture medium for application to HUVECs or SRCL-
transfected fibroblasts on coverslips for 60 min.  Coverslips were washed in DPBS and 
fixed for 15 min with 4% paraformaldehyde.  For visualization of SRCL, cells were blocked 
for 30 min with 10% normal goat serum in PBS, and incubated for 60 min with affinity-
purified antibodies to SRCL or control IgG at 5 μg/mL, and 30 min with Alexa Fluor 594-
labelled goat anti-rabbit IgG at 5 μg/mL.  Polymer binding was visualized directly using the 
fluorescence of the labelled streptavidin, or by multi-layer detection using sequential 
application for 30 min each of fluorescein-labelled anti-streptavidin (Vector), rabbit anti-
fluorescein (Abcam), and Alexa Fluor 488-labelled goat anti-rabbit IgG (Invitrogen), all at 1 
μg/mL in 10% normal goat serum in PBS.  Coverslips were mounted with Vectashield 
aqueous mounting medium containing DAPI (Vector) and sealed.   
 
Immunofluorescence on tissue sections 
Serial sets of tissue array slides of formalin-fixed, paraffin-embedded human normal 
organs were purchased from SuperBioChips.  Slides were dried for 1 h in a 60°C oven, 
deparaffinized in five changes of xylene, and rehydrated through a graded ethanol series 
before immersion in water.  Heat-mediated antigen retrieval was performed by incubating 
slides at 95-99°C for 20 min in antigen unmasking solution from Vector (7.5 mL of 
concentrate diluted in 800 mL).  Staining was performed using the TSA-biotin system as 
described for staining of cultured cells, except that a 15-min incubation with 3% hydrogen 
peroxide in PBS was included prior to blocking to quench endogenous peroxidase activity.  
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A panel of frozen human tissue sections including eight major organs was obtained from 
Biochain.  Slides were warmed to room temperature and stained using the TSA biotin 
system as described for staining of cultured cells. 
 
Microscopy 
Images were collected using a Nikon Eclipse E400 microscope with 10x, 20x, 40x and 
100x (oil immersion) objectives and a DXM1200 digital camera.  For visualization of DAPI, 
excitation was at 330-380 nm, with a 400 nm dichroic mirror and long-pass barrier filter at 
420 nm.  For visualization of Alexa Fluor 488, excitation was at 450-490 nm with 505 nm 
dichroic mirror and long-pass barrier filter at 520 nm.  For visualization of Alexa Fluor 594, 
excitation was at 510-560 nm, with a 575 nm dichroic mirror and 590 nm long-pass barrier 
filter.  Images from each of the three colour channels were aquired as 8-bit grayscale TIFF 
files with software package Lucia GF version 4.60.  Images were converted to 24-bit RGB 
colour, re-coloured to represent the relevant fluorophore, and merged using Corel 
PhotoPaint 12.  In some images of stained tissues, the brightness, contrast or intensity 
were adjusted digitally, with the same adjustment being applied to the whole image and to 
any additional images in the set, including controls.  For each set of images, the exposure 
time in a given colour channel was the same for all images. 
 
Immunoblotting of endothelial cell lines 
EAhy926 cells were grown in DMEM supplemented with 10% fetal bovine serum and 2 
mM L-glutamine.  HMEC-1 cells were grown in MCDB 131 medium supplemented with 
10% fetal bovine serum, 10 ng/mL epidermal growth factor (Sigma), and 1 µg/mL 
hydrocortisone (Sigma).  Each cell line was passaged weekly at a 1:10-1:20 dilution using 
trypsin/EDTA.  Confluent cell cultures were maintained for at least two days before 
analysis to ensure maximal expression of endothelial-specific proteins.  Some cells were 
treated with tumour necrosis factor (TNF)-α (Sigma) at 20 ng/mL for 24 h.  Cells were 
washed with DPBS and harvested with non-enzymatic cell dissociation solution (Sigma) or 
by scraping, and collected by centrifugation.   
Cell pellets were boiled in sample buffer and proteins were resolved by SDS-
polyacrylamide gel electrophoresis and electroblotted on to Protran nitrocellulose 
membranes (Whatman) (Burnette, 1981).  Subsequent incubations and washes were 
carried out at room temperature on a rotary shaker.  The membrane was blocked for 30 
min with 5% BSA in TBS and incubated for 90 min with rabbit polyclonal antibodies to the 
CRD of human SRCL at a dilution of 1:500 in the same solution.  Blots were washed twice 
for 5 min each with TBS and incubated for 1 h with protein A-alkaline phosphatase 
(Calbiochem) diluted 1:5000 in 5% BSA in TBS.  Blots were washed four times for 5 min 
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each with TBS, followed by visualization with phosphatase substrate BCIP/NBT 
(Calbiochem). 
 
2.3 Results 
2.3.1 Detection of SRCL expression in a broad range of tissues 
A survey of SRCL mRNA expression was performed by screening of a panel of human 
tissue cDNA preparations with primers designed to amplify regions of SRCL cDNA.  Using 
primers flanking the portion of the cDNA encoding the CRD, a PCR product of the 
expected size was evident in all tissue cDNAs tested (Figure 2.4).  Tissues showing a 
high level of SRCL cDNA include the intestine, lung, lymph node and pancreas, while 
expression was lowest in liver, kidney, spleen and peripheral blood leukocytes.  In other 
experiments, very similar levels of PCR product were produced from these cDNA 
preparations using the primers flanking the portion of the cDNA encoding the CRD and 
using primers which amplify a region of the cDNA corresponding to the N-terminal region 
of the protein, suggesting that full-length transcript is produced in all tissues tested (data 
not shown).  The broad tissue distribution of SRCL mRNA expression is consistent with 
previous reports (Nakamura et al., 2001a; Ohtani et al., 2001), and is also in contrast to 
many other C-type lectins which show restricted tissue distribution.  In particular, many 
other C-type lectins are expressed predominantly in the liver or in cells of the immune 
system (Spiess, 1990; Cambi and Figdor, 2003; Liu et al., 2004), so the low level of SRCL 
expression in liver, spleen and leukocytes compared to other tissues is unusual. 
The presence of SRCL mRNA in such a broad range of tissues suggests that the 
receptor may be expressed either in a wide range of cell types, or in a small number of 
cell types which are common to many tissues, such as epithelial cells, endothelial cells, 
fibroblasts or myeloid cells.  To investigate how widespread SRCL expression might be at 
the cellular level, a panel of cDNAs from common human cell lines was examined for 
SRCL expression (Figure 2.5).  PCR products were produced using SRCL-specific 
primers with cDNA preparations from the Jurkat (acute T cell leukemia) and MCF7 (ductal 
carcinoma) cell lines.  The relative abundances of the products from different primer pairs 
with Jurkat cell cDNA are similar to those with cDNA from a whole organ (placenta), but 
the products are present at a much lower level, suggesting that full-length SRCL may be 
expressed at a low level in Jurkat cells, and potentially therefore in some populations of 
lymphocytes.  These results are consistent with the expression of SRCL detected in 
peripheral blood leukocytes (Figure 2.4).   
The relative abundances of the products from different primer pairs with MCF7 
cDNA are different from those obtained with placental cDNA, and indicate that the portion 
of the cDNA encoding the N-terminal region of the protein is expressed at a lower level 
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Figure 2.4: PCR screening of human tissue cDNAs for SRCL expression
SRCL cDNA was amplified using PCR primer pair 2 (Figure 2.2).  A portion of the cDNA for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified in order to verify the 
integrity of the cDNA preparations and provide an approximate normalization of cDNA levels 
between samples.
Primers
cDNA
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Figure 2.5: PCR screening of human cell line cDNAs for SRCL expression
Placenta cDNA was included as a positive control for SRCL cDNA amplification.
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than the portion encoding the CRD.  Aberrant transcription or splicing might therefore be 
producing incomplete SRCL transcripts in MCF7 cells.  The other epithelial cell lines HeLa 
(adenocarcinoma) and A431 (squamous cell carcinoma) were negative in this analysis, 
indicating that SRCL is probably absent from epithelial cells in general.   
 
2.3.2 Immunofluorescence detection of SRCL expression in human umbilical vein 
endothelial cells 
The absence of SRCL expression in epithelial cell lines indicates that SRCL expression is 
not ubiquitous at the cellular level.  The wide tissue distribution of SRCL mRNA 
expression may therefore result from gene expression in a limited number of cell types 
which are nonetheless broadly distributed in the body.  This view is consistent with reports 
that SRCL is expressed in endothelial cells (Ohtani et al., 2001), including human 
umbilical vein endothelial cells (HUVECs), which are a commonly-used model endothelial 
cell system.  Using SRCL-specific primers, a PCR product was produced from HUVEC 
cDNA at a similar level to placental cDNA (Figure 2.6), confirming expression of SRCL in 
HUVECs.   
To confirm that SRCL protein as well as SRCL mRNA is present in HUVECs, 
cultured cells were stained with anti-SRCL antibodies.  Rabbit polyclonal antibodies to the 
CRD of SRCL were affinity purified from the immune serum using an affinity column of 
immobilized CRD, in order to enhance the specificity of the antibodies for SRCL.  To 
assess the efficacy of these antibodies in staining cultured cells, they were incubated with 
transfected Rat-6 fibroblasts stably expressing full-length SRCL and antibody binding was 
detected using a fluorescently-labelled secondary antibody (Figure 2.7).  The SRCL-
transfected cells exhibited strong staining, whereas untransfected cells showed no 
staining, demonstrating the efficacy and specificity of the antibodies in cell staining 
applications.   
HUVECs for staining with anti-SRCL antibodies were grown to form confluent 
monolayers so as to represent most closely the endothelium found in blood vessels and 
ensure maximal endothelial differentiation.  However, incubation of cultured HUVECs with 
anti-SRCL antibodies did not result in any staining of the cells, in contrast with the 
transfected fibroblasts stained in parallel (Figure 2.8).  The transfected cells are known to 
express a high level of SRCL, suggesting that the failure to detect SRCL in HUVECs 
might result from insufficient sensitivity in the staining procedure.  A more sensitive 
immunofluorescence staining protocol was introduced, in which additional amplification 
was achieved by use of a horseradish peroxidase-conjugated secondary antibody that 
covalently deposits biotin around the site of antibody binding when supplied with biotinyl 
tyramide substrate.  The deposited biotin is visualized using fluorescently-labelled 
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Figure 2.6: PCR detection of SRCL expression in HUVECs
HeLa cDNA was included as a cell line negative for SRCL expression.
SRCL
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Figure 2.7: Immunofluorescence detection of SRCL expression in transfected cells
Cells were stained with rabbit anti-SRCL antibodies followed by Alexa Fluor 488-labelled goat 
anti-rabbit IgG.  Control fibroblasts are cells transfected with an empty expression vector. 
Nuclei were stained with DAPI.  Scale bar is 100 μm.
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Figure 2.8:  Immunofluorescence detection of SRCL in HUVECs
Top: Antibody binding was detected using Alexa Fluor 488-labelled goat anti-rabbit IgG.  
Bottom: Antibody binding was detected using horseradish peroxidase-conjugated goat anti-
rabbit IgG with biotinyl tyramide reagent, followed by Alexa Fluor 488-labelled streptavidin.  
Staining of CD31 only at the cell junctions in endothelial cells demonstrates that specificity of 
antibody visualization is retained using signal amplification.  Control IgG is the whole IgG 
fraction purified from the serum of unimmunized rabbits and was used at the same 
concentration as the anti-SRCL antibodies.  Scale bars are 100 μm.
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streptavidin.  This procedure produced a substantial amplification of signal, as judged by 
staining of transfected fibroblasts with anti-SRCL.  To confirm the efficacy of this 
procedure in staining HUVECs, cells were stained with rabbit antibodies to CD31, an 
endothelial cell surface receptor which is largely concentrated at cell junctions (Woodfin et 
al., 2007).  Strong staining was observed at cell junctions of HUVECs using anti-CD31 
antibodies, while no staining was observed with antibodies from unimmunized rabbits, 
demonstrating the specific staining of proteins in HUVECs using the signal amplification 
procedure.  Staining of HUVECs using signal amplification revealed a low level of SRCL 
expression in these cells, consistent with the failure to detect SRCL staining by standard 
immunofluorescence detection. 
The SRCL staining observed in HUVECs is much fainter than in the transfected 
cells and also appears to be largely intracellular rather than at the cell surface.  To clarify 
the subcellular localization of SRCL, HUVECs were doubly stained with rabbit antibodies 
to SRCL and mouse antibody to CD31 (Figure 2.9).  In doubly-stained cells, CD31 is 
concentrated at cell contacts, while SRCL is distributed through the cell, suggesting that 
some protein is within cytoplasmic compartments as well as in the plasma membrane.  
HUVECs growing at low density were also stained with anti-SRCL antibodies for 
comparison with the confluent monolayers stained previously (Figure 2.9).  In contrast to 
the diffuse SRCL staining observed in confluent cells, cells growing at low density often 
exhibit more intense SRCL staining concentrated at one side of the cell.  This staining 
may represent the Golgi apparatus or a pool of cytoplasmic vesicles.  SRCL thus appears 
to be redistributed following the transition of the actively dividing and migrating cells found 
in low density cultures to the stable monolayers of non-dividing, more differentiated cells 
in confluent cultures.   
 
2.3.3 Detection of SRCL expression by ligand binding 
Examination of the binding of Lewisx-containing glycoconjugates was used as an 
alternative approach to identify SRCL protein expression in mammalian cells.  
Polyacrylamide molecules of 30 kDa derivatized at 20% of repeating units with Lewisx 
were used as a test ligand, while polyacrylamide molecules derivatized with N-
acetyllactosamine, which is identical to Lewisx except for the absence of fucose, were 
used as a control since terminal fucose is essential for recognition by SRCL (Coombs et 
al., 2005).  Both types of polyacrylamide molecule were also derivatized at 5% of 
repeating units with biotin, to enable polymer binding to be detected using fluorescently-
labelled streptavidin.  Application of free streptavidin to cells was found to result in non-
specific staining, probably due to binding to endogenous biotinylated proteins, therefore 
the polymers were pre-complexed with streptavidin prior to incubation with cells.  A 1:1 
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Figure 2.9: Subcellular localization of SRCL in HUVECs
Top: HUVEC and SRCL-transfected fibroblasts were doubly stained with mouse anti-CD31, 
detected with Alexa Fluor 594-labelled goat anti-mouse IgG, and rabbit anti-SRCL, detected 
using tyramide signal amplification, as described in Figure 2.8.  Bottom: HUVEC at different 
cell densities were stained with anti-SRCL antibodies.  Scale bars are 100 μm.
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molar ratio of streptavidin to biotin was used for complex formation in order to maintain 
solubility of complexes by minimizing cross-linking of polyacrylamide molecules, while 
maximizing the number of fluorophores associated with each molecule.  Unoccupied biotin 
binding sites in the streptavidin-polyacrylamide complexes were blocked by addition of a 
ten-fold molar excess of free biotin.   
Oligosaccharide-containing complexes were incubated with live SRCL-transfected 
fibroblasts for 1 hour, after which time association of Lewisx complexes with cells could 
readily be observed, whereas N-acetyllactosamine complexes were not bound (Figure 
2.10).  Furthermore, staining of cells with anti-SRCL antibody following incubation with 
complexes showed that the bound Lewisx-containing complexes were found exclusively in 
association with the SRCL-expressing cells.  Complexes were frequently observed in the 
perinuclear region, as well as in peripheral regions of the cell, suggesting that they may be 
internalized and trafficked in intracellular vesicles as a result of binding to SRCL.  The 
binding of Lewisx-containing complexes to cells therefore provides an alternative assay of 
SRCL expression independent of antibody recognition of SRCL. 
Incubation of Lewisx-containing complexes with HUVECs did not result in 
observable association of complexes with cells (Figure 2.11).  Binding of complexes to 
cells could still not be observed using a more sensitive method for detecting complexes 
involving sequential application of fluorescein-labelled anti-streptavidin, rabbit anti-
fluorescein and Alexa Fluor 488-labelled goat anti-rabbit IgG, which was estimated to 
achieve a 2-3 fold amplification of the fluorescence signal.  The failure to detect binding of 
oligosaccharide-containing complexes to HUVECs indicates that binding of these 
complexes does not provide a more sensitive assay of SRCL expression than 
visualization of SRCL molecules by antibody binding.  Reduced sensitivity is likely due to 
the inability to detect intracellular protein molecules: because the oligosaccharide 
complexes are applied to live cells, only cell surface expression of SRCL is detected, 
whereas antibodies were applied to fixed and permeabilized cells, enabling detection of 
intracellular protein.  The lack of binding of Lewisx-containing complexes to HUVECs is 
therefore consistent with the low level of surface expression apparent from staining of 
cells with anti-SRCL antibodies.  It is not unusual for only a relatively small fraction of the 
molecules in a recycling pool of endocytic receptors to be present on the cell surface at 
any one time (Spiess, 1990), which would appear to be the case for SRCL in HUVECs. 
The finding that SRCL mRNA is expressed at a reasonable level in HUVECs, but 
the protein is produced at low level and is mostly intracellular, is in agreement with one 
previous report, which failed to detect SRCL in HUVECs by flow cytometry with mouse 
monoclonal antibodies but detected it intracellularly by cell staining (Selman et al., 2008).  
Another report describes surface SRCL expression detected by flow cytometry using a 
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Figure 2.10: Binding of Lewis -containing complexes to SRCL-transfected fibroblasts
Top: Repeating unit composition of derivatized polyacrylamide molecules (molecular weight 
30 kDa) that were complexed with Alexa Fluor 488-labelled streptavidin to generate a reagent 
for detecting SRCL.  Bottom: SRCL-transfected fibroblasts were incubated with 
oligosaccharide-containing complexes.  SRCL was visualized by staining with affinity-
purified rabbit polyclonal antibodies to SRCL followed by Alexa Fluor 594-labelled goat anti-
rabbit IgG.  Scale bar is 50 μm.
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Figure 2.11: Assay for binding of Lewis -containing complexes to HUVECs
Cells were incubated with oligosaccharide-containing complexes as described in Figure 
2.10.  Complexes were detected using intrinsic fluorescence (top panel) or by multi-layer 
detection with fluorescein-labelled anti-streptavidin, rabbit anti-fluorescein and Alexa Fluor 
488-labelled goat anti-rabbit IgG (bottom panel).  Scale bar is 50 μm.
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chicken antibody to SRCL (Ohtani et al., 2001).  This antibody also detected SRCL in 
immunoblots of HUVEC extract.  However, SRCL could not be detected in immunoblots of 
HUVEC extract using our rabbit antibodies (Figure 2.12).  The difference in SRCL 
detection may be due to the antibodies used or to the HUVEC growth conditions.  
Immunoblotting with anti-SRCL antibodies was also undertaken with extracts from two 
commonly-used immortalized endothelial cell lines:  EaHy926, a macrovascular line 
derived from HUVECs, and HMEC-1, a microvascular line (Figure 2.12).  The failure to 
detect SRCL in these cell extracts is consistent with a report that these cell lines do not 
express SRCL mRNA (Selman et al., 2008).  The absence of SRCL expression in 
immortalized endothelial cell lines, compared with low levels of expression in cultured 
normal endothelial cells, suggests that SRCL expression may be lost from endothelial 
cells which are less well differentiated or are dividing.   
 
2.3.4 Immunofluorescence detection of SRCL in endothelial cells in human tissue 
sections  
Protein expression levels may be different between cells in culture and cells in their native 
environment, because the latter are influenced by cell adhesion and by soluble factors.  
Expression of SRCL in cultured HUVECs may therefore be different to expression in 
endothelial cells within the body.  To assess if SRCL is expressed in endothelial cells in 
tissues, and to identify any additional sites of SRCL expression, immunofluorescence 
staining of tissue sections was performed.  SRCL expression was examined using a 
tissue array, which included formalin-fixed, paraffin-embedded human tissue samples 
from a wide range of organs, and also using a panel of frozen tissue sections.  Better 
staining was observed using the frozen sections, but the paraffin sections provided a more 
comprehensive survey of SRCL expression due to the availability of a much larger 
selection of tissues.  As in the staining of cultured HUVECs, it was found that a detection 
method including tyramide signal amplification was required to visualize SRCL in tissue 
sections, indicating that SRCL is also expressed only at low levels in vivo.   
The expression of SRCL in macrovascular endothelial cells was examined using 
the tissue panels.  In frozen tissue sections, staining of muscular arteries with anti-SRCL 
antibodies was observed in tissues including skeletal muscle (Figures 2.13 and 2.14).  No 
staining was observed when the anti-SRCL antibodies were replaced with IgG from 
unimmunized rabbits, demonstrating that the antibodies stain tissues in a specific manner.  
Double-staining with antibodies to SRCL and the endothelial cell surface marker CD31 
showed that SRCL is present in the endothelial layer (Figure 2.13).  There is widespread 
overlap between SRCL and CD31 staining in the endothelial layer, suggesting that SRCL 
is expressed all over the cell surface.  SRCL is additionally found in the smooth muscle 
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Figure 2.12: Assessment of SRCL expression by cultured endothelial cells 
Extracts of endothelial cell lines (EAhy926 and HMEC-1), cultured HUVECs, and SRCL-
transfected fibroblasts were resolved by SDS-polyacrylamide gel electrophoresis, and 
stained with Coomassie blue (left hand lanes) or transferred to nitrocellulose and probed 
with rabbit polyclonal antibody to the CRD of SRCL (right hand lanes).  Endothelial cells 
were cultured with and without tumour necrosis factor (TNF)-α to assess the effect of 
endothelial cell activation on the expression of SRCL.
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Figure 2.13: Immunofluorescence detection of SRCL expression in a muscular artery 
A frozen section of skeletal muscle was doubly-stained as described in Figure 2.9.  Images 
show a longitudinal section through a muscular artery.  The nuclei of endothelial cells are 
indicated by arrows.  The tunica media (M) comprises smooth muscle cells, seen here in 
cross-section.  There is autofluorescence from the internal elastic lamina (IEL).  Scale bar is 
50 μm.
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Figure 2.14: Immunofluorescence detection of SRCL expression in muscular arteries
Top: Experimental details are as described in Figure 2.13.  A single endothelial cell is shown, 
belonging to the same vessel as that depicted in Figure 2.13.  Scale bar is 10 μm.  Bottom: A 
paraffin section of salivary gland was stained as described in Figure 2.8.  The images show a 
longitudinal section through a muscular artery.  Scale bar is 50 μm.  Arrows indicate the 
surface of endothelial cells over the nuclear region.  The tunica media is labelled (M).  
SRCL CD31
DAPI Merge
M
SRCL + DAPI control IgG + DAPI
MM
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cells of the tunica media, which are not stained by anti-CD31.  At higher magnification, the 
co-localization of SRCL and CD31 in the endothelial cell plasma membrane is evident 
(Figure 2.14), indicating that SRCL molecules are present in the cell membrane and 
project from the surface of the endothelial cell.  The flattened nature of endothelial cells 
makes it difficult to discern if SRCL is also present in intracellular compartments, as might 
be expected for an endocytic receptor.  SRCL staining in the smooth muscle cells of the 
tunica media appears to include both the cell surface and the cytoplasm.  Staining of both 
endothelial cells and tunica media smooth muscle cells in muscular arteries was also 
observed in paraffin tissue sections, such as in salivary gland (Figure 2.14), indicating that 
the staining pattern is not significantly altered by different tissue fixation and processing 
methods. 
Veins of the macrovasculature exhibited more varied staining levels than arteries.  
Staining of a medium vein in skeletal muscle shows a similar pattern of SRCL expression 
to staining of arteries, however there is less extensive co-localization of SRCL and CD31 
(Figure 2.15), suggesting that SRCL expression may be lower and less evenly distributed 
in vein endothelial cells compared to artery endothelial cells.  At higher magnification it is 
evident that SRCL and CD31 do not extensively co-localize in the plasma membrane as 
was observed in the arterial section.  However staining for SRCL in the smooth muscle 
cells of the tunica media remains, and is particularly prominent in the sub-endothelial layer 
that is apposed to the endothelial cell.  Veins in the lung show a similar staining pattern, 
with SRCL expression found in the sub-endothelial layer rather than in endothelial cells 
themselves, or potentially concentrated on the face of the endothelial cell that faces the 
tissues rather than the vessel lumen (Figure 2.16). 
Veins in some other tissues do exhibit clear endothelial staining with anti-SRCL 
antibodies.  In a placental vein, staining was observed in cells which have the 
characteristic appearance of endothelial cells, being flattened with nuclei bulging into the 
lumen (Figure 2.17).  Comparable vessels in other tissues exhibited similar staining (data 
not shown).  Staining of HUVECs within umbilical cord tissue was also observed and was 
stronger than in cultured HUVECs (Figure 2.17), suggesting that SRCL expression is 
diminished in endothelial cells cultured outside of the normal tissue environment.  Staining 
of HUVECs appeared to be concentrated round the nuclear region rather than forming a 
continuous ribbon of staining as seen in other images, which may indicate an intracellular 
population of SRCL molecules, but this appearance may be due to contraction of the 
vessel lumen compressing endothelial cells prior to tissue sectioning.  From the limited 
number of veins visible in the tissue array, it is not possible to state conclusively which 
vessels have endothelial SRCL expression and which do not, but it is possible that in 
veins with a more developed tunica media, SRCL is expressed less in the endothelium 
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Figure 2.15: Immunofluorescence detection of SRCL expression in a medium vein
A frozen section of skeletal muscle was doubly-stained as described in Figure 2.9.  Top: An 
oblique section through a medium vein is shown.  Areas of endothelial cell surface are 
indicated by arrows and the tunica media is labelled (M). Scale bar is 50 μm.  Bottom: A single 
endothelial cell belonging to the same vessel as the top image is shown.  The plasma 
membrane over the nuclear region is indicated with an arrow and the tunica media is labelled 
(M).   Scale bar is 10 μm.
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Figure 2.16: Immunofluorescence detection of SRCL expression in veins
A frozen section of lung was stained as described in Figure 2.9.  Sections through two veins 
are shown.  The endothelium is indicated by arrows.  Autofluorescent reticular and elastic 
fibres in the vessel wall appear white in the merged image.  Scale bar is 20 μm.
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Figure 2.17: Immunofluorescence detection of SRCL expression in veins
Paraffin tissue sections were stained as described in Figure 2.8.  The endothelium is 
indicated by arrows.  Erythrocytes appear pale green-blue.  Scale bar is 100 μm.
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and more in the smooth muscle cells, particularly those in the sub-endothelial layer.  
SRCL may perform the same function in both of these cell types, with responsibility for 
SRCL expression merely shifted from one component of the blood vessel wall to another. 
 
2.3.5 Expression of SRCL in capillary endothelial cells 
Examination of vessels of the microvasculature revealed that SRCL is expressed in 
venules, such as in seminal vesicle (Figure 2.18).  This tissue section also shows staining 
of smooth muscle cells, indicating that, in addition to smooth muscle cells of blood 
vessels, SRCL may be expressed in smooth muscle cells more generally.  SRCL staining 
was observed in the thin endothelium of post-capillary venules such as in lung (Figure 
2.18), which are thought of as key sites of leukocyte extravasation, supporting a role for 
SRCL in mediating leukocyte adhesion.  SRCL expression is low or absent in endothelia 
of both venules and arterioles of the digestive tract submucosa, as exemplified by the 
rectal submucosa (Figure 2.18).  However, staining for SRCL was observed in the 
capillaries of the digestive submucosa, such as in the colon (Figure 2.20).  This variation 
in staining suggests that SRCL expression is regulated in accordance with both tissue 
type and vessel type.  Staining for SRCL was observed in the endothelial cells of small 
arterioles such as those of placenta and bladder (Figure 2.19), and in capillary endothelial 
cells in other tissues such as placenta and skeletal muscle (Figures 2.19 and 2.20).   
Staining for SRCL was generally absent from sinusoid and fenestrated capillaries, 
in which the endothelial cells have perforations, with the exception of sinusoidal 
endothelial cells of the placenta (Figure 2.19).  Sinusoidal capillaries are wide, irregularly-
shaped capillaries with discontinuous endothelia and basal laminae, specialized for 
extensive exchange of materials, including whole cells, between blood and tissue (Farr et 
al., 1980; Sasse et al., 1992).  SRCL expression was absent from liver sinusoidal 
endothelial cells, and from liver in general (data not shown), consistent with the low level 
of SRCL expression detected by PCR (Figure 2.4).  The lack of SRCL expression in liver 
sinusoidal endothelial cells is in contrast to the expression patterns of C-type lectins such 
as the mannose receptor and LSECtin, which are located only in these specialized 
endothelia (Stang et al., 1990; Liu et al., 2004).  The absence of SRCL expression from 
liver endothelial cells suggests that SRCL function is not required in permeable 
discontinuous endothelia, or that SRCL expression may be undesirable in certain organs, 
for instance due to the local immunosuppressive environment of the liver (Knolle and 
Gerken, 2000). 
Sinusoids are also found in spleen, which showed similarly low levels of SRCL 
expression to liver by PCR (Figure 2.4).  Staining of spleen sections with anti-SRCL 
antibodies did however reveal sites of antibody binding (Figure 2.21).  The SRCL staining 
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Figure 2.18: Immunofluorescence detection of SRCL expression in venules
Paraffin tissue sections were stained as described in Figure 2.8.  The endothelium is 
indicated by arrows and smooth muscle is labelled (M).  Erythrocytes appear pale green-
blue.  Scale bars are 100 μm (top and centre) and 50 μm (bottom).  
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Figure 2.19: Immunofluorescence detection of SRCL expression in microvasculature
Paraffin tissue sections were stained as described in Figure 2.8.  Endothelial cells are 
indicated by arrows.  The vessels shown are capillaries (C), sinusoids (S) and arterioles (A). 
The trophoblast layer is also indicated (T).   Erythrocytes appear pale green-blue.  Scale bars 
are 50 μm.
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Figure 2.20: Immunofluorescence detection of SRCL expression in capillaries
Paraffin tissue sections were stained as described in Figure 2.8.  Erythrocytes appear pale 
green-blue.  Scale bars are 50 μm.
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Figure 2.21: Immunofluorescence detection of SRCL expression in lymphoid tissues
Paraffin tissue sections were stained as described in Figure 2.8.  Scale bars are 100 μm.
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formed a network through the red pulp of the spleen, being excluded from the white pulp, 
consistent with staining of splenic venous sinusoids.  However the staining did not have 
the appearance of endothelial staining observed in other tissues and was somewhat 
fibrillar in nature.  This staining may result from binding of antibodies to reticular fibres 
which uniquely encircle splenic sinusoidal vessels (Miyata et al., 1993).  Accordingly, in 
other lymphoid tissues, such as lymph node, staining was observed only in endothelial 
cells in continuous microvessels (Figure 2.21).  The prominent staining of the ciliated 
apical surface of the pseudostratified epithelia of bronchus and fallopian tube observed 
with anti-SRCL antibodies (data not shown) may be due to antibody binding to similar 
fibrous structural proteins as in spleen. 
 
2.3.6 Expression of SRCL in non-endothelial cell types 
Expression of SRCL was also detected in non-endothelial cells in tissue sections.  In 
addition to the expression in smooth muscle cells described above, strong staining for 
SRCL was observed in certain cells of kidney glomeruli (Figure 2.22).  The staining 
pattern was different from that observed with anti-CD31 antibodies (data not shown), 
indicating that the SRCL-expressing cells are not the fenestrated endothelial cells of the 
glomerulus, which is consistent with the absence of SRCL in other discontinuous 
endothelial described above.  The morphology and localization of the stained glomerular 
cells suggests that they are podocytes, which envelop the glomerulus and extend fine 
processes that embrace the glomerular capillaries.  Thus in kidney the function of SRCL 
may have been transferred from the permeable endothelial cells to the podocytes which 
surround them and which are exposed to the fluid filtered out of the bloodstream.  The 
expression of the endocytic C-type lectin DC-SIGN in podocytes (Mikulak et al., 2010) 
suggests that podocytes may express multiple receptors for internalization of 
glycoconjugates that are lost from the circulation through the glomerulus.  Kidney is also 
rich in unsialylated glycans with Lewisx groups (Comelli et al., 2006), suggesting a role for 
SRCL in cell-cell interactions. 
In a section of the basal layer of the endometrium, SRCL staining was observed in 
the simple columnar epithelium which lines the uterine glands, as well as in the 
endothelial cells of small arteries and associated smooth muscle cells (Figure 2.22).  
Epithelial cells in general were not stained, suggesting that SRCL expression may be 
connected to the unique function of this epithelium.  The presence of oligosaccharides 
and glycoconjugates containing the SRCL ligand Lewisx has been described in sperm, 
seminal plasma and in early embryos (Muramatsu and Muramatsu, 2004; Pang et al., 
2007; Pang et al., 2009), suggesting functions for the epitope in fertilization, implantation 
and embryonic development, but specific roles or interactions with glycan-binding proteins 
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Figure 2.22: Immunofluorescence detection of SRCL expression in non-endothelial 
cell types
The visceral layer of the glomerular capsule, which consists of podocytes, is indicated by an 
arrow, and the parietal layer, which consists of squamous epithelial cells, by an arrowhead. 
The space between the two layers contains fluid that has filtered out of the glomerular 
capillaries.  Scale bars are 100 μm.
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have not been defined.  Expression of SRCL in placental trophoblasts, which are cells of 
embryonic origin that mediate implantation, has been reported previously (Selman et al., 
2008).  SRCL could not be detected in extracts of cultured trophoblasts by immunblotting 
(data not shown), but faint staining of some regions of the trophoblast layer in tissue 
sections was observed using anti-SRCL antibodies (Figure 2.19), such that SRCL may be 
expressed at very low levels in this cell type.  Like endothelial cells, trophoblasts are in 
contact with the blood and there are functional similarities between the two cell types 
(Zhou et al., 2003). 
The detection of SRCL expression in cDNA preparations from peripheral blood 
leukocytes and from the  T cell-derived Jurkat cell line (Figures 2.4 and 2.5) indicates that 
SRCL is expressed by a subset of leukocytes.  Staining consistent with expression of 
SRCL in lymphocytes was observed in tissue sections, including lung connective tissue 
(Figure 2.22), the lamina propria of the digestive and respiratory tracts, and connective 
tissue of the breast and appendix (data not shown).  Lymphocytes in spleen and lymph 
node were not stained (Figure 2.21), suggesting that SRCL may be expressed in 
lymphocytes underlying epithelia, but not in lymphocytes in lymphoid organs.  SRCL on 
lymphocytes may influence interaction with other cell types through recognition of Lewisx 
epitopes. 
 
2.4 Discussion 
The work presented in this chapter is consistent with the hypothesis that SRCL may have 
a role in mediating leukocyte adhesion or glycoprotein clearance, due to expression of the 
receptor primarily in endothelial cells.  Screening of tissue cDNA preparations for SRCL 
expression showed that the receptor has a broad tissue distribution (Figure 2.4), which 
was confirmed by immunostaining of tissues that revealed SRCL expression in endothelial 
cells across a range of tissues (Figures 2.13-2.20), as well as in some non-endothelial cell 
types (Figure 2.22).  These experiments confirm earlier reports that endothelial cells are a 
major site of SRCL expression (Ohtani et al., 2001; Jang et al., 2009).  Furthermore, the 
broad tissue screen conducted here provides evidence that SRCL is expressed by 
endothelial cells in a large proportion of blood vessels, and by other specialized cell types 
exposed to circulation. 
 These results are in contradiction to a previous immunohistochemical study of 
SRCL localization in human tissues, which found that the receptor is localized to 
macrophages and trophoblasts and that endothelial expression of SRCL is restricted to 
the umbilical vein (Selman et al. 2008).  The differences between the staining patterns 
may result from the use of rabbit polyclonal antibodies in this work as opposed to a mouse 
monoclonal antibody in the earlier study.  Because staining with the polyclonal antibodies 
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was observed only when using enhanced amplication methods for visualization, the 
conclusion that the endothelial cell is a major site of SRCL function can be regarded as 
tentative. 
The expression of SRCL on endothelial cells would enable the receptor to bind to 
Lewisx-containing glycoproteins on the surface of circulating leukocytes, such as the 
neutrophil integrin αMβ2 (Skubitz and Snook, 1987).  The C-type lectins P-selectin and E-
selectin are expressed on endothelial cells and mediate the adhesion of leukocytes to the 
endothelium as a prerequisite for leukocyte extravasation into inflamed tissues (Jung and 
Ley, 1999).  These receptors are only found at the endothelial cell surface in vessels in 
inflamed tissue, because their surface expression is dependent on inflammatory stimuli 
resulting from infection (Smith, 1993).  In the case of P-selectin, the receptor is stored in 
Weibel-Palade bodies in the cytoplasm and is mobilized to the cell surface, whereas E-
selectin is only transcribed in response to inflammation.  In contrast, SRCL appears to be 
expressed in a range of endothelia under normal conditions, suggesting that it does not 
direct leukocytes to inflamed tissues in the same way as the selectins.  However, it is 
possible that SRCL expression is enhanced under inflammatory conditions or is induced 
in vessels that do not express SRCL under normal conditions.  The expression of SRCL 
under inflammatory conditions could be investigated by comparison of SRCL staining in 
sections of normal and inflamed human tissue, or in mouse models of inflammation.  
SRCL might also function upstream of the selectins in the leukocyte recruitment process, 
where its extended neck could assist in capturing circulating cells at the endothelial 
surface prior to selectin-mediated leukocyte rolling.  The expression of SRCL in the 
microvasculature of tissues where there is an interface with the environment, such as the 
respiratory and digestive systems, but not in solid internal organs like liver and kidney, is 
consistent with a role in the response to infection. 
The expression of SRCL in capillaries with continuous endothelia but not in 
fenestrated or sinusoidal capillaries is the inverse situation to that observed for certain 
other C-type lectins, which are expressed exclusively in these specialized endothelial 
cells. LSECtin and DC-SIGNR are found in sinusoidal endothelial cells in liver and lymph 
node and the mannose receptor is present in liver sinusoidal endothelial cells (Pohlmann 
et al., 2001; Liu et al., 2004; Elvevold et al., 2008).  LSECtin and DC-SIGNR also differ 
from SRCL in that they are not endocytic, but may have roles as adhesion receptors in 
promoting viral infection and suppressing T cell function in the liver (Khoo et al., 2008; 
Tang et al., 2009).  SRCL therefore has a distinct function to these related endothelial C-
type lectins, which is also reflected in the specificity of SRCL for Lewisx-containing glycans 
like those found on endogenous glycoproteins, rather than for pathogen-type glycans with 
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terminal mannose or GlcNAc residues (Guo et al., 2004; Coombs et al., 2005; Powlesland 
et al., 2008).   
The absence of SRCL expression in the liver has significance for the potential 
function of SRCL as a clearance receptor because this organ is a major site of clearance 
for circulating molecules, including glycoproteins.  The mannose receptor mediates 
clearance of lysosomal enzymes and glycoprotein hormones by liver sinusoidal 
endothelial cells and Kupffer cells, and endocytic C-type lectins such as the 
asialoglycoprotein receptor are also found in the liver (Spiess, 1990; Fiete et al., 1998; 
Elvevold et al., 2008).  The presence of SRCL throughout the vascular system, rather than 
in endothelial cells in certain organs, suggests that the receptor may be important for 
clearing proteins released locally and limiting their spread into general circulation, in 
contrast to the role of the mannose receptor in regulating circulating glycoprotein 
hormones at the systemic level through clearance into the liver (Fiete et al., 1998).   
SRCL expression was found in endothelial cells in a subset of vessels belonging to 
both microvasculature and macrovasculature, and in subsets of both arteries and veins.  
Because endothelial cells in different locations are functionally heterogeneous (Ribatti et 
al., 2002), SRCL could have multiple functions across different vessel types.  Not all 
functions of SRCL need relate to the sugar-binding activity of the receptor, for example 
SRCL has been reported as the principal receptor for phagocytosis of fungi in endothelial 
cells (Jang et al., 2009).  SRCL expression was also observed in cell types that are 
closely associated with endothelial cells, such as smooth muscle cells underlying 
endothelial cells in larger blood vessels, and podocytes surrounding glomerular 
capillaries, suggesting that SRCL may have functions in the local tissue environment that 
are independent of the specific cell type expressing the receptor.   
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Identification of neutrophil granule proteins as Lewisx-
containing ligands cleared by the scavenger receptor C-
type lectin 
 
3.1 Introduction 
This chapter describes the identification of endogenous ligands for the scavenger receptor 
C-type lectin (SRCL).  SRCL exhibits selective binding to the Lewisx trisaccharide and 
recognizes Lewisx-containing glycoconjugates (Coombs et al., 2005), but no physiological 
ligands for the receptor have been reported.  The endothelial expression of SRCL 
suggested that the receptor might be involved in mediating adhesion of circulating cells to 
the endothelium during leukocyte extravasation, a function analagous to that of the 
selectin family of C-type lectins.  Consistent with a role for SRCL in cell adhesion, the 
Lewisx structure is found on the surfaces of leukocytes and has been implicated in 
neutrophil adhesion (Kerr and Stocks, 1992; Stocks and Kerr, 1992).  It has also been 
proposed that SRCL mediates adhesion of Lewisx-expressing cancer cells to endothelium 
(Elola et al., 2007).  However, identification of the glycoprotein ligands for SRCL that were 
isolated from neutrophils revealed that they are predominantly soluble granule proteins 
rather than cell surface proteins.  The major role for SRCL is therefore likely to be in the 
clearance of glycoproteins released at sites of inflammation, which may be tagged with 
Lewisx epitopes in order to facilitate their uptake by SRCL. 
 
3.2 Materials and Methods 
Bacterial expression of galactose-binding mutant of mannose-binding protein 
A galactose-binding mutant of rat mannose-binding protein A (GalMBP) was created 
previously by making amino acid substitutions and insertions to mimic the binding site in 
the rat asialoglycoprotein receptor major subunit (Iobst and Drickamer, 1994; Iobst et al., 
1994).  GalMBP expressed using the ompA system as described for the CRD of SRCL 
(Chapter 2) forms soluble trimers.  The expression plasmid was transformed into 
Escherichia coli strain JA221.  Luria-Bertani medium (1 L) containing 50 mg/L ampicillin 
was inoculated with 30 mL of an overnight culture and the culture was grown by shaking 
at 30°C.  The culture was induced at OD550 of 0.8 by addition of 10 mg/L IPTG and 100 
mM CaCl2 and grown overnight at 30°C.  Subsequent steps were performed at 4°C.  Cells 
were harvested by centrifugation at 3,500 rpm for 10 min in a Beckman JLA8.1000 rotor.  
The cell pellet was resuspended in 50 mL low-salt loading buffer.  Resuspended pellets 
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from 6 L of culture were pooled and sonicated with a Branson sonifier.  The lysate was 
centrifuged at 10,000 rpm for 15 min in a Beckman JA20 rotor and the supernatant re-
centrifuged at 45,000 rpm for 1 h in a Beckman 45Ti rotor.  The supernatant was loaded 
onto a 5-mL column of galactose-Sepharose.  The column was washed with 5 x 2 mL 
aliquots of low-salt loading buffer and eluted with 5 x 2 mL aliquots of low-salt eluting 
buffer. 
 
Generation of biotin-tagged CRD of SRCL 
To generate a biotinylated version of the CRD of SRCL, the coding sequence for the 
biotinylation tag Gly-Leu-Asn-Asp-Ile-Phe-Glu-Ala-Gln-Lys-Ile-Glu-Trp-His-Glu, in which 
the lysine residue is a target for biotinylation (Schatz, 1993), was added to the C-terminus 
of the CRD and the construct was placed into the expression vector pT5T (Eisenberg et 
al., 1990) as shown in Figure 3.1.  For expression of biotinylated protein, E. coli strain 
BL21/DE3 cells transformed with a plasmid containing the chloramphenicol resistance 
gene and the birA biotin ligase gene (Smith et al., 1998b) were made competent and 
transformed with the expression construct.  Luria-Bertani medium (1 L), containing 50 
mg/L ampicillin and 20 mg/L chloramphenicol, was inoculated with 30 mL of an overnight 
culture. The culture was grown by shaking at 37°C to an OD550 of 0.8, and IPTG and biotin 
were added to final concentrations of 500 µM and 50 µM, respectively. After growth for a 
further 3 h at 37°C, cells were harvested by centrifugation at 3,500 rpm for 10 min in a 
Beckman JLA8.1000 rotor.  Subsequent steps were performed at 4°C.  Bacterial pellets 
were resuspended in 10 mM Tris, pH 7.8, followed by centrifugation at 10,000 rpm for 10 
min in a Beckman JA20 rotor.  Bacteria were lysed by sonication in 25 ml of 10 mM Tris, 
pH 7.8. The lysate was centrifuged at 12,000 rpm for 20 min in a Beckman JA20 rotor to 
pellet inclusion bodies.  The pellet was resuspended in 20 mL of 6 M guanidine 
hydrochloride containing 0.1 M Tris, pH 7.0 by sonication, 0.01% 2-mercaptoethanol was 
added, and the mixture was incubated for 30 min on ice.  The mixture was centrifuged at 
35,000 rpm for 30 min in a Beckman 55.2Ti rotor to remove insoluble material. The 
supernatant was dialysed against three changes (each 1 L) of loading buffer to renature 
the protein, and was centrifuged at 45,000 rpm for 1 h in a Beckman 55.2Ti rotor to 
remove precipitated material.  Galactose-Sepharose column chromatography was 
performed as for the untagged CRD of SRCL (Chapter 2). 
 
Blotting with antibodies and labelled lectins 
To generate radio-iodinated lectins for use in blotting experiments, lyophilized purified 
GalMBP or extracellular domain of SRCL (100 µg) was resuspended in 500 µL of 25 mM 
bicine, pH 8.5, 0.5 M NaCl, 25 mM CaCl2 and incubated for 20 min at room temperature 
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Figure 3.1: Construction of a plasmid for expression of biotin-tagged CRD of SRCL
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with 250 µCi of 125I-Bolton-Hunter Reagent (PerkinElmer).  Labelled protein was repurified 
on a 1-mL column of galactose-Sepharose and fractions were counted on a gamma 
counter.  Peak fractions were added to 25 mL of 2% bovine hemoglobin in low-salt loading 
buffer.  Radiolabelled GalMBP was prepared by A. S. Powlesland and K. Drickamer.  Prior 
to probing with radiolabelled lectins, protein blots and thin layer chromatography plates 
were blocked with 2% bovine hemoglobin in low-salt loading buffer for 60 min at room 
temperature with agitation.  They were incubated with radiolabelled receptor for 90 min 
with agitation, followed by four washes of 10 min each with low-salt loading buffer.  
Radioactivity was detected with a phosphorimaging device from Molecular Dynamics. 
To generate alkaline phosphatase-conjugated oligomers of the CRD of SRCL, 
streptavidin-alkaline phosphatase from Streptomyces avidinii (100 μg, Sigma) was 
incubated at 4°C overnight with rotary agitation with a large excess of purified biotinylated 
CRD of SRCL in loading buffer.  The solution was applied to a 1-mL column of galactose-
Sepharose, which was washed with 4 x 1 mL aliquots of loading buffer and eluted with 5 x 
0.5 ml aliquots of eluting buffer.  Fractions were analysed by SDS-polyacrylamide gel 
electrophoresis and fractions containing SRCL-streptavidin complexes (SRCL-AP) were 
diluted into 25 ml of 2% bovine hemoglobin in low-salt loading buffer.  Prior to incubation 
with SRCL-AP, protein blots were blocked for 30 min at room temperature with shaking in 
2% bovine hemoglobin in low-salt loading buffer.  Blots were incubated with SRCL-AP for 
90 min with shaking and washed four times for 5 min each with TBS, with 0.05% Triton X-
100 added to the second and third washes.  Blots were developed with BCIP/NBT 
(Calbiochem).  Immunoblotting was performed as described in Chapter 2.  Rabbit 
polyclonal antibodies to pan-CEACAM (Abcam) were used at 1:500 dilution.  
 
Purification of ligands from human granulocytes by affinity chromatography 
A GalMBP affinity column was created using >5 mg of GalMBP by the protocol described 
for generation of the SRCL CRD affinity column for antibody purification.  To generate an 
SRCL affinity column for ligand purification, an excess (~5 mg) of biotinylated CRD of 
SRCL in eluting buffer was passed over a 2-mL column of avidin-agarose (Pierce) 
equilibrated with this buffer.  The column was washed extensively with eluting buffer and 
then with loading buffer.  A sample of the washed resin was analysed by SDS-
polyacrylamide electrophoresis to confirm binding of the CRD to the resin.   
Leukocytes were isolated from ~50 mL of fresh human blood containing 1.5 mg/mL 
EDTA as an anticoagulant.  Whole blood was separated by centrifugation at room 
temperature at 3,000 rpm for 10 min in an Eppendorf 5810R centrifuge with no brake.  
The plasma layer was removed.  The buffy coat was aspirated, diluted into 3 mL of DPBS 
and layered on to 2 mL of Ficoll-PaqueTM PLUS (d = 1.077 g/cm3, Amersham 
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Biosciences), and spun at 1,500 rpm for 10 min at 4°C, with no brake.  The supernatant 
containing agranulocytes was removed and mixed with 5 mL of DPBS, and agranulocytes 
were collected by centrifugation at 1,500 rpm for 2 min.  The pellet, containing 
granulocytes and erythrocytes carried over with the buffy coat, was resuspended in 50 mL 
of 155 mM ammonium chloride, 10 mM ammonium bicarbonate, 0.1 mM EDTA, pH 8.0 
and incubated on ice for 5 min to lyse erythrocytes.  Granulocytes were collected by 
centrifugation at 1,500 rpm for 2 min and washed twice in cold DPBS.   
For preparation of protein blots, agranulocyte and granulocyte cell pellets were 
resuspended in sample buffer containing 2-mercaptoethanol and heated to 100°C for 10 
min.  Samples were resolved by SDS-polyacrylamide electrophoresis and proteins were 
transferred onto nitrocellulose membrane.  To prepare granulocyte extract for isolation of 
glycoproteins by affinity chromatography, cells were lysed by sonication in low-salt loading 
buffer containing 1% Triton X-100 and a protease inhibitor cocktail (Calbiochem, final 
inhibitor concentrations: 500 μM AEBSF, 150 nM bovine lung aprotinin, 1 μM E-64, 1 μM 
leupeptin), incubated for 30 min on ice, and centrifuged at 4,000 rpm for 10 min in an 
Eppendorf 5810R centrifuge to pellet insoluble material.  The resulting extract was passed 
over a GalMBP or SRCL affinity column.  The column was washed with 5 x 1 mL aliquots 
of low salt loading buffer containing 0.1 % Triton X-100 and eluted with 5 x 1 mL aliquots 
of low-salt eluting buffer containing 0.1% Triton X-100.  For repurification of ligands, the 
elution fractions were pooled, adjusted to 25 mM CaCl2 and applied to the column again.  
The column was washed and eluted as before, or with the addition of 5 x 1 mL pre-
washes with loading buffer (0.5 M NaCl) containing 0.1% Triton X-100.   
 
Proteomic analysis by mass spectrometry 
Affinity-purified proteins were resolved by SDS-polyacrylamide electrophoresis and 
stained with Coomassie blue.  Bands for proteomic analysis were excised from the gel.  
Each band was diced finely and the gel pieces were destained by incubation at room 
temperature with 200 μl of 50 mM ammonium bicarbonate, pH 8.4 and 200 μl of 
acetonitrile.  The solution was removed and the gel pieces were dried using a vacuum 
centrifuge.  Gel pieces were incubated in 200 μl of 10 mM dithiothreitol in 50 mM 
ammonium bicarbonate, pH 8.4 for 30 min at 56°C to reduce disulfide bonds.  The 
solution was removed and the gel pieces were washed briefly with 200 μl of acetonitrile 
and dried with a vacuum centrifuge.  To carboxymethylate free thiol groups, gel pieces 
were incubated in 200 μl of 55 mM iodoacetic acid in 50 mM ammonium bicarbonate, pH 
8.4 for 30 min at room temperature in the dark.  The solution was removed and the gel 
pieces were washed in 500 μl of 50 mM ammonium bicarbonate, pH 8.4 for 15 min.  The 
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washing solution was removed and gel pieces were shrunk by 5-min incubation in 200 μl 
of acetonitrile before drying on vacuum centrifuge. 
For in-gel trypsin digestion of proteins, a working solution of sequencing-grade 
modified trypsin (Promega) was prepared by dissolving to 1 μg/μL in the buffer supplied 
and diluting to 25 ng/μL in 50 mM ammonium bicarbonate, pH 8.4.  Gel pieces were 
incubated in 30-50 μL of trypsin solution overnight at 37°C.  The supernatant, containing 
hydrophilic tryptic peptides, was removed to a fresh tube.  To retrieve hydrophobic 
peptides, the gel pieces were incubated for 10 min at 37°C with 50 μL of 0.1% 
trifluoroacetic acid in water, and for a further 15 min following addition of 100 μL of 
acetonitrile.  The supernatant was added to the hydophilic peptides and the hydrophobic 
peptide elution steps were repeated once.  The volume of the peptide solution was 
reduced to 10-30 μL by vacuum centrifugation.   
Peptide solution (0.5 μL) was spotted on to a sample plate and allowed to dry 
before being overlayed with 0.5 μL of matrix (10 mg of α-cyano-4-hydroxycinnamic acid in 
1 mL of 50% acetonitrile, 0.05% trifluoroacetic acid in water).  MALDI MS profiles, and 
MS/MS data for the 10 most abundant ions in each sample, were collected on an Applied 
Biosystems 4800 MALDI-TOF/TOF mass spectrometer.  Peak picking for peptide mass 
fingerprint data was performed using GPS Explorer software version 3.6 (Applied 
Biosystems).  A signal-to-noise threshold of 10 was employed, sequazyme peptide mass 
standards were used as external standards for calibration and no contaminant ions were 
excluded.  Peak list generation and database searching for MS/MS experiments were 
conducted using the same software with the default parameters.  MS and MS/MS data 
were used to search 283,454 entries in release 54.2 of the SwissProt database with 
version 2.2 of the Mascot database search algorithm (www.matrixscience.com) with the 
following search parameters: peptide masses were fixed as monoisotopic, the mass 
tolerance was set at 75 ppm for precursor ions and 0.1 Da for fragment ions, partial 
carboxymethylation of cysteine residues and partial oxidation of methionine residues were 
considered, and up to one missed trypsin cleavage site was allowed.  Protein matches 
from both MS and MS/MS data were used to generate probability-based Mowse protein 
scores.  Scores greater than 55 were considered significant (P<0.05) (Perkins et al., 
1999).  Protein matches with scores less than 55 were also evaluated for significance 
based on the consistency of the identified protein with known molecular weight, 
expression pattern and other experimental data. 
 
Glycosidase treatment of neutrophil proteins 
Lactoferrin from human neutrophils was obtained from Sigma as a ~1.5 mg/mL solution in 
50 mM sodium acetate, pH 6.0, 150 mM NaCl.  Lactoferrin from human milk was obtained 
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from Sigma as lyophilized powder.  Both preparations were dialysed against water and 
lyophilized, and protein concentration was determined using the Bradford assay following 
resuspension in appropriate buffer.  
Neuraminidase from Clostridium perfringens (50,000 units/mL) was obtained from 
New England Biolabs.  Lactoferrin (15 μg) was digested overnight with 2 μL of 
neuraminidase at 37°C in a total volume of 50 μL using the supplied G1 reaction buffer 
(50 mM sodium citrate, pH 6.0).  Samples equivalent to 5 μg of lactoferrin were resolved 
on SDS-polyacrylamide gels that were stained with Coomassie blue or transferred to 
nitrocellulose and probed with SRCL-AP as described above. 
Bovine kidney α-L-fucosidase was purchased from Sigma as an ammonium sulfate 
suspension.  Enzyme was resuspended in 100 mM sodium citrate, pH 5.6 at 20 U/mL.  
Milk and neutrophil lactoferrins (5 μg) were digested at 37°C for 48 h in 50 μL of 100 mM 
sodium citrate, pH 5.6 containing 1 U/mL fucosidase.  Samples equivalent to 1 μg of 
lactoferrin were resolved by SDS-polyacrylamide gel electrophoresis and stained with 
Coomassie blue or transferred to nitrocellulose and probed with SRCL-AP or 125I-SRCL as 
described above. 
Matrix metalloproteinases (MMP) 8 and 9 from human neutrophils were obtained 
from Calbiochem in solution at 100 μg/mL in 50 mM Tris, pH 7.0, 200 mM NaCl, 5 mM 
CaCl2, 1 μM ZnCl2, 0.05% BRIJ 35 detergent, 0.05 % sodium azide.  A 50 μL aliquot of 
each protein was supplemented with 0.25 volumes of 1 M sodium citrate, pH 5.6.  A 25 μL 
aliquot of this solution (2 μg of protein) was incubated for 24 h at 37°C with 5 μL of 
fucosidase solution or of buffer without fucosidase.  The reaction was divided between two 
lanes of an SDS-polyacrylamide gel.  One lane was stained with Coomassie and the 
second transferred to nitrocellulose and probed with radiolabelled extracellular domain of 
SRCL as described above. 
LNFPIII-BSA (0.2 μg) was digested overnight at 37°C in 10 μL of 100 mM sodium 
citrate, pH 5.6 containing 1 U/mL fucosidase.  Samples equivalent to 0.1 μg of LNFPIII-
BSA were resolved by SDS-polyacrylamide gel electrophoresis and stained with 
Coomassie blue or transferred to nitrocellulose and probed with 125I-SRCL as described 
above. 
 
Neoglycolipids 
The following oligosaccharides were dissolved in water at 1 mg/ml and 5 μg of 
oligosaccharide was used for coupling to lipid: LNFPIII, unsialylated biantennary N-linked 
glycan (NA2), unsialylated triantennary N-linked glycan (NA3) (Dextra Laboratories).  
Neutrophil lactoferrin and milk lactoferrin N-glycans were prepared from 1 mg of protein 
(equivalent to ~25 nmol of glycan) as described for glycan analysis by mass spectrometry 
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below. Dipalmitoyl phosphatidylethanolamine (Avanti Polar Lipids) was dissolved at 5 
mg/mL in a 1:1 mixture of methanol and chloroform by brief sonication.  Glycans were 
incubated for 2 h at 60°C with 100 μl of lipid solution.  Reduction was performed by 
addition of 100 μg of NaBH3CN (from freshly-prepared stock of 10 mg/mL in methanol) 
followed by further incubation overnight at 60°C.  The neoglycolipids were resolved by thin 
layer chromatography using 5 x 7.5 cm HPTLC aluminium sheets coated with silica gel 60 
F254 (Merck), in chloroform:methanol:water in the ratio 105:100:28.  Duplicate 
chromatograms were prepared.  One was stained with orcinol to visualize all 
carbohydrate, and the second was fixed by immersion for 30 s in a 0.1% solution of 
isobutylmethacrylate in hexanes, and probed with radiolabelled extracellular domain of 
SRCL as described above.  
 
Solid phase binding assays 
Neutrophil lactoferrin and LNFPIII-BSA (Dextra Laboratories, contains 20 LNFPIII groups 
per molecule) were radio-iodinated by the chloramine T method (Hunter and Greenwood, 
1962).  All steps of binding assays were carried out at 4°C.  Immulon 4 polystyrene wells 
were coated overnight with CRD of SRCL in loading buffer or GalMBP in low-salt loading 
buffer.  Wells were blocked with 5% BSA in loading buffer for 2 h and washed twice with 
25 mM MES, 25 mM MOPS, pH 7.2, 0.5 M NaCl, 2.5 mM CaCl2.  For direct binding 
assays, serial dilutions of 125I-lactoferrin were prepared, and for competition binding 
assays, serial dilutions of unlabelled ligands (α-methyl galactoside, Lewisx, neutrophil 
lactoferrin) were prepared and mixed with reporter ligand 125I-LNFPIII-BSA.  The final 
assay buffer composition was 25 mM MES, 25 mM MOPS, pH 7.2, 0.5 M NaCl, 2.5 mM 
CaCl2, 0.1% BSA.  Wells were incubated with ligand solution for 2 hs and washed three 
times with 25 mM MES, 25 mM MOPS, pH 7.2, 0.5 M NaCl, 20 mM CaCl2.  Radioactivity 
in the wells was measured using a gamma counter.  All assays were performed in 
duplicate.  Binding data were fitted using SigmaPlot software (Jandel Scientific).  Direct 
binding assays were fitted allowing for a linearly-increasing background, where k is a 
constant: Measured binding = Maximum binding x [ligand] / (KD + [ligand]) + k[ligand] 
Competition assays were fitted with variable order (a) as follows: 
Measured binding = Maximum binding x KIa / (KIa + [ligand]a) 
 
Surface plasmon resonance 
Surface plasmon resonance measurements were made using a Biacore 3000 instrument 
with Biacore 3000 Control Software and BIAevaluation Software.  Protein ligands were 
coupled to CM5 sensor chips (Biacore) by treating the carboxymethylated dextran matrix 
with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide to create 
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succinimide esters which react with the amino groups of proteins.  After coupling of 
protein ligands to the sensor chip, the remaining succinimide esters were deactivated with 
ethanolamine.  Only a fraction of carboxymethyl groups are converted to succinimide 
esters, leaving the chip surface with net negative charge at pH values above 3.5, which is 
required for pre-concentration of protein ligands on the chip surface. 
Milk and neutrophil lactoferrins were coupled to activated sensor chips by flowing a 
50 μg/mL solution in 10 mM sodium acetate, pH 5.0 over the chip for 10 min at a flow rate 
of 10 μL/min.  CRD of SRCL was resuspended at 1 mg/mL in 10 mM HEPES, pH 7.4, 150 
mM NaCl, 5 mM CaCl2, 0.005% P20 detergent and serial dilutions were prepared using 
the same buffer, with 1 μg/mL as the lowest concentration.  SRCL solutions and one 
solution containing buffer only were flowed over the sensor chip, which was regenerated 
between samples using 10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% P20 
detergent, and sensorgrams were recorded. 
For immobilization on sensor chips, neutrophil lactoferrin was digested with 
fucosidase as described above, except that the reaction was scaled up 2-fold to include 
20 μg of lactoferrin in a final reaction volume of 100 μL.  Control samples were incubated 
in the absence of fucosidase.  Removal of fucose was confirmed by probing protein blots 
with SRCL-AP, as described above.  The protein was dialysed into 10 mM sodium 
acetate, pH 5.0, with a final lactoferrin concentration of 20 μg/mL.  Protein was coupled to 
activated sensor chips by flowing this solution over the surface for 30 min at a rate of 10 
μL/min.  Sensorgrams with the CRD of SRCL were recorded as before. 
CRD of SRCL was coupled to activated sensor chips in 10 mM sodium acetate 
with a flow rate of 10 μL/min.  The following coupling conditions were evaluated: 
 
SRCL concentration  Buffer pH Coupling time 
50 μg/mL   pH 5.0  10 min 
50 μg/mL   pH 4.0  10 min  
250 μg/mL   pH 3.5  30 min 
1000 μg/mL   pH 3.5  30 min 
 
Sensorgrams were collected using serial dilutions of neutrophil lactoferrin at 
concentrations of 330 – 0.33 μg/mL, milk lactoferrin at 150 – 0.15 μg/mL, Lewisx (Glyko, 
molecular weight 530 Da) at 250 – 0.25 μg/mL, and biotinylated Lewisx (GlycoTech, 
molecular weight ~960 Da) at 50 – 0.39 μg/mL. 
The binding of molecules to the sensor chip at each concentration was defined as 
the difference between the surface response at two fixed time points on the sensorgram  
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(as shown in Figure 3.12) and data were fitted to a direct binding equation using 
SigmaPlot software. 
 
Glycan analysis by mass spectrometry 
Purified lactoferrin derived from milk or neutrophils (~0.5 mg) was precipitated with 
trichloroacetic acid and resuspended in 25 μL of 8 M urea, 10 mM HEPES, pH 8.0.  The 
protein was digested at 37°C overnight with TPCK-treated trypsin from bovine pancreas 
(Sigma) at a final concentration of 50 μg/mL in a final volume of 250 μL of 50 mM 
ammonium bicarbonate, pH 8.4.  The digestion was stopped by heating to 100°C for 5 
min.  The sample was applied to a Waters Oasis HLB Plus column pre-conditioned with 5 
mL of methanol, 5 mL of 5% acetic acid, 5 mL of propan-1-ol and 15 mL of 5% acetic acid.  
The column was eluted with 20 mL of 5% acetic acid, 4 mL of 20% propan-1-ol, 4 mL of 
40% propan-1-ol and 4 mL of 100% propan-1-ol.  The 20% propan-1-ol and 40% propan-
1-ol fractions, containing glycopeptides, were reduced in volume by vacuum 
centrifugation, pooled and lyophilized.  The sample was digested at 37°C overnight with 1 
μL of peptide N-glycosidase F (New England Biolabs) in 200 μL of 50 mM ammonium 
bicarbonate, pH 8.4.  The sample was fractionated as described above using a Sep-Pak 
C18 cartridge (Waters).  The 5% acetic acid elution fraction, containing N-glycans, and 
20% propan-1-ol elution fraction, containing O-glycopeptides, were reduced in volume by 
vacuum centrifugation and lyophilized.  O-glycans were released from glycopeptides by 
reductive elimination by incubation at 45°C overnight with 400 μL of 55 mg/mL sodium 
borohydride in 0.1 M potassium hydroxide.  The reaction was terminated with acetic acid 
and desalted using a column of Dowex 50 W-X8 beads (VWR) in a glass Pasteur pipette.  
The column was washed with 15 mL of acetic acid before the sample was loaded.  
Following elution with 5 mL of 5% acetic acid, the sample volume was reduced by vacuum 
centrifugation and lyophilization.  Excess borate was removed by co-evaporation with 10% 
acetic acid in methanol under a stream of nitrogen. 
Some preparation of glycans for MALDI-MS analysis and acquisition of MALDI 
spectra was performed by A. Antonopoulos.  For permethylation of N- and O-glycans, 
sodium hydroxide (5 pellets) was ground into a slurry with 3 mL of anhydrous dimethyl 
sulfoxide.  Slurry (0.5-1.0 mL) was added to the sample followed by 0.2-0.5 mL of methyl 
iodide, and the sample was agitated for 10 min at room temperature.  The reaction was 
quenched by dropwise addition of water.  Chloroform (1-2 mL) was added and the volume 
made up to 5 mL with water.  The sample was mixed and the aqueous layer was 
removed.  The chloroform layer was washed four times with water and dried under a 
stream of nitrogen.  The sample was dissolved in 100 μL of 50% methanol in water and 
fractionated using a Sep-Pak C18 column pre-conditioned with 5 mL of methanol, 5 mL of 
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water, 5 mL of acetonitrile and 15 mL of water.  The column was eluted with 5 mL of water 
and 3 mL each of 15%, 35%, 50% and 75% acetonitrile in water.  The 35% and 50% 
acetonitrile fractions were reduced by vacuum centrifugation and lyophilized.  For MALDI 
analysis, permethylated glycans were dissolved in 10 μL of methanol and 1 μL of this 
solution was mixed with 1 μl of 2,5-dihydroxybenzoic acid matrix solution (10 mg/mL in 
80% methanol).  An aliquot (1 μL) of the sample-matrix mixture was spotted on to a target 
plate and dried. 
MALDI MS and MS/MS data were acquired using an Applied Biosystems 4800 
MALDI-TOF/TOF mass spectrometer.  MS data was also acquired using a Perspective 
Biosystems Voyager-DE STR MALDI workstation positive reflectron mode.  Data were 
acquired using Voyager 5 Instrument Control Software and processed using Data 
Explorer MS processing software.  Calibration was performed using a mixture of leucine, 
enkephalin, bradykinin, bradykinin (fragment 1-8), angiotensin I, neurotensin, insulin, and 
adrenocorticotropic hormone fragments 1-17, 18-39, 7-38 and 1-39.  The 35% and 50% 
acetonitrile fractions of permethylated glycans were analysed.  Larger glycans are found 
in the 50% fractions and data presented relate to this fraction except for the detection of 
antennae fragments released by endo-β-galactosidase digestion.  Monosaccharide 
compositions of singly-charged sodiated molecular ions were deduced using the known 
masses of the permethylated monosaccharide units found in mammalian N-glycans 
(hexose = 204 Da, N-acetylhexosamine = 245 Da, fucose = 174 Da and sialic acid = 361 
Da).   
Some details of the linkages between the component monosaccharides were 
deduced based on the known biosynthetic pathway (Kornfeld and Kornfeld, 1985).  
Additional structural information was acquired by MS/MS fragmentation of the molecular 
ions and using the analyses described below.  Samples of N-glycans from neutrophil 
lactoferrin (equivalent to 50 μg of protein) were treated with hydrogen fluoride and endo-β-
galactosidase.  Hydrogen fluoride treatment was performed by addition of 50 μL of 48% 
hydrogen fluoride to the dry sample and incubation at 4°C overnight.  The reaction was 
terminated by drying under a stream of nitrogen.  The sample was permethylated and MS 
and MS/MS data collected as above.  Endo-β-galactosidase digestion was performed at 
37°C overnight with 50 mU of the enzyme from Bacteroides fragilis in 200 μL of 100 mM 
sodium acetate, pH 5.8.  A second aliquot of enzyme was added and the reaction was 
incubated for a further 12 h.  The sample was lyophilized, permethylated and MS and 
MS/MS data were collected as above. 
Linkage analysis was performed by A. Antonopoulos.  For determination of the 
linkage of sialic acid, samples of neutrophil lactoferrin glycans (equivalent to 50 μg of 
protein) were first digested with sialidases.  Digestion with sialidase S (from Streptococcus 
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pneumoniae, Glyko), to remove only α2,3-linked sialic acid residues, and with sialidase A 
(from Arthrobacter ureafaciens, Glyko), to remove all sialic acid residues, was performed 
at 37°C overnight in 200 μL of 100 mM sodium acetate, pH 5.5.  Samples were lyophilized 
and permethylated as described above.  For linkage analysis to assess the proportion of 
tri- and tetra-antennary glycans, a sample of neutrophil lactoferrin was treated with 
hydrogen fluoride and permethylated as described above.  Permethylated samples were 
fully hydrolysed by incubation at 121°C for 2 h with 200 μL of trifluoroacetic acid.  The 
reactions were allowed to cool, centrifuged and dried under nitrogen.  The hydrolysed 
glycan samples were incubated at room temperature for 2 h with 200 μL of 10 mg/mL 
deuterated sodium borohydride in 2 M ammonium hydroxide to reduce the 
monosaccharides and label them at the C1 position with deuterium.  Reactions were 
terminated using acetic acid.  Samples were dried under nitrogen and 3 x 1 mL aliquots of 
10% acetic acid in methanol were evaporated sequentially from the samples under 
nitrogen.  The dried samples were incubated at 100°C for 1 h with 200 μL of acetic 
anhydride to acetylate free hydroxyl groups.  The samples were dried and dissolved in 1 
mL of chloroform.  The chloroform solution was washed three times with water and dried 
under nitrogen.  The resulting partially-methylated alditol acetates (PMAA) were dissolved 
in ~50 μL of hexanes for analysis by gas chromatography-mass spetrometry (GC-MS).  
Analysis was performed using a PerkinElmer Clarus 500 GC-MS fitted with an RTX-5 
column.  The temperature was held at 90°C for 1 min, increased by 8°C/min to 290°C, 
held at 290°C for 5 min and finally increased to 300°C at a rate of 10°C/min.  Glycans 
from kidney were used as a standard for retention times of PMAA. 
 
Endocytosis assay 
Human umbilical vein endothelial cells (HUVECs) were grown to confluence and SRCL-
transfected fibroblasts to ~70% confluence in normal growth media in wells of 24-well cell 
culture plates.  Cells were removed from two wells with trypsin for cell counting.  For 
assaying of endocytosis, medium was aspirated, wells rinsed with cold HEPES-buffered 
Dulbecco’s modified Eagle’s medium (DMEM), and 250 μL of 125I-LNFPIII-BSA solution (1 
μg/mL in cold HEPES-buffered DMEM) added to each well.  Cells were incubated with 
ligand at 4°C for 30 min to allow binding of ligand to cells, and were transferred to 37°C to 
initiate endocytosis.  Two wells of cells were analysed at time points of 0, 15, 30, 60, 120, 
180 and 240 min.  Medium was aspirated and centrifuged to remove any cellular material.  
An aliquot of supernatant (200 μL) was removed, 5 μg of BSA was added as a carrier, and 
100 μL of 30% trichloroacetic acid was added to precipitate proteins.  After 30 min 
incubation on ice, tubes were centrifuged to remove precipitated protein.  An aliquot (200 
μL) of the supernatant containing acid-soluble radioactivity resulting from degradation of 
112
Chapter 3 
internalized ligand was added to 800 μL of 0.5% potassium iodide in water, 30 μL of 30% 
hydrogen peroxide solution was added and the mixture was incubated for 5 min at room 
temperature to oxidize free iodide.  Free iodine was removed by four extractions with 1 mL 
of chloroform.  An aliquot of the solution (600 μL) was counted using a gamma counter.  
Cell-associated radioactivity was measured by washing wells twice with cold HEPES-
buffered DMEM and lysing cells in 1 mL of 1 M sodium hydroxide for transfer into gamma 
counter tubes. 
 
Internalization of glycoproteins by cells 
Neutrophil lactoferrin (1 mg), BSA (5 mg), and ovalbumin (5 mg, Sigma) were 
resuspended in 1 mL of 100 mM bicine, pH 9.0, 150 mM NaCl.  LNFPIII-BSA (100 μg, 
Dextra) was resuspended in 500 μL of the same buffer.  Five 10-μL aliquots (5 μL for 
LNFPIII-BSA labelling) of fluorescein isothiocyanate stock solution (1 mg/mL in dimethyl 
sulfoxide) were added to each sample with vortexing between each addition.  Reactions 
were incubated at 4°C overnight in the dark.  Excess dye was removed by size exclusion 
chromatography using a 10-mL column of Sepharose G-25 eluted with PBS, collecting 1 
mL fractions.  Dye-containing peak fractions were identified by eye, and samples of all 
fractions were analysed by SDS-polyacrylamide electrophoresis to confirm association of 
dye colour with protein. 
Cells were grown on coverslips and incubated at 37°C for 5 min, 30 min or 60 min 
with fluorescein-labelled proteins diluted to 1 μg/mL in phenol red-free Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum.  
Coverslips were washed in DPBS, fixed for 15 min with 4% paraformaldehyde in PBS, 
washed, and blocked for 20 min with 10% normal goat serum in PBS.  Cells were 
incubated for 60 min with rabbit anti-fluorescein (Abcam) at 5 μg/mL followed by 30 min 
with Alexa Fluor 488-labelled goat anti-rabbit IgG (Invitrogen) at 1 μg/mL in 2% normal 
goat serum in PBS.  Coverslips were mounted with Vectashield aqueous mounting 
medium containing DAPI (Vector) and sealed.   
 
3.3 Results 
3.3.1 Detection of ligands for SRCL in granulocytes 
The expression of SRCL on endothelial cells suggests that the receptor may mediate 
leukocyte adhesion through binding to leukocyte surface glycoproteins.  To detect 
potential physiological ligands for SRCL on leukocytes, freshly-isolated leukocytes were 
fractionated into two populations: granulocytes (predominantly neutrophils, some 
basophils and eosinophils) and agranulocytes (lymphocytes and monocytes).  Cell 
extracts from these two populations were resolved by SDS-PAGE and blotted onto 
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nitrocellulose.  The blots were probed first with radiolabelled extracellular domain of SRCL 
(125I-SRCL), a soluble, trimeric fragment of the receptor that exhibits highly selective and 
high affinity binding to Lewisx (Figure 3.2) (Coombs et al., 2005).  Multiple species were 
detected in the blot of granulocyte extract, but not in agranulocyte extract.  Blots were also 
probed with radiolabelled GalMBP, a trimeric form of mannose-binding protein engineered 
to recognize glycans presenting terminal galactose residues (Iobst and Drickamer, 1994).  
GalMBP exhibits particular preference for Lewisx-containing oligosaccharides and thus 
overlaps with SRCL in ligand-binding specificity (Powlesland et al., 2009).  Blotting with 
125I-GalMBP revealed a similar pattern of bands to 125I-SRCL in the granulocyte extract 
and no reactivity in the agranulocytes.  Thus, several proteins are present in granulocytes 
which are recognized by SRCL and GalMBP and probably carry Lewisx epitopes, 
consistent with the high level of Lewisx expression in these cells, whereas agranulocytes 
do not contain significant quantities of protein recognized by SRCL, consistent with the 
low level of Lewisx expression in these cells (Nakayama et al., 2001).   
Because carcinoembryonic antigen cell adhesion molecule (CEACAM)-1 is known 
to be a major carrier of Lewisx on granulocytes (Stocks et al., 1990; Mahrenholz et al., 
1993; Lucka et al., 2005), blots of granulocyte and agranulocyte extracts were also probed 
with an antibody that recognizes CEACAM-1 and related proteins.  A 175-kDa protein and 
an 80-kDa protein were detected in granulocyte extract using the anti-CEACAM antibody.  
The similarity in size between the proteins recognized by anti-CEACAM and by SRCL and 
GalMBP indicates that CEACAM-1 carrying Lewisx structures is probably one of the 
ligands for SRCL.  No reactivity towards the CEACAM antibody was observed in 
monocyte extracts, consistent with previous studies of CEACAM expression 
(Hammarstrom, 1999). 
To identify the full complement of granulocyte proteins recognized by SRCL, 
ligands were isolated from the crude cell extract by affinity chromatography on 
immobilized GalMBP (Powlesland et al., 2010).  Initially it was felt that, because the 
extracellular domain of SRCL cannot readily be produced in sufficient quantity for this 
application, GalMBP would provide a useful substitute for SRCL since it appears to 
recognize a very similar set of granulocyte proteins.  Granulocyte extract was applied to 
the column in the presence of Ca2+ to allow binding.  After non-binding proteins were 
washed off the column with Ca2+-containing buffer, bound proteins were eluted with buffer 
containing EDTA.  SDS-polyacrylamide gel electrophoresis of fractions resulting from 
fractionation of granulocyte extract showed that a subset of proteins is bound specifically 
by GalMBP and eluted in the presence of EDTA (Figure 3.3).  A corresponding blot 
probed with 125I-SRCL revealed reactive proteins in the elution fractions over a similar 
molecular weight range to those observed on the gel, and little reactivity in the wash 
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Figure 3.2: Detection of ligands for SRCL in granulocytes
Freshly-isolated buffy coats were fractionated into granulocyte and agranulocyte fractions.  
Samples from each fraction were resolved by SDS-polyacrylamide gel electrophoresis 
followed by Coomassie blue staining or transfer to nitrocellulose for probing with 
radiolabelled SRCL, radiolabelled GalMBP, or anti-CEACAM antibody.
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Figure 3.3: Purification of granulocyte ligands for SRCL by GalMBP affinity 
chromatography
Granulocyte extract was fractionated by affinity chromatography on GalMBP.  The column 
2+
was washed with buffer containing Ca  (fractions 1-5) and eluted with buffer containing 
EDTA (fractions 6-10).  The peak elution fraction is highlighted in yellow.  Fractions were 
analysed by SDS-polyacrylamide gel electrophoresis.  Parallel gels were stained with 
Coomassie blue or blotted onto nitrocellulose and probed with radiolabelled SRCL or anti-
CEACAM antibody.
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fractions, indicating that the GalMBP affinity column is an effective method to isolate 
ligands for SRCL.  Probing of a parallel blot with an anti-CEACAM antibody showed that 
the two CEACAM species observed in blots of crude granulocyte extract are bound by the 
GalMBP column, suggesting that these proteins may be Lewisx-carrying ligands for SRCL. 
To identify the proteins purified on the GalMBP column, the elution fractions were 
first repurified on the same column to improve the separation of bound and non-bound 
proteins.  The repurified fractions were precipitated and applied to an SDS-polyacrylamide 
gel so that Coomassie-stained protein bands could be excised for proteomic analysis.  
Excised gel bands were reduced and digested with trypsin, and the resulting peptides 
were eluted and analysed by mass spectrometry.  The set of peptide masses from each 
band was queried against a database of human proteins to identify possible parent 
proteins.  Protein matches with a probability of a random match of <0.05 were taken to be 
genuine, but matches with lower confidence were not automatically excluded, because the 
score reflects the number of peptides detected, which may be low for proteins that are 
scarce, small, have few trypsin cleavage sites, or are post-translationally modified.  
Additional information was used to evaluate lower-confidence matches, such as 
agreement between molecular weight of the suggested protein and apparent molecular 
weight in SDS-polyacrylamide gel electrophoresis, the absence of missed trypsin 
cleavage sites in the suggested protein, the expression pattern and known glycosylation 
of the suggested protein, and any experimental evidence such as the CEACAM 
immunoblotting.  In several instances, the mass spectrometry results suggested that a 
single band contained more than one protein.  In these instances, it was ensured that 
each protein match was derived from non-overlapping sets of detected peptides.  A 
number of proteins were successfully identified using this mass spectrometry approach 
(Figure 3.4). 
The identified proteins include several cell surface proteins that are known carriers 
of Lewisx on neutrophils: CEACAM-1, ICAM-3 and the two subunits of the αMβ2 integrin 
(Skubitz and Snook, 1987; Albrechtsen and Kerr, 1989; Lucka et al., 2005).  These 
proteins are known to bind to DC-SIGN, another C-type lectin that recognizes Lewisx-
containing glycans (van Gisbergen et al., 2005b; Bogoevska et al., 2006; Bogoevska et 
al., 2007), suggesting that DC-SIGN and SRCL may interact with overlapping sets of 
neutrophil glycoproteins to mediate interaction of neutrophils with dendritic cells and 
endothelia, respectively.  The identified proteins also include neutrophil cell surface 
proteins CD45, CD148, and CEACAM-8, and soluble granule proteins MMP8, MMP9, 
NGAL, haptoglobin and orosomucoid, suggesting that both transmembrane and soluble 
proteins are tagged with Lewisx.  The other identified proteins – hemoglobin, actin and 
keratin – are not glycosylated and do not constitute candidate ligands for SRCL.  
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Figure 3.4: Candidate ligands for SRCL isolated by GalMBP affinity chromatography
Granulocyte extract was fractionated on a GalMBP affinity column.  The elution fractions 
were pooled and re-fractionated on the same column.  Fractions of repurified material were 
TCA precipitated and run on an SDS-polyacrylamide gel.  Bands were excised from the gel 
and proteins were identified by mass spectrometric analysis of tryptic fragments.  The results 
shown are derived from two separate experiments.  A small amount of GalMBP is detected 
due to leaching of immobilized protein from the column.
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Hemoglobin contamination is probably due to binding of hemoglobin to haptoglobin during 
preparation of granulocyte extract.  Insoluble cytoskeletal proteins such as actin are 
detected because they difficult to remove during washing steps, and exogenous keratin is 
introduced into the sample during experimental procedures. 
 
3.3.2 Identification of granulocyte ligands for SRCL as soluble granule proteins 
Having established that lectin affinity chromatography can be used to purify ligands for 
SRCL, and that purified ligands can be identified by mass spectrometry, it was still 
desirable to develop an affinity column that would replicate more precisely the glycan-
binding specificity of native SRCL, which is narrower than that of GalMBP and might 
exclude some proteins retained on the GalMBP column.  Although the trimeric 
extracellular domain of SRCL is difficult to produce, the monomeric CRD can be 
expressed in good yield in bacteria.  Because oligomerization of the CRD is required to 
generate a ligand-binding interaction of sufficiently high affinity to enable the purification of 
Lewisx-containing glycoproteins, artificial oligomers of the CRD were created using the 
tetravalent interaction between avidin and biotin.  The expression vector for the CRD of 
SRCL was re-engineered to introduce a biotinylation tag at the protein C-terminus, the 
modified CRD was expressed in bacteria that overexpress biotin ligase, and the resulting 
biotinylated protein was immobilized on avidin-agarose to create a suitable affinity resin 
(Figure 3.5).   
When granulocyte extract was fractionated using the SRCL affinity column, a 
subset of proteins was retained on the column and eluted with EDTA, indicating a specific 
interaction with the CRD of SRCL (Figure 3.6).  Probing of a blot of the fractions with 125I-
SRCL revealed that granulocyte proteins recognized by this native trimeric form of the 
receptor are present in the elution fractions with very little reactivity in the wash fractions, 
and thus are effectively purified using the artificial CRD oligomers of the affinity column.  
Probing of a blot of the fractions with anti-CEACAM antibodies showed that a proportion of 
CEACAM proteins is also bound by the column and eluted with EDTA, while the 
remainder is present in the wash fractions.  Thus only a subset of CEACAM proteins carry 
the appropriate glycosylation to be bound by SRCL, while a larger subset appear to be 
bound by GalMBP, presumably due to the presence of galactose-terminated glycans that 
do not carry fucose. 
Proteins purified by SRCL affinity chromatography were identified by mass 
spectrometry (Figure 3.7).  Unexpectedly, the major constituent of the bound proteins was 
found to be lactoferrin, which was not identified among the proteins purified on the 
GalMBP column.  The remaining abundant proteins were αM integrin, MMP9, and 
haptoglobin, which were also identified among GalMBP-purified proteins.  The other 
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Figure 3.6: Purification of granulocyte ligands for SRCL by affinity chromatography 
using immobilized SRCL
Granulocyte extract was fractionated on an SRCL affinity column.  The peak elution fraction 
is highlighted in yellow.  Fractions were analysed by SDS-polyacrylamide gel 
electrophoresis.  Parallel gels were stained with Coomassie blue or blotted onto 
nitrocellulose and probed with radiolabelled SRCL or anti-CEACAM antibody.
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Figure 3.7: Candidate ligands for SRCL isolated by SRCL affinity chromatography
Elution fractions from fractionation of granulocyte extract on an SRCL affinity column were 
pooled and re-fractionated on the same column.  The fractions from repurification were TCA 
precipitated and resolved by SDS-polyacrylamide gel electrophoresis.  Coomassie-stained 
bands were excised as shown and proteins identified by mass spectrometric analysis of 
tryptic fragments.  Avidin and the CRD of SRCL are detected due to leaching of these proteins 
from the column resin.
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proteins that were purified using GalMBP were not initially identified in the SRCL-purified 
material: CD148, CD45, ICAM-3, integrin β2, CEACAM-8, MMP-8 (high molecular weight 
species), and orosomucoid.  However, examination of the mass spectrometry data for 
unassigned peptides uncovered peptides attributable to integrin β2, ICAM-3, CEACAM-8, 
and MMP-8 in the appropriate molecular weight bands.  Peptides from these proteins 
were possibly harder to detect in the protein samples from the SRCL column due to 
masking by the abundance of peptides arising from lactoferrin, which covers a similar 
molecular weight range on the SDS-polyacrylamide gel.  Peptides derived from CD45 and 
CD148 were not found in the material purified on the SRCL column, which suggests that 
these cell surface proteins may carry galactose-terminated glycans which are ligands for 
GalMBP, but not the Lewisx structures required for binding to SRCL.  Three additional 
proteins were found in the SRCL-purified material but were not identified from the GalMBP 
column: PGRP, cathepsin G and YKL40.  The two former proteins are potential ligands for 
SRCL, but in the case of the YKL40, the slow release of the protein from the column in the 
presence of EDTA, and its known GlcNAc-binding activity, suggest that it may be binding 
to the glycans of avidin bound to the resin, rather than to SRCL (Volck et al., 1998; 
Houston et al., 2003).  The neutrophil proteins purified using the two different affinity 
columns show general agreement, but illustrate the lower selectivity of GalMBP for 
Lewisx-containing glycans compared to SRCL, and the novel SRCL column was essential 
for the identification of lactoferrin as a major SRCL ligand. 
The identification of ligands for SRCL illustrates the powerful approach of coupling 
affinity chromatography to mass spectrometry-based proteomic analysis to identify ligands 
for novel glycan-binding receptors.  The approach enables multiple proteins to be 
identified in a complex mixture, but is not infallible.  Where an abundant protein has a 
similar molecular weight to a scarcer protein, it is seemingly difficult to detect the scarcer 
protein.  The degree of glycosylation also affects the sensitivity of protein detection since 
glycopeptides are uninformative in protein identification due to their heterogeneous mass 
and are thus excluded from the analysis.  Therefore, even though CEACAM-1 is known to 
carry Lewisx groups and is a candidate ligand for SRCL because it was detected in 
immunoblots of SRCL ligands, it was not detected by mass spectrometry.   
The potential ligands for SRCL isolated by affinity chromatography can be 
categorized into two groups: cell surface transmembrane proteins, and soluble proteins of 
secondary granules (Figures 3.8 and 3.9).  The results therefore confirm the well-
established presence of Lewisx epitopes on neutrophil cell surface proteins like integrin 
αMβ2, ICAM-3 and CEACAM-1, which are also ligands for the Lewisx-binding C-type lectin 
DC-SIGN (van Gisbergen et al., 2005b; Bogoevska et al., 2006; Bogoevska et al., 2007).  
However the most abundant ligand for SRCL is the soluble granule protein lactoferrin.  
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Figure 3.9: Candidate granulocyte ligands for SRCL identified by mass spectrometry
Proteins were identified by mass spectrometry in material purified from granulocyte extracts 
by affinity chromatography using SRCL or GalMBP.  Proteins identified with a high 
confidence level have a probability p<0.05 of resulting from a random match with the detected 
peptides.  Proteins identified with a lower confidence level have a probability p>0.05 of 
resulting from a random match, or were identified by manual examination of detected peptide 
masses that were not assigned to a parent protein by the search software.  The subcellular 
localization of each protein within the neutrophil is indicated.  Secretory vesicles are not 
included as a separate category because their membrane proteins are very similar to those of 
the cell surface and their soluble proteins originate from serum.
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Additional candidate SRCL ligands including MMP-8, MMP-9 and haptoglobin are also 
soluble proteins found in granules.  These results suggest that a distinct group of soluble 
proteins contained within secondary granules are hitherto undiscovered major carriers of 
Lewisx in neutrophils.  The failure of previous investigations to identify these protein as 
carriers of Lewisx may be due to the use of anti-CD15 antibodies (Albrechtsen and Kerr, 
1989; Stocks et al., 1990), which may show preferable binding to Lewisx groups in certain 
types of glycans that are found on cell surface proteins more than granule proteins.  
Research has also tended to the focus on the glycosylation of cell surface molecules 
involved in cell adhesion rather than the glycosylation of granule proteins.   
The fact that the majority of the ligand molecules for SRCL in neutrophils are 
soluble granule proteins rather than cell surface proteins suggests that rather than 
functioning principally as an adhesion receptor, SRCL may have a role in clearing soluble 
secondary granule proteins that are released by degranulation of neutrophils at sites of 
inflammation.  Such a role would be consistent with the known endocytic capability of the 
receptor (Coombs et al., 2005) and would complement that of the macrophage mannose 
receptor, which clears myeloperoxidase released from neutrophil primary granules 
(Shepherd and Hoidal, 1990).  The Lewisx structure would therefore act as a recognition 
tag added to a range of soluble proteins to facilitate their clearance following exocytosis.  
This idea was investigated further using lactoferrin, the major neutrophil granule-derived 
ligand for SRCL, as a model for neutrophil secondary granule glycoproteins in general. 
 
3.3.3 Demonstration of high-affinity binding of neutrophil lactoferrin to SRCL 
Lactoferrin is the principal soluble component of neutrophil secondary granules and has 
been intensively studied for its iron-binding, antimicrobial and immunomodulatory 
properties (Faurschou and Borregaard, 2003; Legrand et al., 2008).  In addition to being 
found in neutrophil granules, lactoferrin is found in most body fluids due to secretion by 
various epithelial cell types, making it possible to investigate cell type-specific differences 
in lactoferrin glycosylation. 
Initial attempts to probe the interaction of neutrophil lactoferrin with SRCL were 
based on studies of binding to GalMBP.  Radiolabelled purified lactoferrin binds to 
GalMBP-coated wells in a solid-phase binding assay with a KD of 57 nM (Figure 3.10).  
Lactoferrin is also recognized by 125I-GalMBP in a protein blot (data not shown), and may 
account for much of the reactivity of GalMBP with blots of whole granulocyte extract.  In 
contrast, radiolabelled lactoferrin did not bind well to wells coated with the CRD of SRCL 
in this direct binding assay (Figure 3.10).  The bound radioactivity was low in comparison 
to binding to GalMBP, and binding was dominated by a linearly-increasing background.  
The greater binding of lactoferrin to GalMBP compared to SRCL in the solid-phase 
126
2
5
4
1
-
-
c
t
f
rr
i
 
o
u
n
d
 (
c
p
x
 1
0
)
I
la
o
e
n
b
m
 
0 0.25 0.50 0.75 1.00 1.25 1.50
125
I-Lactoferrin concentration (μM)
0
1
2
3
4
5
6
SRCL
GalMBP
K  = 57 nM
D
Figure 3.10: Direct binding assay for binding of lactoferrin to SRCL and GalMBP
Radiolabelled human neutrophil lactoferrin was incubated with polystyrene wells coated with 
the CRD of SRCL or with GalMBP.  Wells were washed and bound radioactivity was 
measured using a gamma counter.
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binding assay format may be due to the ability of GalMBP to bind a higher proportion of 
lactoferrin glycans, and to increased avidity of binding resulting from multivalent 
interaction with trimeric GalMBP compared to monomeric CRD of SRCL.  The importance 
of multivalency and the disposition of glycans on lactoferrin, which carries only two N-
glycans that project from diametrically opposite sites of the molecule, may also underlie 
the surprising finding that neutrophil lactoferrin does not bind to the GalMBP affinity 
column.   
Potentially, binding to the trimeric extracellular domain of SRCL might be more 
readily observed, but the amount of protein required to coat assay wells is prohibitive.  A 
competition binding assay using unlabelled tests ligands to compete with radiolabelled 
reporter ligand LNFPIII-BSA for binding to SRCL-coated wells was therefore employed as 
an alternative approach to measure lactoferrin binding.  Lactoferrin effectively competed 
with LNFPIII-BSA for binding, giving a KI of 6.1 μM, compared to values of 87 μM for 
Lewisx and 15.9 mM for α-methyl galactoside (Figure 3.11).  Lactoferrin thus binds to 
SRCL with approximately 10-fold higher affinity than does Lewisx.  It has been observed 
that glycoproteins bind to glycan-binding proteins with higher affinity than free glycans, 
even where the enhancement cannot be due to multivalent effects (Coombs et al., 2010).  
The difference in binding affinity between lactoferrin and Lewisx may therefore be due to 
presentation of the Lewisx structure on a glycoprotein rather than to multivalent 
interactions between lactoferrin and SRCL.   
As an additional strategy to measure directly the affinity of lactoferrin binding to 
SRCL, binding was monitored by surface plasmon resonance.  Sensor chips coated with a 
carboxymethylated dextran matrix were activated to generate succinimide esters which 
react with the amine groups of proteins, and lactoferrin was immobilized on the sensor 
chip surface (Figure 3.12).  The CRD of SRCL was flowed over the chip at varying 
concentrations.  Because the CRD of SRCL is monomeric, the binding detected 
represents the interaction of one protein molecule with one glycan.  From the dependence 
of the surface response on the concentration of SRCL, a binding constant of 4.7 μM was 
obtained for the CRD of SRCL binding to neutrophil lactoferrin, in good agreement with 
the value obtained using the competition assay.  However this is a preliminary experiment, 
and the response of a reference surface when SRCL sample solution is flowed over 
should be subtracted from the response of the lactoferrin-coated surface, to remove the 
bulk contribution to the signal prior to fitting the data to a binding equation.  Therefore this 
KD value, and those reported below, are tentative values. 
In an attempt to test the effect of the disposition of the two glycans on lactoferrin, 
the set-up of the surface plasmon resonance experiment was reversed such that the CRD 
of SRCL was immobilized on the sensor chip and lactoferrin flowed over the chip surface.  
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Figure 3.11: Competition assay for binding of lactoferrin to SRCL
 
The binding of ligands to the CRD of SRCL immobilized in a well plate was measured using
125
I-LNFPIII-BSA as a reporter ligand.  K  values are reported as the mean
I
 ± standard 
deviation based on experiments performed twice in duplicate.  Representative data from one 
experiment are shown.
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Figure 3.12: Measurement of affinity for binding of SRCL to lactoferrin by surface 
plasmon resonance
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Under the immobilization conditions employed for lactoferrin, no CRD of SRCL was 
immobilized on the chip surface (Figure 3.13).  The theoretical isoelectric point of the CRD 
of SRCL is at pH 4.7, such that the protein would not carry the net positive charge 
required for electrostatic pre-concentration at the pH of 5.0 used for this attempt at 
immobilization. (Johnsson et al., 1991).  Dropping the pH of the coupling buffer to pH 4.0 
resulted in association of SRCL with the chip surface, although the overall immobilization 
level was still poor.  The immobilization level was increased slightly by raising the 
concentration of CRD to compensate for poor pre-concentration, as well as increasing the 
reaction time and lowering the pH further to 3.5.  The pH could not be dropped below 3.5 
because the carboxymethylated dextran matrix would no longer be negatively charged.   
A binding constant of 0.1 μM was obtained for neutrophil lactoferrin binding to the 
SRCL-coated chip (Figure 3.14), but the accuracy of this value may be affected by the low 
signal and high linearly-increasing background.  An attempt was made to measure a 
binding constant for Lewisx binding to the SRCL-coated chip for comparison with 
lactoferrin, but no binding was detected above the level of noise in the signal, and a 
linearly-increasing background dominated the signal overall.  To try to achieve a stronger 
signal, binding of a Lewisx derivative with a higher molecular weight was recorded, but did 
not provide better data than the Lewisx alone.  The low signals obtained with all samples 
reflect the low level of CRD of SRCL which could be immobilized on the chip. 
 
3.3.4 Cell type-specific glycosylation of lactoferrin 
To provide a routine assay for SRCL binding, an improved reagent for detection of SRCL 
ligands on nitrocellulose membranes was developed.  Radiolabelled extracellular domain 
of SRCL had been used for this purpose, but was inconvenient in terms of protein 
production and the need for radio-iodination.  To circumvent these problems and provide a 
faster, enzyme-based colorimetric detection method,  biotinylated CRD of SRCL was 
complexed with alkaline phosphatase-conjugated streptavidin, creating a multivalent 
reagent, as was done to create the SRCL affinity resin.  Streptavidin was incubated with a 
large excess of biotinylated CRD of SRCL to maximize streptavidin site occupancy.  
Complexes could be conveniently purified using galactose-Sepharose affinity 
chromatography, because the excess uncomplexed CRD of SRCL binds only weakly to 
galactose and could be removed from the column by extensive washing with Ca2+-
containing buffer, whereas the CRD clusters created by complexing with streptavidin have 
a higher affinity for galactose, like the trimeric extracellular domain of the receptor, and 
are only removed from the column with EDTA (Figure 3.15).  
The complex of biotinylated CRD of SRCL with alkaline phosphatase-conjugated 
streptavidin, referred to as SRCL-AP, was tested for its ability to detect the Lewisx-
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Figure 3.13: Optimization of SRCL immobilization on surface plasmon resonance 
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Figure 3.14: Binding of neutrophil lactoferrin to immobilized SRCL detected by surface 
plasmon resonance
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Figure 3.15: Creation and validation of a SRCL-streptavidin-alkaline phosphatase 
complex (SRCL-AP) for detecting SRCL ligands in protein blots
Top: Biotin-tagged CRD of SRCL was incubated with streptavidin-alkaline phosphatase and 
applied to a column of galactose-Sepharose.  Weakly-binding monomeric CRD molecules 
2+
were removed by washing with buffer containing Ca .  Strongly-binding CRD-streptavidin 
complexes were eluted with buffer containing EDTA.  The peak fraction is highlighted.  
Bottom: The specificity of SRCL-AP in binding to purified glycoproteins (5 μg) was examined 
by comparing binding to asialo-orosomucoid (ASOR) with soybean agglutinin (SBA).  
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containing glycoprotein asialo-orosomucoid, which is recognized by the trimeric 
extracellular domain of SRCL (Coombs et al., 2005), with soybean agglutinin, which 
carries exclusively high-mannose glycans (Dorland et al., 1981), used as a negative 
control (Figure 3.15).  The asialo-orosomucoid reacted very strongly with SRCL-AP, while 
there was no reaction to soybean agglutinin, indicating that SRCL-AP is able to recognize 
Lewisx-carrying glycoproteins in protein blots in a specific manner.  Probing of human 
granulocyte extract with SRCL-AP revealed multiple reactive bands (Figure 3.16), in a 
similar pattern to the reactivity observed with radiolabelled extracellular domain of SRCL 
and granulocyte extracts (Figure 3.2), suggesting that the two reagents have similar 
activity in the recognition of SRCL ligands.  The major species detected using SRCL-AP 
was a doublet band at 70-80 kDa, which coincides with the major band of reactivity on a 
blot probed with anti-lactoferrin antibodies, consistent with lactoferrin being the major 
ligand for SRCL in neutrophils.   
To determine if the addition of glycans recognized by SRCL to lactoferrin might 
represent a neutrophil-specific tagging of the protein, or if lactoferrin attracts similar 
glycosylation in multiple tissues, the reactivity of SRCL-AP towards lactoferrin purified 
from human neutrophils was compared with the reactivity towards lactoferrin isolated from 
human milk (Figure 3.17).  Although any interaction of SRCL with milk-derived lactoferrin 
is probably not of physiological relevance given the expression pattern of SRCL, milk is a 
convenient source of epithelial cell-derived lactoferrin that was expected to have 
undergone different glycan processing to neutrophil-derived lactoferrin.  SRCL-AP was far 
more reactive towards neutrophil-derived lactoferrin than milk lactoferrin, suggesting that 
the neutrophil protein carries more Lewisx structures which are recognized by SRCL.  
Consistent with the poorer binding of SRCL-AP to milk lactoferrin, a KI value for milk 
lactoferrin in the solid-phase competition binding assay could not be measured accurately 
because sufficiently high protein concentrations could not be achieved, although the KI 
appeared to be similar to Lewisx (data not shown).  Surface plasmon resonance data for 
the interaction of milk lactoferrin and the CRD of SRCL could also not be satisfactorily 
fitted to a direct binding equation, possibly because the binding was too weak (data not 
shown). 
The much greater reactivity of SRCL-AP with neutrophil lactoferrin is consistent 
with the documented abundance of the Lewisx modification in neutrophils (Babu et al., 
2009), and is indicative of neutrophil-specific glycosylation of lactoferrin.  Similar 
glycosylation may be applied to lactoferrin and other neutrophil granule proteins that are 
ligands for SRCL, constituting a common recognition tag.  The small degree of reactivity 
of SRCL-AP towards milk lactoferrin probably also results from the presence of Lewisx 
structures in milk lactoferrin glycans (Matsumoto et al., 1982; Spik et al., 1982).  The 
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Figure 3.16: Detection of SRCL ligands in granulocyte extract using SRCL-AP
Granulocyte extract was resolved by SDS-polyacrylamide gel electrophoresis and stained 
with Coomassie blue or transferred to nitrocellulose for probing with SRCL-AP and anti-
lactoferrin antibodies.
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Figure 3.17: Differential binding of SRCL to lactoferrin from neutrophils and milk
Top: Comparison of binding of SRCL-AP to milk and neutrophil lactoferrins.  Bottom: 
Fractionation of lactoferrin on an SRCL affinity column.
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difference in reactivity may simply reflect the presence of Lewisx groups on a higher 
proportion of neutrophil lactoferrin molecules, or may be due to different presentation of 
the Lewisx structures, for example on poly-N-acetyllactosamine extensions or on multiple 
antennae, which creates a higher-affinity interaction with SRCL. 
Additional evidence for differential interaction of SRCL with milk and neutrophil 
lactoferrin was obtained by fractionation of the lactoferrin samples on an SRCL affinity 
column (Figure 3.17).  Some neutrophil lactoferrin was washed off the column with Ca2+-
containing buffer, but most was only released using EDTA, indicating that the majority of 
neutrophil lactoferrin molecules bind with high affinity to SRCL.  In contrast, almost all of 
the milk-derived protein was washed off the column with Ca2+-containing buffer, with only 
a very minor proportion being eluted with EDTA, indicating that the majority of molecules 
do not bind to SRCL or bind with low affinity.  High-affinity binding leading to retention of 
proteins on the SRCL column may result from multivalent interaction of multiple Lewisx 
groups, either on separate glycans or on different branches of the same glycan, with 
SRCL CRD molecules.  A low-affinity monovalent interaction between a glycoprotein and 
SRCL may be insufficient to cause retention of the protein.  A possible interpretation of the 
fractionation of lactoferrin samples on the SRCL affinity column is therefore that neutrophil 
lactoferrin carries multiple Lewisx groups per molecule whereas a milk lactoferrin molecule 
carries on average a single Lewisx group or no Lewisx groups. 
 
3.3.5 Fucose-dependent binding of SRCL to neutrophil granule proteins  
If the binding of SRCL-AP to lactoferrin molecules is due to binding to Lewisx groups as 
proposed, then the removal of fucose residues should abolish binding.  To ascertain the 
dependency of SRCL binding on fucose residues, milk and neutrophil lactoferrin 
preparations were digested with α-L-fucosidase from bovine kidney, which can remove all 
fucose residues from mammalian N-glycans (Koles et al., 2005).  Blots of digested and 
undigested lactoferrin were probed with SRCL-AP and with 125I-SRCL, and both lactoferrin 
preparations were found to exhibit greatly reduced reactivity with SRCL following 
fucosidase treatment (Figure 3.18).  The radioactivity-based detection method, in which 
the measured response is linearly proportional to the number of SRCL molecules bound, 
shows a greater reduction in SRCL binding following fucosidase treatment than the 
enzyme-based detection method, suggesting that non-linearity in the signal with this 
method over-represents the binding of SRCL to defucosylated samples.  The reactivity of 
SRCL with defucosylated samples is probably due to residual fucose which has not been 
removed, since fucosidase treatment of the neoglycoprotein SRCL ligand LNFPIII-BSA 
also did not completely eliminate reactivity even though, in this defined neoglycoprotein, 
only Lewisx groups are responsible for binding of SRCL.  The efficiency of fucose 
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Figure 3.18: Effect of fucosidase treatment on SRCL binding to Lewis -containing 
glycoconjugates
Top and centre: Blots of milk and neutrophil lactoferrins (1 μg each) resolved by SDS-
polyacrylamide electrophoresis were probed with SRCL-AP or radiolabelled extracellular 
domain of SRCL.  Bottom: LNFPIII-BSA (0.2 μg) was probed with radiolabelled extracellular 
domain of SRCL.  Lanes treated with fucosidase are marked F.  The fucosidase protein is 
detected by the extracellular domain of SRCL but not by the CRD, suggesting a non-
carbohydrate-based interaction with the neck region of SRCL.
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cleavage is also known to be reduced on larger and more complex glycans (Koles et al., 
2005).   
The reduction in SRCL binding to milk and neutrophil lactoferrin following 
fucosidase treatment confirms that fucose residues are responsible for the binding of 
SRCL to lactoferrin from both sources.  An attempt was made to observe loss of binding 
of SRCL to neutrophil lactoferrin by surface plasmon resonance following fucosidase 
digestion (Figure 3.19).  Digested and undigested lactoferrin samples were immobilized 
on a sensor chip and the binding of the CRD of SRCL to the chips was monitored.  
However, similar binding constants were obtained for SRCL binding to both lactoferrin 
samples, suggesting that the residual fucose following digestion is sufficient to mediate 
maximal SRCL binding in this experimental situation. 
The difference in SRCL binding to milk and neutrophil lactoferrins might be due to 
differences in sialylation.  SRCL does not bind to sialyl-Lewisx structures, and therefore 
might not recognize milk lactoferrin glycans because they are capped with sialic acid.  
Digestion of the milk and neutrophil lactoferrin samples with neuraminidase brought about 
a shift in the electrophoretic mobility of the proteins, indicating that the treatment had 
removed sialic acid residues from the glycans (Figure 3.20).  The mobility shift was more 
prominent for milk lactoferrin than for neutrophil lactoferrin, suggesting that milk lactoferrin 
carries more sialic acid residues.  If lactoferrin carries sialyl-Lewisx groups, then 
neuraminidase treatment would create additional Lewisx groups and increase binding of 
SRCL.  However, neuraminidase digestion did not affect the reactivity of SRCL-AP with 
the lactoferrin samples, indicating that few sialyl-Lewisx groups are present in either 
sample.  The difference in binding of milk and neutrophil lactoferrins to SRCL is therefore 
not due to masking of Lewisx epitopes in milk lactoferrin by sialic acid capping.  However, 
if sialylation and fucosylation are mutually exclusive, as these results suggest, then the 
greater degree of sialylation in milk lactoferrin will reduce the number of glycan antennae 
available for display of unsialylated Lewisx groups. 
To investigate the structures of lactoferrin N-glycans further, the N-linked glycans 
were enzymatically cleaved from lactoferrin samples and covalently linked to lipid to 
generate neoglycolipids that were resolved by thin-layer chromatography and probed with 
radiolabelled SRCL (Chai et al., 2003).  In addition to using glycans released from 
lactoferrin, neoglycolipids were also synthesized using LNFPIII, to serve as a positive 
control for SRCL binding, and using unsialylated biantennary and triantennary N-linked 
glycans, in order to provide an approximate indication of glycan size.  The neoglycolipids 
produced from both lactoferrin samples appear to be complex mixtures, because they do 
not fully resolve into discrete bands, and SRCL binds to a range of neoglycolipids in both 
lactoferrin samples (Figure 3.21).  The majority of the reactive glycolipids from the 
141
Figure 3.19: Binding of SRCL to fucosidase-treated lactoferrin detected by surface 
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Figure 3.20: Effect of neuraminidase treatment on recognition of lactoferrin by SRCL
Lactoferrin from milk and neutrophils (5 μg) was digested with neuraminidase (lanes marked 
N).
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Figure 3.21: Binding of SRCL to neoglycolipids synthesized using N-linked glycans 
from lactoferrin
Glycans were cleaved from milk and neutrophil lactoferrins and coupled to lipid.  
Neoglycoproteins were also synthesized using lacto-N-fucopentaose-III (LNFPIII), which 
x
includes the Lewis  epitope, and galactose-terminated biantennary and triantennary N-linked 
glycans.  Neoglycolipids were resolved by thin-layer chromatography before staining with 
orcinol or probing with radiolabelled extracellular domain of SRCL.
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neutrophil sample were less mobile than unsialylated triantennary glycans, suggesting 
that they are larger glycans with additional antennae or N-acetyllactosamine extensions.  
The neoglycolipids produced from the milk sample were generally more mobile than those 
from the neutrophil sample, suggesting that they tend to be smaller.  The differences in 
mobility may also reflect differences in sialylation and fucosylation.  However, the 
neoglycolipid mixtures are too complex to permit identification of the structures of 
individual glycans recognized by SRCL by mass spectrometry (Chai et al., 2003).   
The fucose-dependency of SRCL binding to two additional neutrophil granule 
proteins isolated by SRCL affinity chromatography was also investigated.  MMP-8 and 
MMP-9 from human neutrophils were digested with fucosidase and blots probed with 125I-
SRCL (Figure 3.22).  Strong reactivity was observed with MMP-9, and the binding was 
eliminated by fucosidase treatment.  A smaller amount of fucose-dependent reactivity was 
observed with MMP-8, which appears as a range of proteolytic fragments, as observed 
with granulocyte extract (Figures 3.4 and 3.7).  Fucose-dependent binding of SRCL to 
MMP-8 and -9 in addition to lactoferrin suggests that SRCL recognizes glycan structures 
common to a range of neutrophil granule proteins, and that lactoferrin can be used as a 
model for this group of proteins. 
 
3.3.6 Mass spectrometry analysis of lactoferrin glycans 
To determine the structures of the glycans present on milk and neutrophil lactoferrin, 
mass spectrometry analysis was performed on the total glycan pool released from 
lactoferrin samples.  Human lactoferrin has three potential N-glycosylation sites, two of 
which occur at equivalent positions in the two homologous lobes of the protein, while the 
third is located in the C-terminal lobe.  It has been known for some time that human milk 
lactoferrin carries only two N-linked glycans (Monsigny and Montreuil, 1966).  Analysis of 
the lactoferrin amino acid sequence using the NetNGlyc 1.0 server, which predicts N-
glycosylation sites in human proteins, suggests that the two occupied sites are those that 
are located at equivalent positions in the two lobes of the protein, and experiments using 
glycosylation site mutants indicate that this is indeed the case for the majority of lactoferrin 
molecules (van Berkel et al., 1996).   
The structure of milk lactoferrin glycans in fractionated glycopeptides has been 
characterized by monosaccharide composition and linkage analysis and 1H-NMR (Spik et 
al., 1982).  The structures were assigned as biantennary with core fucose, with the 
Manα1,3Man arm terminated with sialic acid, and the Manα1,6Man arm terminated with 
sialic acid, galactose, or Lewisx.  Additional, very minor components were similar glycans 
containing one or two extra fucosyl-N-acetyllactosamine units.  No site specificity of 
glycosylation was observed.  A second study provided similar results, with the addition of 
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Figure 3.22: Effect of fucosidase treatment on SRCL binding to neutrophil
matrix metalloproteinases
Neutrophil-derived matrix metalloproteinases 8 and 9 (MMP-8 and MMP-9, 2 μg) were 
probed with radiolabelled extracellular domain of SRCL.  Lanes treated with fucosidase are 
marked F.
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unsialylated versions of the glycans (Matsumoto et al., 1982).  Using similar techniques to 
those applied to the milk lactoferrin, it was found that human neutrophil lactoferrin glycans 
are homogeneous biantennary structures with terminal sialic acid and the complete 
absence of fucose, even from the core (Derisbourg et al., 1990).   
The reported absence of fucose from lactoferrin N-glycans is surprising, since the 
widespread expression of the various human fucosyltransferases might be expected to 
result in fucosylation of at least some molecules.  The apparent homogeneity of the 
glycans would also be unusual, yet no further investigation into the structure of neutrophil 
N-glycans has been conducted to confirm these findings.  The fucose dependency of 
SRCL binding demonstrated here is in direct contradiction of this report and indicates that 
the structures of neutrophil lactoferrin glycans need to be re-examined.  There is also no 
published account of the structure of human milk lactoferrin glycans as determined using 
modern mass spectrometry techniques, despite interest in the therapeutic potential of 
lactoferrin and in the interaction of lactoferrin with a sugar-binding receptor in the intestine 
(Suzuki et al., 2001; Lonnerdal, 2009), so its glycan composition was studied in parallel.   
To prepare glycans from lactoferrin for mass spectrometry analysis, the lactoferrin 
polypeptides were linearized by reduction and carboxymethylation, and digested with 
trypsin to enable isolation of glycopeptides.  Intact N-glycans were released from 
glycopeptides using peptide N-glycanase F (PNGase F) to cleave the bond between 
GlcNAc and asparagine.  Glycans were detected using matrix-assisted laser desorption 
ionization (MALDI) mass spectrometry (MS), following permethylation to improve the 
sensitivity of detection.  No O-glycans were detected following reductive elimination of 
either milk or neutrophil lactoferrin glycopeptides.  Since there have been no previous  
reports of O-glycosylation in lactoferrin, and no O-glycan attachment sites were predicted 
upon submitting the amino acid sequence of lactoferrin to the NetOGlyc 3.1 server, which 
predicts mucin-type O-glycosylation in mammalian proteins, all subsequent experiments 
were directed towards N-glycans.   
 
3.3.7 Analysis of N-glycans from milk lactoferrin 
The MALDI MS molecular ion profile of N-glycans released from milk lactoferrin shows 
several peaks, indicating heterogeneity in the glycan structures (Figure 3.23).  The 
deduced monosaccharide compositions indicate that, as might be expected for a mature 
secretory protein, all the glycans have been processed to complex type structures rather 
than remaining as high-mannose or hybrid structures (Table 3.1).  The majority of the 
glycans have a minimal biantennary HexNAc4Hex5 skeleton without additional N-
acetyllactosamine units on the antennae.  Virtually all glycan species are fucosylated and 
some are sialylated. 
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m/z Glycan composition 
2070.5 HexNAc4Hex5 
2244.6 HexNAc4Hex5Fuc1 
2418.7 HexNAc4Hex5Fuc2 
2431.7 HexNAc4Hex5NeuAc1 
2592.9 HexNAc4Hex5Fuc3 
2605.9 HexNAc4Hex5Fuc1NeuAc1 
2767.0 HexNAc4Hex5Fuc4 
2780.0 HexNAc4Hex5Fuc2NeuAc1 
2868.1 HexNAc5Hex6Fuc2 
2954.1 HexNAc4Hex5Fuc3NeuAc1 
2967.1 HexNAc4Hex5Fuc1NeuAc2 
3042.2 HexNAc5Hex6Fuc3 
3055.2 HexNAc5Hex6Fuc1NeuAc1 
3216.3 HexNAc5Hex6Fuc4 
3229.3 HexNAc5Hex6Fuc2NeuAc1 
3391.4 HexNAc5Hex6Fuc5 
3403.4 HexNAc5Hex6Fuc3NeuAc1 
3577.6 HexNAc5Hex6Fuc4NeuAc1 
3679.6 HexNAc6Hex7Fuc2NeuAc1 
3852.7 HexNAc6Hex7Fuc3NeuAc1 
4026.8 HexNAc6Hex7Fuc4NeuAc1 
 
 
Table 3.1: Monosaccharide compositions of N-glycans from milk lactoferrin 
 
There are several possibilities regarding the positions of the fucose and sialic acid 
residues within the glycans, which can be distinguished to some extent using MS/MS 
fragmentation data.  A single fucose residue may be linked to the core GlcNAc, but a 
glycan including two or more fucose residues must have outer-arm fucose residues 
connected to N-acetyllactosamine units in the antennae.  Outer-arm fucose may be linked 
to GlcNAc in an α1,3 or α1,4 linkage, forming the Lewisx and Lewisa structures 
respectively if the GlcNAc residue is that nearest the antenna terminus, or may be α1,2-
linked to terminal galactose, forming an H antigen.  Fucosylation of terminal galactose and 
adjacent GlcNAc residues produces the Lewisy and Lewisb structures.  Lewisx and Lewisa 
structures also occur in sialylated forms.  Which of these structures is found depends on 
the interplay of fucosyltransferases, sialyltransferases and galactosyltransferases 
expressed in the cell.   
It has been established previously that the antennae on neutrophil glycans contain 
fucose in the α1,3 linkage of the Lewisx epitope but not the α1,4 linkage of the Lewisa 
structure (Fukuda et al., 1984).  1H-NMR data on milk lactoferrin glycans indicate that the 
fucose in these glycans is also α1,3 linked (Spik et al., 1982).  It is possible that milk 
lactoferrin may include some Lewisa structures because epithelial cells in general are 
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known to express the α1,4-fucosyltransferases FUT3 and FUT5, and an enzyme with this 
specificity can be purified from human milk (Brinkman-Van der Linden et al., 1996).  The 
structures of the free oligosaccharides that are found in milk in large quantities reflect 
genetic polymorphisms in the α1,2- and α1,4-fucosyltransferase genes and can include 
Lewisa and Lewisb groups (Erney et al., 2001), however it is not known to what extent 
these enzymes modify the protein-linked glycans in milk in addition to free 
oligosaccharides.  For the purpose of this analysis, glycans will be assumed to carry 
Lewisx rather than Lewisa, but both structures are recognized by SRCL (Coombs et al., 
2005).   
The configuration of fucose and sialic acid residues within milk lactoferrin glycans 
was deduced by fragmentation of molecular ions.  Looking at the smallest unsialylated 
glycans (Figure 3.24), the singly-fucosylated form is a mixture of two isoforms: the major 
component has core fucose, while the minor form instead has outer-arm fucose forming a 
Lewisx epitope.  Similarly, the form with two fucose residues is a mixture of one structure 
with core fucose and a single Lewisx epitope and a second structure with two Lewisx 
epitopes and no core fucose.  The three-fucose form is a single isoform with core fucose 
and two Lewisx epitopes.  Among the sialylated counterparts of these glycans, the sialic 
acid and fucose residues are always found on separate antennae, so that the sialyl-Lewisx 
epitope is not observed (Figure 3.25).  This arrangement reflects the acceptor specificities 
of the glycosyltransferases: sialyltransferases cannot act on fucosylated antennae, while 
only a subset of fucosyltransferases are able to act on sialylated termini.  Previous data 
suggest that the sialylated antenna stems from the Manα1,3Man branch (Spik et al., 
1982), such that outer-arm fucose residues are found only on the Manα1,6Man branch.   
The absolute segregation of fucosylation and sialylation means that the 
monosialylated, trifucosylated glycan (HexNAc4Hex5Fuc3NeuAc1) has Lewisy as the 
terminal structure on the unsialylated antenna.  The presence of Lewisy in several milk 
lactoferrin glycans is suggested by monosaccharide compositions in which the number of 
fucose residues exceeds the number of GlcNAc residues available to accept fucose, 
indicating that fucose must also be present in an α1,2-linkage to galactose: for example, 
HexNAc4Hex5Fuc4, HexNAc5Hex6Fuc5, HexNAc4Hex5Fuc3NeuAc1, and 
HexNAc5Hex6Fuc4NeuAc1.  The Lewisy structure can be detected directly in MS/MS 
analysis of some milk lactoferrin glycans by the presence of the fragment ion m/z 834 
[Fucα1-2Galβ1-4(Fucα1-3)GlcNAc], and loss of this fragment from the molecular ion.  
Lewisy-containing glycans have not previously been detected in milk lactoferrin, illustrating 
the ability of mass spectrometry to identify very minor glycan species.  Lewisy epitopes in 
secretions including milk are produced by the action of the α1,2-fucosyltransferase FUT2 
(Mollicone et al., 1995).  No Lewisy-containing glycans were detected in MS and MS/MS 
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xFigure 3.24: MS/MS analysis of milk lactoferrin glycans showing Lewis  groups
The molecular ion peak is at the far right and arrows indicate portions of the antennae lost by 
fragmentation of the molecular ion.
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Figure 3.25: MS/MS analysis of milk lactoferrin glycans showing separation of 
fucosylation and sialylation on separate antennae
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analysis of neutrophil lactoferrin (below), consistent with absence of expression of either 
human α1,2-fucosyltransferase (FUT1 or FUT2) in granulocytes (Mollicone et al., 1995). 
The molecular ion profile of milk lactoferrin glycans shows that glycans with 
additional N-acetyllactosamine units are present in low abundance, making them harder to 
analyse by MS/MS.  It is however apparent from fragmentation data that these structures 
are biantennary glycans, rather than triantennary glycans, in agreement with previous 
reports (Matsumoto et al., 1982; Spik et al., 1982) (Figure 3.26).  Furthermore, the 
additonal N-acetyllactosamine units are added to one antenna only, and it is this antenna 
that carries fucose residues, while the unextended antenna is capped with sialic acid.  The 
extended, fucosylated antenna is therefore presumably the Manα1,6Man branch while the 
unextended sialylated antenna is the Manα1,3Man branch.   
 
3.3.8 Analysis of N-glycans from neutrophil lactoferrin 
The mass spectrometry analysis described above indicates that a large proportion of milk 
lactoferrin glycans carry the Lewisx structure, which accounts for the recognition of milk 
lactoferrin by SRCL.  Given that the binding of SRCL to milk lactoferrin is weak in 
comparison to binding to neutrophil lactoferrin, it is expected that neutrophil lactoferrin will 
show significant differences in the number or presentation of Lewisx groups that make it a 
superior ligand for SRCL.   
The MALDI-MS molecular ion profile of neutrophil lactoferrin N-glycans shows a 
greater number of peaks than that of milk lactoferrin, indicating that lactoferrin from 
neutrophils carries a greater range of glycan structures (Figure 3.27 and Table 3.2).  The 
glycans are also of generally greater size than those from milk lactoferrin, with a large 
portion of the molecular ions found in the mass range above m/z 3500, where very few 
glycans from milk lactoferrin were detected.  Thus neutrophil lactoferrin glycans commonly 
have up to five additional N-acetyllactosamine units added to the basic core, whereas milk 
lactoferrin glycans are predominantly without additional N-acetyllactosamine units.  The 
glycans from neutrophil lactoferrin can be grouped into six series with skeletons of 
compositions HexNAc4Hex5, HexNAc5Hex5, HexNAc6Hex7, HexNAc8Hex9, HexNAc9Hex10.  
The glycans in each series are elaborated by the addition of variable numbers of fucose 
and sialic acid residues.  While virtually all glycans in both milk and neutrophil lactoferrins 
are fucosylated, the degree of sialylation in neutrophil lactoferrin is markedly lower than 
for milk lactoferrin, in agreement with the smaller electrophoretic shift observed following 
neuraminidase digestion (Figure 3.14).   
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Figure 3.26: MS/MS analysis of milk lactoferrin glycans showing that larger glycans 
are biantennary with poly-N-acetyllactosamine extension of one antenna only
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m/z Glycan composition 
2244.6 HexNAc4Hex5Fuc1 
2418.7 HexNAc4Hex5Fuc2 
2592.8 HexNAc4Hex5Fuc3 
2693.9 HexNAc5Hex6Fuc1 
2779.9 HexNAc4Hex5Fuc2NeuAc1 
2868.0 HexNAc5Hex6Fuc2 
3042.1 HexNAc5Hex6Fuc3 
3143.2 HexNAc6Hex7Fuc1 
3216.2 HexNAc5Hex6Fuc4 
3229.3 HexNAc5Hex6Fuc2NeuAc1 
3317.3 HexNAc6Hex7Fuc2 
3403.4 HexNAc5Hex6Fuc3NeuAc1 
3491.5 HexNAc6Hex7Fuc3 
3665.6 HexNAc6Hex7Fuc4 
3766.7 HexNAc7Hex8Fuc2 
3840.7 HexNAc6Hex7Fuc5 
3855.7 HexNAc6Hex7Fuc3NeuAc1 
3943.7 HexNAc7Hex8Fuc3 
4117.8 HexNAc7Hex8Fuc4 
4218.9 HexNAc8Hex9Fuc2 
4291.9 HexNAc7Hex8Fuc5 
4302.0 HexNAc7Hex8Fuc3NeuAc1 
4393.0 HexNAc8Hex9Fuc3 
4479.0 HexNAc7Hex8Fuc4NeuAc1 
4565.2 HexNAc8Hex9Fuc4 
4653.5 HexNAc7Hex8Fuc5NeuAc1 
4740.2 HexNAc8Hex9Fuc5 
4841.4 HexNAc9Hex10Fuc3 
4915.7 HexNAc8Hex9Fuc6 
4928.5 HexNAc8Hex9Fuc4NeuAc1 
5016.4 HexNAc9Hex10Fuc4 
5102.5 HexNAc8Hex9Fuc5NeuAc1 
5190.3 HexNAc9Hex10Fuc5 
5363.4 HexNAc9Hex10Fuc6 
 
 
Table 3.2: Monosaccharide compositions of N-glycans from neutrophil lactoferrin 
 
MS/MS analysis of glycans in the HexNAc4Hex5 series shows that the unsialylated 
forms with 1-3 fucose residues have the same structures as in milk lactoferrin, but core 
fucose is potentially present on a higher proportion of glycans (data not shown).  Of the 
sialylated versions of these glycans, only the difucosylated glycan is detectable in 
neutrophil lactoferrin due the general reduction in sialylation levels compared with milk 
lactoferrin.  However in both milk and neutrophil lactoferrin glycans, fucose and sialic acid 
residues are always separated on different antennae.   
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Glycans in the HexNAc4Hex5 series are therefore similar in structure in milk and 
neutrophil lactoferrin, except for the reduced level of sialylation in the neutrophil protein.  
Glycans in the larger series have more scope for structural variability because the 
additional N-acetyllactosamine units can be added to the core in different ways.  Up to two 
additional antennae are commonly added to mammalian glycans and any of these 
antennae can be extended with additional N-acetyllactosamine units.  Thus for the largest 
neutrophil glycans – those in the HexNAc8Hex9 and HexNAc9Hex10 series – there are 
multiple possible configurations for the glycan skeleton.  The number of structural isomers 
is increased further when the skeleton is elaborated with core fucose and with variable 
numbers of fucose and sialic acid residues on the antennae.  It is probable that a large, 
moderately-abundant neutrophil lactoferrin glycan such as HexNAc8Hex9Fuc4 exists as a 
number of different isomers because it may be equally likely, for example, for a fucose 
residue to be added to one antenna of the glycan as to another.  However it is also likely 
that some structures are more common than others, for example due to extension of 
antennae being more prevalent than initiation of new antennae.  Such details are 
important when considering the interaction of lactoferrin with SRCL because the way in 
which Lewisx groups are displayed (such as on poly-N-acetyllactosamine extensions, or 
on multiple antennae) may influence binding.  The locations of fucose residues within the 
glycan are particularly significant because only fucose that is linked to the GlcNAc residue 
of a terminal N-acetyllactosamine unit is recognized by SRCL – fucose linked to the 
GlcNAc residue of an internal N-acetyllactosamine unit cannot bind to the receptor 
because there is no adjacent terminal galactose residue available for binding. 
 
3.3.9 Branching and fucosylation in neutrophil lactoferrin N-glycans 
To make an assessment about the structures of larger neutrophil glycans, it was 
necessary to supplement MS/MS data on the glycans with information from additional 
mass spectrometry-based approaches.  To assess the extent to which the glycans are 
branched to form tri- or tetra-antennary glycans, gas chromatography (GC)-MS linkage 
analysis was performed.  A permethylated glycan sample was fully hydrolysed and the 
resulting free hydroxyl groups were acetylated, thus marking which hydroxyl groups were 
involved in glycosidic bonds.  The resulting partially-methylated alditol acetates (PMAAs) 
were resolved and detected by GC-MS, and were identified based on established elution 
times.  All glycans contain one core mannose residue bonded at the 3 and 6 positions (or 
3, 4 and 6 positions if bisecting GlcNAc is present), which was used to normalize signal 
levels.   
To examine branching in neutrophil lactoferrin, the linkages of the mannose 
residues which lie at the bases of the antennae were examined (Table 3.3).  Biantennary 
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glycans contain mannose bonded only at the 2 position because in both antennae the 
initiating GlcNAc residue is connected to mannose in β1,2 linkage.  Additional antennae 
are initiated by the actions of GlcNAc-transferase IV, which transfers GlcNAc in a β1,4 
linkage to the Manα1-3Man branch, and GlcNAc-transferase V, which transfers GlcNAc in 
a β1,6 linkage to the Manα1-6Man branch.  Triantennary glycans therefore contain 50% 
mannose bonded at the 2 position and 50% mannose bonded at the 2+4 or 2+6 positions, 
and tetra-antennary glycans contain 50% mannose bonded at the 2+4 positions and 50% 
bonded at the 2+6 positions.  Linkage analysis indicated that 47% of mannose in 
neutrophil lactoferrin carries β1,2-linked GlcNAc, 20% carries β1,2- and β1,4-linked 
GlcNAc, and 32% carries β1,2- and β1,6-linked GlcNAc.  The presence of substantial 
amounts of β1,4- and β1,6-linked GlcNAc in neutrophil lactoferrin indicates that unlike milk 
lactoferrin, it carries a significant fraction of branched glycans.  The results are however 
consistent with a range of possible distributions of bi-, tri- and tetra-antennary glycans.  At 
one extreme, the glycans could be almost entirely triantennary, while at the other extreme, 
they could be divided roughly equally into biantennary and tetra-antennary populations 
with only a minor triantennary component. 
 
Mannose linkage Peak area % of total mannose 
Mannose bonded at 2 position 1136054 47.2 
Mannose bonded at 2 and 4 positions 489991 20.4 
Mannose bonded at 2 and 6 positions 778855 32.4 
Total 2404900 100.0 
 
Table 3.3: Detection of branching in neutrophil lactoferrin N-glycans by GC-MS 
linkage analysis 
 
 
To assess what proportion of neutrophil lactoferrin glycans have core fucose, and 
thus determine how many fucose residues in each glycan must be outer-arm fucose, 
glycans were treated with hydrogen fluoride to remove only outer-arm fucose.  Removal of 
outer-arm fucose eliminated a substantial amount of the heterogeneity in glycan 
compositions, such that each series of glycans (HexNAc4Hex5, HexNAc5,Hex6 etc.) was 
represented in the molecular ion profile by no more that four species, corresponding to 
forms with and without core fucose, and their sialylated forms (Figure 3.28 and Table 3.4).  
For each size of glycan skeleton, the molecular ion peak corresponding to the core 
fucosylated form was around four times larger than the peak corresponding to the form 
without core fucose, indicating that around 80% of glycans have core fucose. 
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m/z Glycan composition 
2069.9 HexNAc4Hex5 
2243.9 HexNAc4Hex5Fuc1 
2519.1 HexNAc5Hex6 
2605.1 HexNAc4Hex5Fuc1NeuAc1 
2693.1 HexNAc5Hex6Fuc1 
2968.3 HexNAc6Hex7 
3054.3 HexNAc5Hex6Fuc1NeuAc1 
3142.4 HexNAc6Hex7Fuc1 
3417.5 HexNAc7Hex8 
3503.5 HexNAc6Hex7Fuc1NeuAc1 
3591.6 HexNAc7Hex8Fuc1 
3867.7 HexNAc8Hex9 
3952.7 HexNAc7Hex8Fuc1NeuAc1 
4040.8 HexNAc8Hex9Fuc1 
4319.0 HexNAc9Hex10 
4403.0 HexNAc8Hex9Fuc1NeuAc1 
4491.0 HexNAc9Hex10Fuc1 
 
 
Table 3.4: Monosaccharide compositions of N-glycans from neutrophil lactoferrin 
following treatment with hydrogen fluoride 
 
The consolidation of multiple fucosylated forms into single peaks following 
hydrogen fluoride treatment not only simplified the molecular ion profile but increased the 
intensity of the peaks, facilitating MS/MS analysis (data not shown).  MS/MS analysis of 
only a few peaks was therefore sufficient to provide insight into the structures of the 
glycan skeletons shared by a range of fucosylated glycans.  HexNAc5Hex6 skeletons 
represent a mixture of tri- and biantennary forms, whereas HexNAc6Hex7 skeletons are 
predominantly biantennary with each antenna extended by one N-acetyllactosamine unit.  
Larger glycans (HexNAc7Hex8, HexNAc8Hex9, HexNAc9Hex10) appear as a mixture of bi- 
and triantennary forms, with the triantennary component increasing with glycan size.  
Overall there is a tendency for antennae to be similar in length, rather than for only one 
antenna to be elaborated with a long poly-N-acetyllactosamine extension.  The molecular 
ion profile of hydrogen fluoride-treated glycans highlighted the fact that sialylated glycans 
are fairly rare, because only minor peaks representing sialylated species were observed 
even following the consolidation of multiple fucosylated variants.  The only prominent 
signal for a sialylated glycan was that for the smallest, HexNAc4Hex5Fuc1NeuAc1, which 
was produced by defucosylation of the fairly abundant glycan HexNAc4Hex5Fuc2NeuAc1. 
A final analysis used to add to information about the structure of the glycan 
skeleton and on the locations of fucose residues was to digest neutrophil lactoferrin 
glycans with endo-β-galactosidase.  This enzyme cleaves the glycosidic bond between 
the galactose and GlcNAc residues in internal, but not terminal, N-acetyllactosamine units 
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of glycan antennae.  Cleavage is also blocked by the presence of fucose on the GlcNAc 
residue.  Therefore in some cases different isomers of a glycan could be distinguished 
based on their susceptibility to endo-β-galactosidase digestion.  The molecular ion profile 
of neutrophil lactoferrin glycan digested with endo-β-galactosidase included several 
truncated glycans, indicating that endo-β-galactosidase had removed portions of the 
antennae from a subset of the glycans (Figure 3.29 and Table 3.5). 
 
m/z Glycan composition 
2244.3 HexNAc4Hex5Fuc1 
2285.3 HexNAc5Hex4Fuc1 
2418.4 HexNAc4Hex5Fuc2 
2489.4 HexNAc5Hex5Fuc1 
2592.5 HexNAc4Hex5Fuc3 
2605.4 HexNAc4Hex5Fuc1NeuAc1 
2663.5 HexNAc5Hex5Fuc2 
2693.5 HexNAc5Hex6Fuc1 
2734.5 HexNAc6Hex5Fuc1 
2779.5 HexNAc4Hex5Fuc2NeuAc1 
2867.6 HexNAc5Hex6Fuc2 
2908.6 HexNAc6Hex5Fuc2 
2938.6 HexNAc6Hex6Fuc1 
3041.7 HexNAc5Hex6Fuc3 
3112.7 HexNAc6Hex6Fuc2 
3142.7 HexNAc6Hex7Fuc1 
3228.8 HexNAc5Hex6Fuc2NeuAc1 
3286.8 HexNAc6Hex6Fuc3 
3316.8 HexNAc6Hex7Fuc2 
3402.9 HexNAc5Hex6Fuc3NeuAc1 
3490.9 HexNAc6Hex7Fuc3 
3665.0 HexNAc6Hex7Fuc4 
3736.0 HexNAc7Hex7Fuc3 
3766.0 HexNAc7Hex8Fuc2 
3852.1 HexNAc6Hex7Fuc3NeuAc1 
3911.1 HexNAc7Hex7Fuc4 
3940.2 HexNAc7Hex8Fuc3 
4115.3 HexNAc7Hex8Fuc4 
4290.0 HexNAc7Hex8Fuc5 
 
 
Table 3.5: Monosaccharide compositions of N-glycans from neutrophil lactoferrin 
following digestion with endo-β-galactosidase 
Truncated glycans produced by endo-β-galactosidase digestion are shown in red. 
 
The abundances of molecular ions in the profiles of neutrophil lactoferrin glycans 
with and without endo-β-galactosidase digestion could be easily compared because the 
HexNAc4Hex5 series glycans, including the most abundant glycan HexNAc4Hex5Fuc2, are 
not susceptible to cleavage, providing internal standards in the spectra.  The most 
abundant glycans with a single additional N-acetyllactosamine unit (HexNAc5Hex6Fuc2 
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and HexNAc5Hex6Fuc3) showed significant resistance to cleavage, suggesting that they 
are mostly enzyme-resistant triantennary structures with some susceptible biantennary 
forms.  Accordingly, only a small peak is observed representing the product of digestion of 
the biantennary form (HexNAc4Hex4Fuc2).   
Among glycans with two additional N-acetyllactosamine units (HexNAc6Hex7), the 
forms with 2, 3 or 4 fucose residues were common, and all showed a degree of resistance 
to digestion.  These glycans are probably bi- or tri-antennary, such that loss of a single 
antenna Lewisx-containing antenna (HexNAc1Hex2Fuc1) accounts for the appearance of 
strong signals for HexNAc5Hex5Fuc1 and HexNAc5Hex5Fuc2.  Minor tetra-antennary 
components may account for the enzyme-resistant portion of the glycan population. 
Of the HexNAc7Hex8 series of glycans, the forms with 2, 3 or 4 fucose residues 
were major components of neutrophil lactoferrin glycans, but were almost entirely 
eliminated following digestion.  Loss of signals for HexNAc7Hex8Fuc2, HexNAc7Hex8Fuc3 
and HexNAc7Hex8Fuc4 is accompanied by gain of signals for HexNAc6Hex6Fuc1, 
HexNAc6Hex6Fuc2 and HexNAc6Hex6Fuc3, indicating that a single Lewisx-containing 
antenna was removed from these glycans, consistent with tri- or tetra-antennary forms. 
The 15 largest glycans (mostly HexNAc8Hex9 and HexNAc9Hex10 series) observed 
in native glycans were not detected following digestion, despite very low noise in the 
signal, indicating that all of these have at least one bond susceptible to cleavage.  
Digestion of these large glycans produced the truncated glycans HexNAc7Hex7Fuc3 and 
HexNAc7Hex7Fuc4 where one antenna was cleaved, and HexNAc6Hex5Fuc1 and 
HexNAc6Hex5Fuc2 where two antennae were cleaved.  HexNAc6Hex5Fuc1 is likely to be a 
tetra-antennary structure, indicating that the largest glycans include a significant tetra-
antennary sub-population. 
Fragments released from the antennae of glycans by endo-β-galactosidase 
digestion were also examined by mass spectrometry (Figure 3.30).  The major peak 
corresponded to a fragment HexNAc1Hex2Fuc1, which contains Lewisx, and which was 
much more abundant than the same fragment without fucose, reflecting the general 
abundance of fucose on lactoferrin glycans.  Larger cleaved fragments were detected only 
in very minor quantities, suggesting that each antenna in a glycan rarely bears more than 
one additonal N-acetyllactosamine unit without being protected from endo-β-galactosidase 
digestion by fucosylation.  No signal was detected for loss of an antenna containing sialic 
acid, consistent with the MS/MS data showing that antennae are not extended with 
additional N-acetyllactosamine units prior to capping with sialic acid (data not shown). 
Bringing together information from MS/MS of native glycans, mannose linkage 
analysis, hydrogen fluoride treatment and endo-β-galactosidase digestion, it is evident 
that the molecular ion peaks do not represent single structural isoforms, with the 
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Figure 3.30: MALDI-MS detection of fragments released from glycans by endo-β-
galactosidase digestion
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exception of glycans such as HexNAc4Hex5Fuc3, for which the structure can be 
unambiguously described.  Representative structures for each molecular ion are shown in 
Figure 3.31, but the glycans are in fact a mixture of bi-, tri- and tetra-antennary forms, with 
and without core fucose.  However, most of the glycans have in common the presence of 
one or more Lewisx groups.   
To complete the analysis of neutrophil lactoferrin glycans, the linkages of sialic 
acid residues were determined by examining the relative amounts of galactose bonded at 
the 3 and 6 positions using GC-MS linkage analysis (Table 3.6).  A native glycan sample 
was compared with samples digested with sialidase S, which removes only α2,3-linked 
sialic acid, and sialidase A, which removes both α2,3- and α2,6-linked sialic acid.  
Because galactose bonded at the 3 position is found within the type II poly-N-
acetyllactosamine extensions [-4GlcNAcβ1-3Galβ1-] present on many neutrophil 
lactoferrin glycans, only a proportion of the signal for this galactose disappears following 
sialidase treatment, whereas galactose bonded at the 6 position is only produced by sialic 
acid capping and disappears completely following sialidase A digestion.  Similar values for 
the amount of galactose bonded at the 3 position were obtained following desialylation 
with sialidase A and sialidase S, and these values were averaged and subtracted from the 
amount in an undigested sample to derive the amount of galactose bearing α2,3-linked 
sialic acid, which was then compared with the amount of galactose bonded at the 6 
position in the undigested sample.  This analysis revealed that both α2,3- and α2,6-linked 
sialic acid are found in neutrophil lactoferrin, with α2,6-linked sialic acid accounting for 
57% of the total sialylation.   
In contrast, milk lactoferrin was previously reported to contain only α2,6-linked 
sialic acid (Spik et al., 1982).  The sialic acid in milk lactoferrin is present on the antenna 
linked to the Manα1-3Man branch of the glycan.  It is not clear if certain antennae in 
neutrophil lactoferrin are sialylated in preference to others, but MS/MS analysis indicates 
that, unlike in milk lactoferrin, antennae can be extended before being capped with sialic 
acid (data not shown).  The enzymes responsible for generating α2,3- and α2,6-linked 
sialic acid in neutrophil lactoferrin are likely to be ST3GalIV and ST6GalI respectively 
(Harduin-Lepers et al., 2001).  The limited degree of sialylation of neutrophil lactoferrin 
glycans may stem from the high activity of fucosyltransferases such as FUT9 relative to 
these sialyltransferases, since human sialyltransferases cannot act on fucosylated 
antennae (Sujino et al., 2000; Blixt et al., 2008).  However, a novel model for the control of 
neutrophil cell surface glycoprotein sialylation involves neutrophil sialidase (Gadhoum and 
Sackstein, 2008), raising the possibility that this enzyme, which is expressed at the same 
time and in the same cellular compartments as lactoferrin (Faurschou and Borregaard, 
2003), may also affect the glycosylation of lactoferrin.  If sialylation were rendered 
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reversible by the presence of sialidase, while fucosylation remained irreversible, there 
would be a shift in lactoferrin towards fucosylated antennae.  Sialidase might also 
irreversibly convert sialyl-Lewisx antennae to Lewisx, accounting for the absence of the 
former structure on lactoferrin glycans. 
 
Galactose linkage Peak area relative to core mannose 
 Untreated Sialidase A Sialidase S 
Bonded at 3 position 0.734 0.515 0.509
Bonded at 6 position 0.298 0.000 0.218
 
Table 3.6: Determination of sialic acid linkage in neutrophil lactoferrin N-glycans by 
GC-MS linkage analysis 
 
3.3.10 Identification of high-affinity glycan ligands for SRCL from neutrophil 
lactoferrin 
The structural analysis performed on the total pool of N-glycans released from neutrophil 
lactoferrin demonstrates the presence of abundant Lewisx epitopes, but does not reveal 
which Lewisx-containing structures bind particularly well to SRCL.  To isolate a fraction of 
neutrophil lactoferrin that binds strongly to SRCL and a fraction that does not, a sample of 
lactoferrin was applied to an SRCL affinity column (Figure 3.32).  Lactoferrin molecules 
that did not bind to the column, or bound weakly, were washed off with buffer containing 
Ca2+, whereas lactoferrin molecules that bound strongly were eluted using buffer 
containing EDTA.  The majority of the protein was found in the binding fraction.  To ensure 
that this protein was genuinely bound by a high-affinity interaction, it was repurified on the 
same SRCL affinity column, and almost all of the protein was again recovered in the 
elution fractions.  This strategy may not fully separate glycans that are recognized by 
SRCL from glycans that are not, because each lactoferrin molecule carries two glycans, 
which may have different structures.  Nonetheless, the molecular ion profiles obtained for 
the binding and non-binding samples are strikingly different, particularly in the region of 
the spectrum above m/z 3400, which includes several major peaks for the binding sample, 
but only a very minor fraction of the glycans in the non-binding sample (Figure 3.33 and 
Tables 3.7 and 3.8). 
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Initial fractionation
2+
Ca  washes EDTA elutions
Repurification of elution fractions
Figure 3.32: Isolation of SRCL binding and non-binding fractions of neutrophil 
lactoferrin for glycan structural analysis
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Non-binding fraction used for MS glycan analysis
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m/z Glycan composition 
2245.0 HexNAc4Hex5Fuc1 
2419.1 HexNAc4Hex5Fuc2 
2593.1 HexNAc4Hex5Fuc3 
2606.1 HexNAc4Hex5Fuc1NeuAc1 
2694.2 HexNAc5Hex6Fuc1 
2780.2 HexNAc4Hex5Fuc2NeuAc1 
2868.2 HexNAc5Hex6Fuc2 
2967.3 HexNAc4Hex5Fuc1NeuAc2 
3040.3 HexNAc5Hex6Fuc3 
3056.3 HexNAc5Hex6Fuc1NeuAc1 
3143.4 HexNAc6Hex7Fuc1 
3229.4 HexNAc5Hex6Fuc2NeuAc1 
3317.4 HexNAc6Hex7Fuc2 
3491.5 HexNAc6Hex7Fuc3 
3592.5 HexNAc7Hex8Fuc1 
3678.5 HexNAc6Hex7Fuc2NeuAc1 
3767.6 HexNAc7Hex8Fuc2 
3941.6 HexNAc7Hex8Fuc3 
 
Table 3.7: Monosaccharide compositions of N-glycans from neutrophil lactoferrin: 
SRCL non-binding fraction 
Glycans not detected in the total glycan pool are shown in red. 
 
 
m/z Glycan composition 
2245.0 HexNAc4Hex5Fuc1 
2419.1 HexNAc4Hex5Fuc2 
2593.1 HexNAc4Hex5Fuc3 
2694.2 HexNAc5Hex6Fuc1 
2780.2 HexNAc4Hex5Fuc2NeuAc1 
2868.2 HexNAc5Hex6Fuc2 
3042.3 HexNAc5Hex6Fuc3 
3216.4 HexNAc5Hex6Fuc4 
3230.4 HexNAc5Hex6Fuc2NeuAc1 
3317.4 HexNAc6Hex7Fuc2 
3404.5 HexNAc5Hex6Fuc3NeuAc1 
3491.5 HexNAc6Hex7Fuc3 
3665.6 HexNAc6Hex7Fuc4 
3766.6 HexNAc7Hex8Fuc2 
3853.6 HexNAc6Hex7Fuc3NeuAc1 
3941.7 HexNAc7Hex8Fuc3 
4115.7 HexNAc7Hex8Fuc4 
4289.8 HexNAc7Hex8Fuc5 
4302.8 HexNAc7Hex8Fuc3NeuAc1 
4390.8 HexNAc8Hex9Fuc3 
4476.8 HexNAc7Hex8Fuc4NeuAc1 
4564.9 HexNAc8Hex9Fuc4 
4738.9 HexNAc8Hex9Fuc5 
 
Table 3.8: Monosaccharide compositions of N-glycans from neutrophil lactoferrin: 
SRCL binding fraction 
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Comparing the glycan compositions found in the two samples shows that the 
extent to which a glycan is retained on the SRCL column depends strongly on the number 
of fucose residues in the structure (Figure 3.34).  Glycans with only one fucose residue 
were for the most part found in the non-binding fraction, because this single fucose is 
usually attached to the core GlcNAc residue and is not part of a Lewisx group.  In contrast, 
glycans with three or more fucose residues – generally corresponding to two or more 
outer-arm fucose residues – were found almost exclusively in the binding fraction.  
Glycans with two fucose residues, typically one of which is outer-arm, were found in both 
binding and non-binding fractions.  Thus the presence of more that one Lewisx group on a 
glycan significantly enhances the retention of the glycoprotein on the SRCL affinity 
column, and may be sufficient to cause retention of the protein molecule even if the glycan 
at the other position does not carry any Lewisx.  Where a glycan carries only one Lewisx 
group, it is possible that a second similar glycan is required to be present on the same 
molecule to enable retention on the column.  The isolation of a lactoferrin fraction that 
does not bind to SRCL served to enrich rare glycans that were not discernable in the 
molecular ion profile of total neutrophil lactoferrin glycans (Table 3.7), including a 
biantennary glycan in which both antennae are capped with sialic acid, which is common 
in serum glycoproteins but very rare in neutrophil lactoferrin. 
 
3.3.11 SRCL mediates endocytosis of Lewisx-containing glycoproteins 
For SRCL to function in the clearance of soluble neutrophil glycoproteins, the receptor on 
the surface of endothelial cells must bind and internalize these proteins.  The binding of 
Lewisx-containing complexes to SRCL-transfected fibroblasts (Figure 2.10) demonstrates 
that SRCL expressed on the cell surface can mediate binding of Lewisx-containing 
glycoconjugates to cells.  It has also been shown previously that these cells internalize 
and degrade the Lewisx-containing neoglycoprotein LNFPIII-BSA (Coombs et al., 2005).  
To assess if endothelial cells naturally expressing SRCL would also exhibit uptake and 
degradation of Lewisx-containing ligands, HUVECs were assayed for endocytosis of 
LNFPIII-BSA in parallel with transfected fibroblasts.  Cells in 24-well plates were 
incubated with radiolabelled LNFPIII-BSA and endocytosis was measured by the release 
of acid-soluble radioactivity into the medium as a result of lysosomal degradation of the 
protein.  As was found previously, the transfected cells exhibited a steady release of acid-
soluble radioactivity into the medium following an initial lag period (Figure 3.35).  In 
contrast, HUVECs showed no increase in the amount of acid-soluble radioactivity in the 
medium over the four-hour course of the experiment. 
The failure to observe endocytosis in HUVECs in this assay was probably due to 
insufficient sensitivity.  The level of SRCL expression in the endothelial cells is much lower 
171
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Figure 3.34: Stuctures of lactoferrin glycans found in binding and non-binding 
fractions following fractionation by SRCL affinity chromatography
x
Lewis  groups are highlighted.  The structures shown are representative of multiple isomers, 
including forms with different numbers of antennae, with different arrangements of outer-arm 
fucose residues, and without core fucose.
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Figure 3.35: Assay for SRCL-mediated endocytosis based on ligand degradation
Cells were grown in 24-well plates.  Wells of confluent HUVEC contained 70,000 cells.  Wells 
of SRCL-transfected fibroblasts at ~70% confluence contained 1,600,000 cells.  Cells were 
incubated with radio-iodinated LNFPIII-BSA, and endocytosis measured by counting acid-
soluble radioactivity in the medium, representing lysosomally degraded LNFPIII-BSA.  
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than in the transfected cells (Figure 2.8).  In addition, even though the endothelial cells 
used in the assay were confluent, whereas the fibroblasts were only at moderate density, 
differences in cell size and growth behaviour mean that the assay measured endocytosis 
in around 20-fold fewer endothelial cells than fibroblasts.  Thus even if the endothelial 
cells processed ligand at the same rate at the transfected fibroblasts, the signal after 4 
hours would not be detectable above the background.   
A potentially more sensitive assay for endocytic activity was developed by 
visualizing endocytosis of ligand molecules directly, rather than looking for degradation of 
ligand as in the radioactivity-based assay.  LNFPIII-BSA was labelled with fluorescein and 
incubated with SRCL-transfected fibroblasts.  To amplify the signal resulting from ligand 
binding, the fluorescein-tagged LNFPIII-BSA was visualized using an anti-fluorescein 
primary antibody followed by a fluorescently-labelled secondary antibody.  Fluorescein-
tagged LNFPIII-BSA can be seen to associate with SRCL-transfected fibroblasts within 5 
minutes and to accumulate in intracellular compartments over the hour-long duration of 
the experiment, demonstrating that the ligand is internalized (Figure 3.36).  Internalization 
must be due to the specific binding of Lewisx groups to SRCL rather than to non-specific 
uptake processes because fluorescein-labelled BSA that does not carry Lewisx groups 
shows no internalization.  Incubation of cells with an epitope-tagged Lewisx-containing 
glycoconjugate thus provides a convenient assay for endocytosis mediated by SRCL. 
To look for SRCL-mediated endocytosis in HUVECs, cells were incubated for 1 
hour with fluorescein-tagged LNFPIII-BSA, which was visualized by two-step antibody 
staining as before (Figure 3.37).  No internalization of LNFPIII-BSA was evident in the 
HUVECs, and the cells were indistinguishable from controls incubated with fluorescein-
tagged BSA.  SRCL-transfected fibroblasts assayed in parallel showed accumulation of 
LNFPIII-BSA inside the cells.  It therefore appears that the low level of natural SRCL 
expression in HUVECs, in which a large proportion of the protein may also be within 
intracellular compartments at any time, makes HUVECs an intractable experimental 
system in which to study the biology of SRCL.  In the absence of a suitable endothelial 
cell system to study SRCL, the overexpression of SRCL in transfected fibroblasts provides 
a useful model to study the behaviour of the receptor in ligand binding and endocytosis. 
SRCL expressed in transfected fibroblasts can mediate binding and endocytosis of 
polyacrylamide and BSA molecules derivatized with Lewisx (Figures 2.10 and 3.36) 
(Coombs et al., 2005).  These artificial glycoconjugates carry upwards of 20 Lewisx groups 
per molecule, and can therefore be expected to be very good ligands for SRCL, but they 
do not resemble potential natural glycoprotein ligands for SRCL, which will carry fewer 
Lewisx groups, and present them on N-linked or O-linked glycans.  To determine if SRCL 
can mediate endocytosis of endogenous Lewisx-containing glycoproteins, ligand uptake 
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LNFPIII-BSA, 5 min LNFPIII-BSA, 30 min
LNFPIII-BSA, 60 min BSA, 60 min
Figure 3.36: Internalization of LNFPIII-BSA by SRCL-transfected fibroblasts
SRCL-transfected fibroblasts were incubated with fluorescein-labelled LNFPIII-BSA or 
fluorescein-labelled unconjugated BSA.  Fluorescein-labelled proteins were visualized using 
rabbit anti-fluorescein and Alexa Fluor 488-labelled goat anti-rabbit IgG.  Scale bar is 20 μm.
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Figure 3.37: Assay for SRCL-mediated endocytosis using fluroescein-tagged ligand
Cells were incubated for 60 min with fluorescein-tagged LNFPIII-BSA or fluorescein-tagged 
unconjugated BSA.  Fluorescein-labelled protein were visualized using rabbit anti-
fluorescein and Alexa Fluor 488-labelled goat anti-rabbit IgG.  Scale bar is 50 μm.
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experiments were performed with SRCL-transfected fibroblasts and neutrophil lactoferrin.  
In the ligand degradation-based assay using 125I-lactoferrin, the amount of radioactivity in 
the medium did not show appreciable increase over time as was observed with 125I-
LNFPIII-BSA (Figure 3.38).  However, internalization of fluorescein-tagged lactoferrin was 
readily observed in the SRCL-transfected fibroblasts (Figure 3.38), suggesting that the 
failure to observe endocytosis in the ligand-degradation assay may be due to slower 
lysosomal degradation of the natural ligand compared to LNFPIII-BSA.  Uptake of 
fluorescein-tagged lactoferrin in SRCL-transfected cells required specific glycans, 
because cells incubated with fluorescein-tagged ovalbumin, which carries high-mannose 
and hybrid N-glycans without Lewisx groups, were indistinguishable from cells incubated 
in the absence of ligand.  SRCL can therefore mediate internalization of natural Lewisx-
containing glycoproteins, which is consistent with the proposal that the receptor clears 
such glycoproteins at sites of inflammation. 
 
3.4 Discussion 
The work presented in this chapter suggests a role for SRCL in mediating the clearance of 
proteins released by degranulation of neutrophils in inflamed tissues.  Glycoprotein 
ligands for SRCL from human neutrophils were isolated by affinity chromatography and 
were found to consist primarily of soluble proteins of the secondary granules (Figure 3.9).  
Fucose-dependent binding to SRCL was demonstrated for the neutrophil granule 
glycoproteins lactoferrin and MMP-9 (Figures 3.18 and 3.22), indicating that the presence 
of Lewisx groups in granule protein glycans may target a range of granule proteins for 
clearance by SRCL.  Because neutrophil secondary granule proteins are all synthesized 
during the same phase of neutrophil development (Nauseef, 1999; Faurschou and 
Borregaard, 2003), they are all exposed to the same repertoire of glycosylation enzymes 
and could be expected to receive similar glycosylation to lactoferrin.  These results are 
therefore consistent with a role for SRCL in clearing a range neutrophil proteins through 
interaction with common glycan structures.   
Detailed analysis of the N-glycans of neutrophil lactoferrin by mass spectrometry 
revealed a range of large and highly-fucosylated structures (Figure 3.31).  Despite 
considerable heterogeneity in the number and positioning of additional N-
acetyllactosamine units and of fucose residues, the vast majority of the glycan carried 
Lewisx groups, often on multiple antennae.  The glycan skeleton thus serves as a scaffold 
for the display of Lewisx groups, which are recognized by SRCL, analogously to the 
recognition of other glycan terminal structures by glycan-binding proteins (Figure 1.2).  
The display of Lewisx structures on multiple, similarly-sized antennae may represent the 
optimum disposition of carbohydrate groups for binding to SRCL, since such glycans 
177
Lactoferrin Ovalbumin
Figure 3.38: Internalization of lactoferrin by SRCL-expressing cells
125
Top: SRCL-transfected fibroblasts were incubated with I-neutrophil lactoferrin and 
radioactivity associated with cells and acid-soluble radioactivity in the medium was counted.  
Squares indicate radioactivity when cells were incubated with a 50-fold excess of unlabelled 
neutrophil lactoferrin. Bottom:  Cells were incubated for 60 min with fluorescein-tagged 
neutrophil lactoferrin, fluorescein-tagged ovalbumin, or without ligand.  Fluorescein-labelled 
proteins were visualized using rabbit anti-fluorescein and Alexa Fluor 488-labelled goat anti-
rabbit IgG.  Scale bar is 20 μm.
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appear to bind to the receptor with higher affinity than small glycans with only one Lewisx 
group (Figure 3.34).  This arrangement of binding groups on lactoferrin is in contrast to 
that found in PSGL-1, the ligand for the C-type lectin P-selectin, which displays a single 
sialyl-Lewisx group on one extended O-glycan antenna (Sperandio et al., 2009). 
The abundance of Lewisx groups in neutrophil glycoproteins is likely to be due to 
expression of the α1,3-fucosyltransferase FUT9, which is particularly selective for 
synthesis of this structure and is responsible for addition of Lewisx epitopes to neutrophil 
cell surface proteins (Nishihara et al., 1999; Bogoevska et al., 2006).  A recent study 
showed that SRCL recognizes CEACAM-1 expressed in transfected cells only when cells 
are also transfected with FUT9, as well as confirming the recognition by SRCL of proteins 
in a blot of neutrophil extract (Samsen et al., 2010).  Expression of FUT9 is limited to a 
small number of cell types, including granulocytes, neurons, and an unidentified cell type 
in the kidney (Nishihara et al., 2003; Comelli et al., 2006), indicating that the synthesis of 
Lewisx may be regulated to enable its use as a specific recognition tag.   
The uptake of neutrophil lactoferrin by SRCL-expressing cells (Figure 3.38) 
suggests that, in neutrophils, one function of Lewisx-tagging of glycoproteins is to facilitate 
their clearance by SRCL following release at sites of inflammation.  SRCL expressed on 
endothelial cells could clear neutrophil granule glycoproteins through multiple routes 
(Figure 3.39).  Granule glycoproteins could be cleared from circulation following direct 
release of proteins into the bloodstream, or following diffusion into the bloodstream after 
release in sub-endothelial tissues.  Glycoproteins may be cleared locally by SRCL 
molecules on inflamed endothelium, or systemically by SRCL molecules spread 
throughout the vasculature.  Glycoproteins may also be cleared from the tissue 
surrounding the blood vessel by SRCL molecules expressed on the surface of the 
endothelial cell facing the tissue. 
The recognition of Lewisx-tagged proteins by SRCL represents a second case in 
which cell-specific glycosylation directs interaction of neutrophil glycoproteins with 
endothelial glycan-binding receptors, since neutrophil proteins tagged with sialyl-Lewisx 
mediate cell adhesion through binding to the selectins (Sperandio et al., 2009).  These 
two distinct carbohydrate-recognition events are made possible by the different pathways 
of synthesis of the sialyl-Lewisx and Lewisx epitopes from terminal type II N-
acetyllactosamine units (Figure 1.15): sialyl-Lewisx is formed by the sequential actions of 
sialyltransferase ST3GalIV and fucosyltransferase FUT7 (Sperandio et al., 2009), 
whereas Lewisx is formed by the action of FUT9 and is far more abundant  (Babu et al., 
2009).  The substrate selectivity of the enzymes involved in the synthesis of these 
structures is matched by the selectivity of glycan recognition in the cognate receptors 
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Figure 3.39: Potential roles for SRCL in the clearance of neutrophil granule proteins
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(Revelle et al., 1996; Coombs et al., 2005).  The interactions underlying selective Lewisx 
binding in SRCL are illustrated in Figure 3.40 (Feinberg et al., 2007). 
The function of the Lewisx structure in neutrophils and other cells has remained 
unclear even though the epitope has been recognized for some time.  The Lewisx epitope 
is an optimal structure for recognition by glycan-binding proteins because it is not only an 
accessible terminal structure, but also adopts a single, fixed conformation whether it is 
free in solution or bound to a protein (Imberty, 1997), indicating that there is little entropy 
penalty for binding, which is advantageous because glycan-binding proteins typically 
make few contacts to a bound glycan (Weis and Drickamer, 1996).  A role for Lewisx in 
mediating communication between neutrophils and dendritic cells through binding to the 
glycan-binding receptor DC-SIGN has been proposed (van Gisbergen et al., 2005a).  The 
work presented here is consistent with a function for Lewisx in mediating protein clearance 
through interaction with SRCL, suggesting that the Lewisx tag may have multiple functions 
through interaction with different glycan-binding proteins in different cell types. 
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Figure 3.40: Recognition of the Lewis trisaccharide by SRCL
Drawing based on the Protein Data Bank 
entry 2OX9 (Feinberg et al., 2007) viewed using Protein Data Bank ProteinWorkshop 3.6.  
The bound oligosaccharide and key amino acid side chains are shown in ball-and-stick 
representation (black, carbon; blue, nitrogen; red, oxygen) and the path of the main chain is 
represented by the green line.  Dotted lines represent interactions in the binding site: 
hydrogen bonds, red; coordination of calcium ion, blue; hydrophobic interactions, black.
x
Lewis  in the sugar-binding site of mouse SRCL.  
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Identification of prolectin, a novel C-type lectin, and 
characterization of its expression 
 
4.1 Introduction 
This chapter describes the identification of prolectin, a novel C-type lectin, in the human 
genome.  Following the cloning of prolectin, the tissue localization of the receptor was 
defined by PCR screening of cDNA preparations and immunostaining of tissue sections.  
Prolectin has a large cytoplasmic domain which contains phosphorylatable tyrosine 
residues and proline-rich sequences that could serve as interaction sites with intracellular 
signalling molecules.  Although a number of glycan-binding proteins are known to 
influence intracellular signalling pathways, such clear potential for signalling together with 
confirmed sugar-binding activity is unprecedented in a C-type lectin.  Defining the 
localization of prolectin expression in human tissues is an essential step in determining 
physiological roles for the receptor as a coupler of extracellular glycan recognition and 
intracellular signalling.   
 
4.2 Materials and methods 
Screening of DNA databases for novel C-type lectins 
Human cDNA sequences encoding C-type lectin-like domains (CTLDs) were identified by 
searching the translated National Center for Biotechnology Information (NCBI) human 
nucleotide database with various human CTLD sequences using the basic local alignment 
search tool (BLAST).  Potential genes for CTLD-containing proteins in the Ensembl 
human genome database were identified by searching for genes annotated as encoding 
proteins matching the InterPro profile IPR001304 (C-type lectin), which incorporates the 
profiles from the member databases Pfam (Lectin_C PF00059), PROSITE 
(C_TYPE_LECTIN_2 PS50041), and SMART (CLECT SM00034).  
 
Cloning and expression of prolectin 
Cloning methods and reagents were as described in Chapter 2.  Prolectin was cloned 
from a human spleen first-strand cDNA preparation (Clontech) by S. Yan (Graham et al., 
2009).  For bacterial expression of a soluble fragment of the receptor, the portion of the 
cDNA encoding the extracellular domain (Figures 4.1 and 4.2) was inserted into the 
expression vector T5T (Eisenberg et al., 1990), which was used to transform Escherichia 
coli strain BL21(DE3).  Luria-Bertani medium (1 L) containing 50 μg/mL ampicillin was 
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Figure 4.1: Prolectin constructs used to produce affinity-purified rabbit polyclonal 
antibodies for tissue staining
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Figure 4.2: Prolectin cDNA sequence showing positions of primers
The primer pair labelled cloning was used to clone full-length prolectin from human spleen 
cDNA.  The primer pairs labelled PCR were used to screen cDNA preparations from a variety 
of cells and tissues for prolectin expression.
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• PCR 1 
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Prolectin
Exons
 AGCCCTGGCTGCCACTTGTCAGGTTCCCTGTGCTAGACATGCATAATCTGTATTCCATC   59
7
ACTGGGTACCCGGACCCACCAG 119
27
GGACCATGGAGGAGGAGGAG 179
47
GAGGATGATGACTATGAGAACTCAACACCTCCCTACAAGGACCTTCCTCCCAAGCCAG 239
67
299
87
GTTCAAGTGCTCCACCAAGACCTCCAAGGGCAG 359
107
GCCTGGACCTCGCCGCTGTC 419
127
ACCTGTCCACCTCCTCAACTGG 479
147
CAACTCCAGTCCCCTGGCTCAATCAGAGGTCTGGAGGTCCTGGCTGCTGCCAGAAG 539
167
AGGTGGATGGTGTACCTGTGTCTGCTGGTGGTGACTTCCCTGTTCCTGGGCTGCCTTGGT 599
187
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TGACTGGCATGGCAGGGCTAGCTGGCCTGAAGCAT 719
227
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327
GATGGGTCTCCTGTGACATTAAG 1079
347
1139
367
1199
378
1259
1319
                                        
   
  
  
  
MetHisAsnLeuTyrSerIle
GGACCATGGAGGAGGAGGAGGAGGATGATGACTATGAG
ThrGlyTyrProAspProPro
AACTCAACACCTCCCTACAAGGACCTTCCTCCCAAGCCAG
GG
ACCATGGAGGAGGAGGAGGAGGATGATGACTATGAGAACTCAACACCTCCCTACAAGGAC
CTTCCTCCCAAGCCAG CAAAGGAAACA
GlySerSerAlaProProArgProProArgAlaAlaLysGluThr
GAGAAACCCCCACTTCCTTGCAAGCCCCGGAACATGACAG
GluLysProProLeuProCysLysProArgAsnMetThrGlyLeuAspLeuAlaAlaVal  
CTGTGAATCTTGAGCCTTCTCCATTGCAGCCATCCCTG
ThrCysProProProGlnLeuAlaValAsnLeuGluProSerProLeuGlnProSerLeu  
GCCG
AlaAlaThrProValProTrpLeuAsnGlnArgSerGlyGlyProGlyCysCysGlnLys  
ArgTrpMetValTyrLeuCysLeuLeuValValThrSerLeuPheLeuGlyCysLeuGly
ACCAGGAGTTGATGGAAGAACTGAGAATGTTAAGCTTT
LeuThrValThrLeuIleLys
CAGCAGATGACGTGGCGAACAAATA
GACTGCCGCCGAATTACCTGTCCTGAAGGCTGGCTGCCCTTTGAGGGCAAGTGTTACTAC 
TTCTCCCCAAGCACCAAGTCATGGGATGAGGCCCGGATGTTCTGCCAGGAGAATTACTCT 
CACTTGGTCATCATCAATAGCTTTGCTGAGCAC
CTTCTGGGAGCCAGAGGAACCCAATAACATCCACGAT
GAGGACTGTGCTACCATGAACAAAGGTGGCACCTGGAATGATCTCTCTTGCTACAAAACT
ACGTATTGGATTTGTGAGCGGAAATGTTCCTGTTGAAGCCCAGGGCCGAGGCTGGGGGTC
CATATCTGAGTGTCTCTTTGAGATGAGAATCTCCTGCCCTTTCGTGGACGGCCTTGCCTC
TTCGTGAGTGGACACACAGATGTGCCTCAAACAGGATTGGCACCCTGGATGCAGCAAGTT
  
  
  
  
  
  
 
 
 
 
 
 
 
GlyThrMetGluGluGluGluGluAspAspAspTyrGlu
AsnSerThrProProTyrLysAspLeuProProLysProGlyThrMetGluGluGluGlu   
GluAspAspAspTyrGluAsnSerThrProProTyrLysAspLeuProProLysProGly   
ThrMetGluGluGluGluGluAspAspAspTyrGluAsnSerThrProProTyrLysAsp   
LeuProProLysPro
  
  
  
 
  
 
  
 
TyrGlnGluLeuMetGluGluLeuArgMetLeuSerPhe
GlnGlnMetThrTrpArgThrAsnMetThrGlyMetAlaGlyLeuAlaGlyLeuLysHis  
AspIleAlaArgValArgAlaAspThrAsnGlnSerLeuValGluLeuTrpGlyLeuLeu  
AspCysArgArgIleThrCysProGluGlyTrpLeuProPheGluGlyLysCysTyrTyr  
PheSerProSerThrLysSerTrpAspGluAlaArgMetPheCysGlnGluAsnTyrSer  
HisLeuValIleIleAsnSerPheAlaGluHisAsnPheValAlaLysAlaHisGlySer  
ProArgValTyrTrpLeuGlyLeuAsnAspArgAlaGlnGluGlyAspTrpArgTrpLeu  
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inoculated with 30 mL of an overnight culture grown at 25°C.  Cultures were grown at 
37°C until an OD550 of 1.0 was reached.  Cells were induced with 100 mg/L of IPTG and 
grown for a further 2.5 h at 37°C.  Cells were harvested by centrifugation for 15 min at 
4,000 rpm in a Beckman JLA8.1000 rotor.  Pellets from 6 L of culture were pooled in 400 
mL of 10 mM Tris, pH 7.8 and spun for 10 min at 8,000 rpm in a Beckman JA14 rotor.  
Cells were resuspended in 100 mL of 10 mM Tris, pH 7.8 and lysed by sonication.  The 
lysate was spun for 15 min at 10,000 rpm in a Beckman JA14 rotor to pellet inclusion 
bodies containing prolectin.  Inclusion bodies were resuspended in 100 mL of 6 M 
guanidine-HCl, 100 mM Tris, pH 7.0 by brief sonication and incubated for 30 min with 
0.01% 2-mercaptoethanol to denature the protein.  Insoluble material was removed by 
centrifugation for 30 min at 35,000 rpm in a Beckman 45Ti rotor.  Triton X-100 was added 
to a final concentration of 1% and the solution was diluted slowly into 400 mL of loading 
buffer to renature the protein.  The protein was dialysed against three changes of loading 
buffer (each 2 L).  Insoluble material was removed by centrifugation for 30 min at 45,000 
rpm in a Beckman 55.2Ti rotor followed by filtration through glass wool.  Prolectin was 
isolated by affinity chromatography on a 5-mL column of mannose-Sepharose.  The 
column was washed with 10 mL of loading buffer and protein was eluted with 10 x 1 mL 
aliquots of eluting buffer.  A prolectin construct consisting of a minimal CRD (Figures 4.1 
and 4.2) was produced in the same way as the extracellular domain with the following 
adjustments: the overnight starter culture was grown at 30°C, no Triton X-100 was added 
during protein renaturation, and the volume of each elution fraction was 2 mL. 
 
Production of affinity-purified antibodies to prolectin 
Production of affinity-purified antibodies to prolectin was performed by S.A.F. Jégouzo.  
Antibodies were raised against the extracellular domain of prolectin (0.8 mg of lyophilized 
protein) using a 28-day rabbit polyclonal antibody program from Eurogentec, in which two 
rabbits were given four injections of antigen on days 0, 7, 10 and 18, and blood was 
collected on days 21 and 28.  Antibodies were assessed by immunoblotting against 
purified CRD of prolectin.  A prolectin affinity column for purification of antibodies was 
made using the same protocol as for the SRCL CRD affinity column (Chapter 2).  Purified 
CRD of prolectin (1.5 mg) in 100 mM HEPES, pH 7.8, 150 mM NaCl, 10 mM CaCl2 was 
coupled to 1 mL of Affigel-10 resin.  Prolectin antibodies were affinity purified using the 
same protocol as for SRCL antibodies (Chapter 2).  Affinity-purified antibodies were 
validated by immunoblotting against purified CRD of prolectin.  Affinity-purified antibodies 
were stored in aliquots at -20°C and used at a concentration of 10 μg/mL for tissue 
staining. 
 
186
Chapter 4 
Immunostaining of tissues 
The following mouse monoclonal antibodies were obtained from Dako and used for tissue 
staining: 
Antigen Clone  Dilution Antigen retrieval method 
Ki67  MIB-1  1:80  Heat-mediated 
CD68  KP1  1:40  Heat-mediated 
CD21    1:33  Enzymatic 
 
Enzymatic antigen retrieval was performed using trypsin enzymatic antigen 
retrieval solution (Abcam).  The trypsin solution was diluted 1:4 in the buffer supplied and 
incubated on the slide for 20 min at 37°C.  Negative control mouse IgG1 was obtained 
from Dako.  Formalin-fixed paraffin-embedded human bone marrow and fetal liver slides 
were purchased from Spring Bioscience.   
Tissue sections were blocked with 10% normal goat serum in PBS, and incubated 
for 90-120 min with primary antibodies diluted in 2% serum.  For immunofluorescence 
detection, sections were incubated for 30 min with Alexa Fluor 488-labelled goat anti-
rabbit IgG and Alexa Fluor 594-labelled goat anti-mouse IgG (Invitrogen), each at 5 
μg/mL.  For immunohistochemical detection, sections were incubated for 30 min with 
biotinylated goat anti-rabbit IgG or anti-mouse IgG at 7.5 μg/mL.  Following quenching of 
endogenous peroxidase activity by incubation for 15 min in 3% hydrogen peroxide in PBS, 
the biotinylated secondary antibody was detected using a complex of avidin and 
biotinylated horseradish peroxidase.  The complex was prepared using the VectaStain 
Elite ABC Kit: 2 drops of reagent A were added to 5 mL of PBS containing 0.5 M NaCl, 
followed by 2 drops of reagent B, and incubated for 30 min at room temperature before 
use.  The complex was visualized with the 3,3’-diaminobenzidine (DAB) Substrate Kit.  To 
prepare the substrate, 2 drops of buffer stock solution were added to 5 mL of water, 
followed by 4 drops of DAB and 2 drops of hydrogen peroxide solution.  Sections were 
incubated for 5 min with the substrate and washed in water.  Sections were 
counterstained with Vector Hematoxylin QS for 30 s, washed in tap water, dehydrated 
through a graded ethanol series, cleared with xylene and mounted with VectaMount 
permanent mounting medium.  All reagents were from Vector unless stated otherwise.  
Additional experimental details were as described in Chapter 2. 
 
Microscopy 
Fluorescence microscopy was performed as described in Chapter 2.  Light microscopy of 
immunohistochemically-stained tissues was perfomed using the same microscope, 
camera and software as for fluorescence microscopy.  The colour balance of light 
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microscopy images was adjusted using Corel PhotoPaint 12 to achieve a white 
background.  Confocal microscopy was perfomed using a Leica SP2 upright confocal 
microscope.  The Alexa Fluor 488 fluorophore was excited with a 488 nm Argon laser, and 
emitted light from 520-550 nm was recorded.  The Alexa Fluor 594 fluorophore was 
excited with a 561 nm diode laser, and emitted light from 590-670 nm was recorded.  
Appropriate dichroic mirrors were used.  A 100x oil immersion objective was used with 2x 
zoom.  The pinhole was set at 1 Airy unit and the speed was set at 400 Hz.  Gain and 
offset of the photomultiplier tube were adjusted to minimize the number of empty and 
saturated pixels.  Lines were averaged 8 times to improve signal-to-noise ratio.  Images 
were acquired at 1024x1024 pixel resolution with Leica LCS software and merged using 
Corel PhotoPaint 12. 
 
Cell culture 
The Ramos human Burkitt’s lymphoma cell line was obtained from the German Collection 
of Microorganisms and Cell Cultures (DSMZ) and cultured in Roswell Park Memorial 
Institute (RPMI) 1640 medium with 20% fetal bovine serum.  Cultures were split three 
times per week at 1:3-1:4 dilution.  The BL-41 human Burkitt’s lymphoma cell line was 
obtained form DSMZ and cultured in RPMI 1640 medium with 10% fetal bovine serum.  
Cultures were split twice per week at 1:3-1:4 dilution.  The Jurkat, clone E6-1 acute T cell 
leukemia line was obtained from the American Type Culture Collection (ATCC).  Cells 
were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and split 
twice per week at a dilution of 1:4-1:6. 
 
cDNA synthesis 
cDNA from cultured cells was synthesized using the SuperScript III CellsDirect cDNA 
Synthesis System (Invitrogen).  Cells were collected by centrifugation, washed with DPBS 
and resuspended in DPBS at 107 cells/mL.  Cells (104 in 1 μL DPBS) were incubated for 
10 min at 75°C with 10 μL of resuspension buffer and 1 μL of lysis enhancer to lyse cells 
and stabilize RNA.  Following addition of 5 μL of deoxyribonuclease I and 1.6 μL of 
deoxyribonuclease I buffer, the lysate was incubated for 5 min at room temperature to 
remove genomic DNA.   The digestion was terminated by addition of 1.2 μL of 25 mM 
EDTA and incubation for 5 min at 70°C.  The preparation was incubated for a further 5 
min at 70°C following addition of 2 μL of 50 mM oligo(dT)20 and 1 μL of 10 mM 
deoxyribonucleotide triphosphate mix.  Following addition of 6 μL of 5x reverse 
transcription buffer, 1 μL of RNAseOUT recombinant ribonuclease inhibitor (40 U/μL), 1 
μL of SuperScript III reverse transcriptase (200 U/μL) and 1 μL of 0.1 M dithiothreitol, the 
cDNA synthesis reaction was performed for 50 min at 50°C.  The reaction was terminated 
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by 5-min incubation at 85°C.  The cDNA preparation was incubated for 20 min at 37°C 
with 1 μL of ribonuclease H (2 U/μL) to remove RNA, and stored at -20°C.  
 
PCR 
The following oligonucleotide primer pairs were used to amplify regions of the prolectin 
cDNA using 35 cycles of PCR (Figure 4.2): 
 
Primer pair 1 (N-terminal region of prolectin, 376 base pairs) 
CCTGTGCTAGACATGCATAATCTG  (forward) 
GGCCTGTCATGTTCCGGGGCTTGC (reverse)  
 
Primer pair 2 (C-terminal region of prolectin, 404 base pairs) 
GGGATGAGGCCCGGATGTTCTGCC (forward) 
CACGAAGAGGCAAGGCCGTCCACG (reverse) 
 
The reverse primer of pair 2 lies outside the cloned region of prolectin to preclude plasmid 
DNA acting as a template in PCR experiments.  Additional experimental details were as 
described in Chapter 2. 
 
4.3 Results 
4.3.1 Identification of prolectin, a novel C-type lectin, by DNA database screening 
Two approaches were adopted to search for novel human C-type lectins in DNA 
databases.  In the first approach, DNA sequences from genome and cDNA sequencing 
projects in the NCBI database were screened for potential C-type lectins by querying the 
translated nuecleotide database with amino acid sequences of CRDs from known C-type 
lectins.  Querying the database with the CRD sequence from human DC-SIGN returned a 
translation of a region of a cDNA derived from peripheral blood mononuclear cells and 
sequenced by the NEDO Human cDNA Sequencing Project, which did not match any 
known protein.  This polypeptide, denoted as FLJ45910 protein, was a type II 
transmembrane protein, with a cytoplasmic domain of ~170 residues and an extracellular 
domain of ~110 residues, of which the final ~60 residues appeared to be the N-terminal 
portion of a CTLD, corresponding approximately to the first exon of the CRD from DC-
SIGN (Figure 4.3). 
In the second approach to identify novel human C-type lectins, the Ensembl 
human genome database, in which the translations of known and predicted genes are 
automatically screened against profile-recognition algorithms to identify protein domains, 
was mined for sequences matching the CTLD profile.  A protein model was identified in 
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Figure 4.3: Identification of prolectin by searching of DNA databases
The translation of the cDNA cloned by us is shown in red, labelled Prolectin.  Regions of 
sequence derived from DNA database entries that differ from the cloned sequence are boxed.
Sequence type Source
Nucleotide Protein
NEDO Human cDNA Sequencing ProjectcDNA BAC87146AK127809
GenBank accession
Gene model Celera Genomics EAW84437
BC140848cDNA NIH Mammalian Gene Collection Project AAI40809
Sequences found in DNA databases encoding a novel C-type lectin
Comparison of translated sequences
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the Celera Genomics annotation of the human genome that included a complete CTLD 
together with a transmembrane domain and N-terminal cytoplasmic region.  The amino 
acid sequence overlapped with that of the translated cDNA, but did not include the first 
~120 residues from the N-terminus of the putative cytoplasmic region. 
Oligonucleotide primers for PCR were designed using both of these sequences to 
incorporate both the longer cytoplasmic region and the complete CTLD of the putative 
protein.  A PCR product was amplified from a human spleen cDNA preparation and 
cloned (cloning was performed by S. Yan).  Sequencing of this cloned cDNA indicated 
that both the extended cytoplasmic region and complete CTLD were indeed present, and 
the novel protein was named prolectin.  The sequence of a longer cDNA derived from 
pooled multiple tissues and sequenced by the NIH Mammalian Gene Collection Project 
was subsequently deposited in the database and was found to match exactly that of the 
cloned cDNA.  The structure of the prolectin gene was deduced from comparison of the 
cDNA and genomic DNA sequences (Figure 4.4).  The Human Genome Organization 
Gene Nomenclature Committee has recently assigned the symbol CLEC17A to the 
prolectin gene.   
Comparison of the prolectin sequences found in the databases, the sequence of 
prolectin cloned by us, and the genomic DNA sequence reveals two errors in the genome 
annotation.  Firstly, the N-terminus of the protein was predicted incorrectly, with an 
internal methionine selected as the start residue, probably due to the lack of homology 
between the N-terminal region and any known protein, and the presence of sequence 
repeats.  Secondly, one splice site is different from that predicted.  The cloned cDNA 
sequence indicates that a rare non-canonical donor splice site, in which the standard GU 
sequence is replaced with GC, is used at the end of the penultimate exon in prolectin.  
The genome annotation misses this GC splice site, and assumes usage of a GU site 
which by chance is found exactly 12 bases downstream, such that selection of the site 
inserts four amino acids into the translation without perturbing the reading frame of the 
final exon.  GC sites such as the one found in prolectin account for less than 1% of the 
total donor splice sites (Thanaraj and Clark, 2001).  The substitution of U with C generally 
appears to be compensated for by optimization of the sequence flanking the splice site, 
and the sequence flanking the GC splice site in prolectin (AGGCAAGT) is indeed the 
optimal sequence for binding to the spliceosome.    The alternative protein C-terminus in 
the translation of the cDNA sequence deposited by the NEDO cDNA Sequencing Project 
(Figure 4.3) is produced by complete omission of the penultimate exon, which shifts the 
reading frame of the final exon leading to abrupt termination, even though the final exon is 
present in the cDNA in its entirety. 
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Figure 4.4: Prolectin gene structure
Scale diagram of the prolectin gene.  Exons are expanded 10-fold relative to introns for clarity.  
Based on genome assembly GRCh37.
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Prolectin is not well annotated in other genomes, particularly in the region of the 
CTLD, probably because of the presence of the GC splice site and the uniqueness of the 
non-CTLD regions.  In addition, the introns within the CTLD, while not exceptionally large, 
are bigger than those found within related CTLDs.  Although only partial data are available 
from lower-coverage genomes, prolectin appears to be generally well conserved in 
placental mammals, with similar but more distantly related sequences found in the 
platypus and chicken genomes.  However examination of mammalian genomes shows 
that the prolectin gene is absent in a subset of rodents that includes mouse and rat, but 
not kangaroo rat and guinea pig, due to a chromosomal rearrangement that resulted in the 
loss, relative to the human genome, of ~500 kilobases of genomic DNA containing nine 
genes. 
 
4.3.2 Analysis of the prolectin polypeptide sequence and biochemical 
characterization of the receptor 
The prolectin gene encodes a 378-residue type II transmembrane protein (Figure 4.5).  
The organization of the prolectin polypeptide resembles that of CTLD-containing proteins 
of the type II receptor family, except that prolectin has a uniquely large 168-residue 
cytoplasmic domain.  The cytoplasmic domain contains three consecutive 26-residue 
repeats produced by exon duplication, and is rich in motifs that may mediate interaction 
with intracellular signalling proteins.  Unlike other CTLD-containing proteins with signalling 
functions, prolectin does not contain consensus ITIMs in the cytoplasmic domain, or 
charged residues in the transmembrane region which could mediate interaction with 
ITAM-containing transmembrane adaptor molecules (Graham and Brown, 2009).  Instead 
there are a number of tyrosine residues – two near the N-terminus and two in each of the 
repeat regions – which, if phosphorylated, could provide binding sites for SH2 domain-
containing proteins, such as adaptor molecules like Grb2, and soluble tyrosine kinases of 
the Src and Syk families (Machida and Mayer, 2005).  There are also several instances of 
the PXXP motif that is the canonical recognition site for SH3 domains found in Grb2 and 
other adaptor and kinase molecules (Kaneko et al., 2008).  A non-canonical SH3 domain-
binding motif of the form RXXK, which is recognized by Grb2 and related SH3 domain-
containing proteins (Berry et al., 2002; Liu et al., 2003) is also present in the cytoplasmic 
tail of prolectin.  In addition, each repeat contains a run of eight acidic residues which may 
contribute to the binding of intracellular molecules through electrostatic interactions. 
The extracellular domain of prolectin contains a C-terminal CTLD separated from 
the transmembrane region by a neck region, which contains two potential N-glycosylation 
sites.  The CTLD of prolectin is most closely related to the CTLDs in proteins of the type II 
receptor family, particularly the gene cluster which in humans comprises DC-SIGNR, DC-
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SIGN, LSECtin and CD23.  There is around 40% identity between the amino acid 
sequences of the CTLDs in human prolectin and DC-SIGN, including conservation of the 
critical residues involved in binding to mannose and related sugars (Figure 4.5).  
Homology of these CTLDs is also evident in the conservation of exon-intron boundary 
positions and the pattern of four disulfide bonds, although prolectin also contains an 
additional unpaired cysteine residue near the C-terminus of the domain.  The prolectin 
gene and the DC-SIGN gene cluster are both located on the short arm of chromosome 19, 
around 7 megabases apart.  Identification of syntenic regions in other vertebrate genomes 
indicates that there has been extensive local shuffling of genes in this region during 
speciation, which would account for the separation of the prolectin and DC-SIGN genes 
following gene duplication.   
Expression and characterization of the prolectin protein was performed by S.A.F. 
Jégouzo, A.S. Powlesland, M.E. Taylor and K. Drickamer (Graham et al., 2009).  Sugar-
binding activity in prolectin was demonstrated by affinity chromatography, solid-phase 
binding competition assays, and screening of a glycan array, in which two major 
categories of ligand were identified: oligosaccharides terminating in mannose, such as 
high-mannose N-linked glycans, and oligosaccharides bearing terminal fucose, such as 
the Lewisx, Lewisa, and Lewisy epitopes.  Some structures with terminal GlcNAc were also 
bound.  Prolectin expressed on the cell surface of transfected fibroblasts did not mediate 
uptake and degradation of a neoglycoprotein ligand, and prolectin was also found to 
release ligand only at particularly low pH (half-maximal release at pH 5.2), indicating that it 
is unlikely to function as a classical endocytic receptor, despite the presence of tyrosine-
containing motifs in the cytoplasmic tail which could interact with components of the 
endocytic machinery (Spiess, 1990).  However, tyrosine residues in the cytoplasmic tail 
were found to be phosphorylated, and the receptor was observed to associate with Grb2, 
indicating that prolectin may interact with intracellular signalling pathways through binding 
to cytoplasmic SH2 domain-containing proteins.   
 
4.3.3 Identification of germinal centres as the principal site of prolectin expression 
To assist in the development of hypotheses regarding the biological role of signalling and 
sugar-binding activities in prolectin, the sites of prolectin expression in human tissues 
were investigated.  With no information available on the physiological expression of 
prolectin, an immunohistochemical screening approach was taken to define sites of 
expression, in which a slide array of human tissue samples was probed with affinity-
purified rabbit polyclonal antibodies to prolectin.  The array included a large range of 
tissues, but expression of prolectin was almost exclusively restricted to secondary 
lymphoid tissues, including lymph node, tonsil, appendix, stomach, intestine, appendix 
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and spleen (Figures 4.6, 4.7, 4.8 and data not shown).  Clusters of prolectin-expressing 
cells were observed within germinal centres in these tissues.  Therefore, to identify which 
cell types were expressing prolectin, staining with anti-prolectin antibodies was compared 
with staining for markers of cell types found in germinal centres. Tingible body 
macrophages were identified by expression of the general macrophage marker CD68 
(Micklem et al., 1989).  Follicular dendritic cells were identified by expression of CD21, 
which is not found on conventional dendritic cells (Schriever et al., 1989).  Dividing B cells 
were identified using the proliferating cell marker Ki67 (Cattoretti et al., 1992).   
In germinal centres from multiple tissues, prolectin was found to localize to the 
same regions as the Ki67 antigen, and did not overlap substantially with CD68 or CD21, 
indicating that prolectin is found in dividing B cells but not in macrophages or follicular 
dendritic cells (Figures 4.6, 4.7, 4.8).  Germinal centres are described as having a dark 
zone, where B cell proliferation occurs, and a light zone, where follicular dendritic cells are 
located and interact with B cells (Allen et al., 2007).  Prolectin is therefore concentrated in 
the dark zone, associated with proliferating centroblasts.  The chronic germinal centres of 
tonsil, which are constantly exposed to antigen, have a different appearance to the acute 
germinal centres of lymph node and other lymphoid tissues (Brachtel et al., 1996).  Here, 
the germinal centres of tonsil were observed to have a central light zone region that is 
particularly rich in follicular dendritic cells, and a peripheral dark zone area adjacent to the 
mantle zone rich in dividing and prolectin-expressing cells.  Germinal centres in other 
tissues had the classic appearance of an eccentric dark zone with the light zone oriented 
towards incoming antigen (Allen et al., 2007).   
Isolated prolectin-expressing cells were observed outside the germinal centre, in 
the mantle zone and T cell zone, in a similar distribution to Ki67-expressing cells (Figures 
4.6, 4.7 and 4.8 and data not shown), suggesting that these cells are also dividing B cells, 
possibly in transit to or from the germinal centre.   
 
4.3.4 Expression of prolectin in dividing B cells of germinal centres 
To confirm that prolectin is expressed by the same cells as the Ki67 antigen, as is 
suggested by the immunohistochemical staining described above, double 
immunofluorescence staining for prolectin and Ki67 antigen was performed on tissue 
sections.  Prolectin-expressing cells both in the germinal centre and in the mantle zone 
expressed Ki67 antigen, confirming that cells expressing prolectin are dividing (Figure 
4.9).  In addition, all Ki67-expressing cells appeared also to express prolectin, suggesting 
a strong link between cell proliferation and prolectin expression in germinal centre cells. 
The finding that prolectin is expressed by dividing cells within germinal centres (Figure 
4.9) strongly suggests that expression of the receptor is restricted to B cells.  To confirm 
196
Prolectin CD21
Ki67 CD68
Rabbit IgG Mouse IgG
Figure 4.6: Immunohistochemical detection of prolectin in a lymph node germinal 
centre
Formalin-fixed paraffin-embedded tissue was stained with affinity-purified rabbit polyclonal 
antibodies to prolectin, or with mouse monoclonal antibody to CD21 (follicular dendritic 
cells), CD68 (macrophages), or Ki67 (proliferating cells), or with isotype-matched negative 
control antibody.  Antibody was detected using biotinylated secondary antibody followed by 
streptavidin-horseradish peroxidase complex and visualized with 3,3’-diaminobenzidine 
(DAB) (brown).  Nuclei were counterstained with hematoxylin (blue).  Regions of lymphoid 
tissue shown are the germinal centre (GC), mantle zone (M) and T cell zone (T).  Scale bar is 
100 μm.
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Figure 4.7: Immunohistochemical detection of prolectin in a tonsil germinal centre
Experimental details were as described in Figure 4.6.  Scale bar is 100 um.
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Figure 4.8: Immunohistochemical detection of prolectin in gut-associated lymphoid 
tissue
Experimental details were as described in Figure 4.6.   The images show part of the pylorus 
region of the stomach, containing a germinal centre (GC) with mantle zone (M), surrounded 
by the lamina propria (LP) which contains pyloric glands.  The arrow indicates the direction of 
the gastric lumen.  Scale bar is 100 μm.
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Figure 4.9: Immunofluorescence detection of prolectin and Ki67 in germinal centres
Sections of tonsil and appendix were doubly stained using anti-prolectin antibodies, detected 
with Alexa Fluor 488-labelled secondary antibody, and a mouse monoclonal antibody against 
the proliferating cell marker Ki67, detected with Alexa Fluor 594-labelled secondary antibody.  
Germinal centres (GC) and mantle zones (M) are indicated.  Scale bar is 50 μm.
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that the prolectin-expressing cells are B cells, double immunofluorescence staining was 
performed with antibodies to prolectin and to the B cell marker CD19 (Stamenkovic and 
Seed, 1988).  Prolectin-expressing cells in germinal centres in both lymph node and 
spleen were stained using the anti-CD19 antibody, confirming that the cells expressing 
prolectin are B cells (Figures 4.10 and 4.11).  A proportion of CD19-expressing cells in the 
germinal centre, as well as the vast majority of CD19-expressing cells in the mantle zone, 
were not stained with anti-prolectin antibodies, indicating that prolectin is restricted to 
dividing B cells of the germinal centre and is not expressed by the resting B cells of the 
mantle zone.  
In prolectin-expressing cells outside germinal centres in the T cells zones, CD19 
expression is lower or undetectable (Figure 4.10 and data not shown), suggesting that 
these cells, which were ascertained to be dividing by expression of Ki67 antigen (Figure 
4.9), may be at a different stage of differentiation or maturity to cells within the germinal 
centre.  Plasmablasts produced by germinal centres in secondary lymphoid tissues 
continue to divide but lose expression of CD19 as they migrate and differentiate into 
plasma cells (Terstappen et al., 1990).  These characteristics are consistent with 
observations made on prolectin-expressing cells outside germinal centres, suggesting that 
these cells may be migrating plasmablasts derived from germinal centre cells. 
The expression of prolectin in the spleen was examined because this organ has a 
different organization to other secondary lymphoid tissues, reflecting its unique role in 
filtering the blood for antigens (Chadburn, 2000).  The spleen is largely composed of red 
pulp, in which cords of blood cells are separated by blood-filled sinusoids.  The remainder 
is white pulp, which consists of sheaths of lymphoid cells (primarily T cells) surrounding 
arterioles.  Proliferation of activated B cells creates nodules with germinal centres 
extending from the periarteriolar lymphoid sheath, and aggregates of prolectin-expressing 
cells, which also stained for the B cell marker CD19, were found within such germinal 
centres (Figure 4.11).  Isolated prolectin-expressing cells were also observed in the 
periarteriolar lymphoid sheath, in a similar distribution to Ki67-expressing proliferating 
cells (Figure 4.11), suggesting that splenic prolectin-expressing cells outside of germinal 
centres may be dividing.  Prolectin thus appears to be present in similar cell types in all 
secondary lymphoid tissues, including spleen. 
 
4.3.5 Subcellular localization of prolectin 
Prolectin is predicted to be a cell surface protein.  The lack of overlap of staining in cells 
stained with antibodies to prolectin and to Ki67, a nuclear antigen (Cattoretti et al., 1992), 
demonstrates that prolectin is not found in the nucleus (Figure 4.9), but the subcellular 
localization of prolectin cannot be pinpointed accurately using conventional light 
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Figure 4.10: Immunofluorescence detection of prolectin and CD19 in a lymph node 
germinal centre
A lymph node section was doubly stained with antibodies to prolectin, detected with Alexa 
Fluor 488-labelled secondary antibody, and with a monoclonal antibody against the B cell 
marker CD19, detected with Alexa Fluor 594-labelled secondary antibody.  The germinal 
centre (GC) contains prolectin-expressing B cells, the mantle zone (M) contains resting B 
cells and the T cell zone (T) contains mostly T cells.  Scale bar is 100 μm.
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Figure 4.11: Immunofluorescence and immunohistochemical detection of prolectin in 
spleen
Top: A splenic B cell nodule with germinal centre, stained as described in Figure 4.10.  
Bottom: Splenic white pulp surrounding a central arteriole (A), stained for prolectin or Ki67 as 
described in Figure 4.6.  Scale bars are 100 μm.  
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microscopy.  To ascertain if prolectin is found at the cell surface, the co-localization of 
prolectin in doubly-stained tissue with CD19, a cell surface protein (Stamenkovic and 
Seed, 1988), was examined by confocal microscopy.  In germinal centre B cells, CD19 
staining clearly highlighted only the cell membrane, whereas prolectin staining was found 
partially at the cell membrane, but mostly within the cytoplasm (Figure 4.12).  Because 
prolectin is not an endocytic receptor (Graham et al., 2009), this staining is not due to 
receptor recycling through cytoplasmic vesicles, but may represent receptor in the 
secretory pathway, or a mobilizable pool of prolectin-containing intracellular vesicles.  
Such vesicles could fuse with the plasma membrane in response to signalling to the 
cytoplasmic domain of prolectin. 
 
4.3.6 Expression of prolectin in hemopoietic tissues and in testis 
Secondary lymphoid tissues contain only mature B cells, but the correlation of prolectin 
and Ki67 antigen expression in B cells suggested that prolectin may also be expressed 
during cell division in B cell development, which occurs in primary lymphoid tissues 
(Osmond, 1990; Melchers et al., 1991).  Adult hemopoiesis begins in the bone marrow, 
where lymphoid, myeloid and erythroid cells at various stages of differentiation and 
maturation are found in hemopoietic cords along with stromal reticular cells and sinusoidal 
blood vessels, separated by large intervening adipocytes (Lord, 1990).  Maturation of B 
cells occurs entirely within the bone marrow, until mature B cells are released into the 
blood, where they home to the peripheral lymphoid tissues and begin to recirculate 
(Osmond, 1990).  Fetal hemopoiesis occurs in large blood-filled sinusoidal spaces 
between the hepatocytes of the liver, which is not yet required for digestive processes 
(Tavassoli, 1991). 
To determine if dividing cells in primary lymphoid tissue express prolectin, sections 
of bone marrow and fetal liver were doubly stained with antibodies to prolectin and Ki67 
antigen.  In bone marrow, large numbers of prolectin-expressing cells were found in the 
hemopoietic cords, but were not proliferating, as evidenced by lack of staining for Ki67 
antigen (Figure 4.13).  Overall, very few Ki67-expressing cells were observed, consistent 
with a model of hemopoiesis in which new blood cells are created by cell division in a very 
minor population of stem cells, with most of the bone marrow taken up by non-proliferating 
cells in later stages of maturation (Sieburg et al., 2002).  In fetal liver, prolectin-expressing 
cells were observed both amongst the hepatocytes and in the sinusoidal spaces and were 
not stained by antibody to Ki67 antigen (Figure 4.14).  The prolectin-expressing cells in 
these tissues were characterized by abundant cytoplasm and large round eccentric nuclei 
with clumps of chromatin around the edge of the nucleus.  It is difficult to distinguish 
different cell types in hemopoietic tissue sections without immunochemical staining, and it 
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Figure 4.12: Immunofluorescence detection of prolectin and CD19 in tonsil 
germinal centre cells
A tonsil section was doubly stained as described in Figure 4.10.  Images were obtained using 
a confocal microscope.
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Figure 4.13:  Immunofluorescence and immunohistochemical detection of prolectin 
in bone marrow
Top: Bone marrow stained for prolectin as described in Figure 4.6  The bone marrow 
contains cords of hemopoietic cells (C) and blood-filled sinusoid capillaries (S) between 
adipocytes (A).  Bottom: Bone marrow stained for Ki67 antigen and prolectin as described in 
Figure 4.9.  Ki67-expressing cells are indicated with arrows and prolectin-expressing cells 
with arrowheads.  Erythrocytes appear yellow.  Scale bar is 50 μm.
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Figure 4.14: Immunofluorescence and immunohistochemical detection of prolectin in 
fetal liver
Top: Fetal liver stained for prolectin as described in Figure 4.6.  The image shows 
hepatocytes (H) separated by sinusoidal spaces (S) filled with leukocytes (L) and 
erythrocytes.  Centre and bottom: Fetal liver stained for prolectin and Ki67 as described in 
Figure 4.9, with DAPI nuclear counterstain (blue).  Prolectin-expressing cells (arrows) are 
found among the hepatocytes (centre) and in the sinusoids (bottom).  Erythrocytes appear 
orange.  Scale bar is 50 μm.
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is possible that the prolectin-expressing cells are B lymphoblasts or other hemopoietic 
progenitor cells.  However the morphological characteristics, lack of proliferation and 
abundance of the prolectin-expressing cells suggest that they may be plasma cells.  Thus, 
prolectin-expressing cells in germinal centres may maintain prolectin expression during 
differentiation into plasma cells and homing to the bone marrow (Benner et al., 1981). 
The only non-lymphoid tissue where prolectin expression was observed in tissue 
array screening was in the testis (Figure 4.15).  In this tissue, prolectin was expressed 
only by the spermatogonia, which are germ cells found at the outer edge of the 
seminiferous tubules, against the basement membrane (Phillips et al., 2010).  Division of 
spermatogonia maintains the population of spermatogonia and produces spermatocytes 
which mature into spermatozoa that are released into the lumen of the seminiferous 
tubule.  Like germinal centre B cells, spermatogonia are a cell type which routinely 
undergo cell division in the adult, suggesting that a connection between the cell cycle and 
prolectin expression may exist in multiple cell types.  However, not all dividing cells 
express prolectin, since Ki67-expressing epithelial stem cells in sections of digestive tract 
tissue were not stained with anti-prolectin antibodies (data not shown). 
 
4.3.7 Expression of prolectin mRNA in tissues and a Burkitt’s lymphoma cell line 
To complement the analysis of prolectin expression by tissue staining, the expression of 
prolectin mRNA was investigated by PCR screening of cDNA preparations from a range of 
tissues.  Prolectin expression levels were highest in spleen, lymph node and peripheral 
blood leukocytes, with moderate expression detected in the small and large intestine and 
in lung and pancreas (Figure 4.16).  Screening was performed using one pair of primers 
designed to amplify a region of the cDNA corresponding to the N-terminal portion of the 
protein, and another pair designed to amplify a region corresponding to the C-terminal 
portion.  Both primer sets gave very similar results, with the amplification of cDNA from 
liver with only one primer set being the only significant difference.  Thus the full-length 
prolectin mRNA is generally correctly spliced in the tissues in which it is transcribed.   
Prolectin expression in germinal centre B cells is a probable source of prolectin 
transcript in spleen, lymph node and the jejunum portion of the small intestine.  
Expression of prolectin transcript throughout the intestine and in the lung is consistent with 
staining for prolectin in non-organized lymphoid tissue such as the lamina propria of the 
intestine (data not shown).  Tissue beneath epithelia is frequently infiltrated with immune 
cells, including naïve lymphocytes and plasma cells, to provide immune protection if the 
epithelium is breached (Bulek et al., 2010).   The low level of prolectin transcript in some 
cardiovascular tissues may similarly represent infiltration of inflamed tissue by 
lymphocytes (Tedgui and Mallat, 2006).  Prolectin transcript was also detected in bone 
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Figure 4.15: Immunofluorescence detection of prolectin in testis
Testis stained for prolectin as described in Figure 4.9, with DAPI nuclear counterstain.  
Arrows show the layers of prolectin-expressing spermatogonia at the outer edges of two 
adjacent seminiferous tubules.  Scale bar is 50 μm.
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Figure 4.16: PCR detection of prolectin expression in human tissues
A panel of cDNA preparations from human tissues was screened for the presence of prolectin 
cDNA using two sets of primers, which amplify different regions of the cDNA, as shown in 
Figure 4.2.  Amplification of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA 
confirms the integrity of the cDNA  preparations.
GAPDH
Prolectin
Pair 1
Prolectin
Pair 2
Primers
cDNA
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marrow, consistent with staining for prolectin in bone marrow tissue sections (Figure 
4.13).  The only tissue in which prolectin transcript is unlikely to arise from lymphocytes is 
the pancreas, which does not have associated lymphoid tissue, and prolectin expression 
was not observed in the pancreas in immunohistochemical staining (data not shown). 
The presence of high levels of prolectin transcript in peripheral blood leukocytes is 
significant because it indicates that prolectin is expressed in a circulating lymphocyte 
subset as well as in lymphocytes within lymphoid organs.  Preliminary staining of 
peripheral blood mononuclear cells with antibodies to prolectin suggests that the receptor 
is expressed in a minor population of these cells (data not shown).  It is possible that 
prolectin is expressed in naïve B cells in circulation but is downregulated when these cells 
enter secondary lymphoid organs.  However, the expression of prolectin in germinal 
centre B cells suggests that circulating cells expressing prolectin may be of germinal 
centre origin, such as plasmablasts homing to the bone marrow or recirculating memory B 
cells (Duchosal, 1997).   
The expression of prolectin was also examined in cell lines derived from Burkitt’s 
lymphoma, a malignancy thought to arise from germinal centre B cells, which are 
intrinsically vulnerable to malignant transformation because they are dividing and 
undergoing genomic DNA rearrangement and mutation (Klein and Dalla-Favera, 2008).  
cDNA was prepared from the Burkitt’s lymphoma cell lines BL41 and Ramos and from the 
Jurkat cell line, which is of T cell origin.  Prolectin cDNA was detected in the BL41 cell line 
but not in Ramos or Jurkat cell lines (Figure 4.17), suggesting that prolectin is expressed 
in a subset of B cell lymphomas.  Certain B cell lymphoma cell lines may therefore be 
useful in studying prolectin function.  In addition, prolectin expression may be indicative of 
the origin of lymphocytic malignancies and may represent a highly specific marker for 
particular classes of B cell neoplasm. 
 
4.4 Discussion 
The work presented in this chapter suggests that the novel C-type lectin prolectin has a 
role in the migration of B cells during and after cell differentiation in germinal centres.  
Screening of tissue sections by immunohistochemical staining and of tissue cDNA 
preparations by PCR indicated that prolectin is expressed predominantly in secondary 
lymphoid tissues, and further immunostaining localized this expression to dividing B cells 
both in germinal centres and in the surrounding mantle and T cell zones (Figures 4.5-4.10 
and 4.16).  In addition, prolectin expression was found in non-dividing cells in hemopoietic 
tissues (Figures 4.13 and 4.14) and in peripheral blood leukocytes (Figure 4.16).   
The role of germinal centres is to produce plasma cells and memory B cells with 
immunoglobulin that has high affinity for antigen, through a process of random mutation of 
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Figure 4.17: PCR detection of prolectin expression in lymphocytic cell lines
cDNA was synthesized from BL41, Ramos and Jurkat cell lines.  Amplification of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA demonstrates successful 
synthesis of cDNA from the cell cultures.  Spleen cDNA was included for comparison of 
prolectin cDNA amplification.
Primers
cDNA
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the immunoglobulin gene followed by cell selection (Klein and Dalla-Favera, 2008).  
Germinal centres are also the site of immunoglobulin class switching, which produces 
antibodies with different effector functions.  The cell interactions and movements 
connected with germinal centres are illustrated in Figure 4.18.  The presence of clumps of 
prolectin-expressing cells within germinal centres and isolated, individual prolectin-
expressing cells in other regions of the lymphoid tissue is consistent with the cells outside 
of germinal centres being in transit between a germinal centre and the blood or lymph.  
The expression of prolectin in non-proliferating cells in bone marrow resembling plasma 
cells (Figure 4.13) suggests that the migrating prolectin-expressing cells outside of 
germinal centres in secondary lymphoid organs are plasmablasts homing to the bone 
marrow, but some may also be recently activated B cells migrating into the germinal 
centre. 
The clearly defined margin between the prolectin-expressing B cells of the 
germinal centre and the non-expressing B cells of the mantle zone (Figure 4.10) reflects 
the tight regulation of the migration of cells out of the germinal centre by mechanisms 
including expression of the chemokine receptor CXCR5, which retains cells in the 
germinal centre through detection of the follicular dendritic cell chemokine CXCL13 
(Cyster et al., 2000).   B cells within the germinal centre cycle between the dark zone, 
where they undergo cell division accompanied by somatic hypermutation of 
immunoglobulin genes, and the light zone, where they stop dividing and undergo selection 
(Allen et al., 2007).  The presence of prolectin only in dividing cells of the dark zone 
indicates that expression of the prolectin gene is being switched on and off as cells move 
between the two zones and between dividing and quiescent states.  The movement of B 
cells between the zones is regulated in part by expression of the chemokine receptor 
CXCR4, which draws cells towards CXCL12 produced by stromal cells in the dark zone, 
and is downregulated to enable cells to move into the light zone (Allen et al., 2004).  
Expression of prolectin and CXCR4 may therefore be co-ordinately regulated by an 
upstream signal in germinal centre cells.  Consistent with this proposal, CXCR4 
expression returns after differentiation of germinal centre cells into plasmablasts, and is 
involved in homing of plasma cells to the bone marrow (Kunkel and Butcher, 2003).  In 
mouse, Ki67-positive dividing B cells are distributed throughout the germinal centre rather 
than being concentrated in the dark zone (Camacho et al., 1998; Rahman et al., 2003; 
Wang and Carter, 2005).  The absence of the prolectin gene in mouse is therefore 
consistent with a connection between prolectin expression and germinal centre 
organization. 
Prolectin has unprecedented potential among mammalian C-type lectins for 
interaction with components of intracellular signalling pathways such as soluble tyrosine 
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Figure 4.18: Cell movements in secondary lymphoid organs
Facing page: Organization of a lymph node. A lymph node is typically 2-10 mm in 
diameter.This page: Cell types in germinal centres.  Cells are coloured according to cell type: 
B cells, yellow; T cells, green; conventional dendritic cells, blue; follicular dendritic cells, pink; 
macrophages, purple; plasmablasts/memory B cells, orange.  Activated lymphocytes are 
outlined in red.  Compiled using Immunobiology, 7th edition, Murphy, Travers and Walport 
(lymph node drawing based on Fig 1.18).  
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kinases and adaptor molecules, due to the presence in the cytoplasmic tail of multiple 
motifs that may be recognized by SH2 and SH3 domains.  The finding that tyrosine 
residues in prolectin are phosphorylated when the receptor is expressed in mammalian 
cells (Graham et al., 2009) confirms that prolectin is a substrate for tyrosine kinases.  
Glycan-binding activity in prolectin may therefore be regulated by intracellular signalling.  
In particular, immunostaining results indicate that trafficking of prolectin to the cell surface 
may be a point of regulation.  Immunofluorescence staining combined with confocal 
microscopy imaging revealed that prolectin is found not only at the cell surface, but also 
within the cytoplasm (Figure 4.12).  Because prolectin is not an endocytic receptor 
(Graham et al., 2009), this distribution is suggestive of a pool of prolectin-containing 
transport vesicles which may undergo regulated fusion with the plasma membrane to 
increase the amount of prolectin on the cell surface.  Vesicle fusion may be regulated by 
phosphorylation of prolectin in response to upstream signalling (Liu, 1997).  Transfer of 
prolectin to the cell surface by vesicle exocytosis could bring about cell adhesion through 
interaction of prolectin with fucose-containing glycans (Graham et al., 2009) on other cells 
or in the extracellular matrix.   
Germinal centres are the source of almost all B-cell non-Hodgkin lymphomas, and 
the genetic lesions in these cells represent malfunctions of normal germinal centre 
processes (Klein and Dalla-Favera, 2008).  The expression of prolectin in a Burkitt’s 
lymphoma cell line (Figure 4.17) indicates that prolectin expression may be retained in 
some B cells following malignant transformation.  Prolectin may therefore represent a 
novel diagnostic marker and therapeutic target.  B-cell glycan-binding proteins of the 
siglec family have been targeted with antibody-based therapies for treatment of leukemia, 
lymphoma and autoimmune disease (O'Reilly and Paulson, 2009).  Furthermore, recent 
work describes the use of glycan ligands for the siglec CD22 to target chemotherapy 
drugs to lymphoma and leukemia cells and bring about cell death (Chen et al., 2010), 
illustrating the potential for therapeutic exploitation of specific protein-carbohydrate 
interactions.   
In addition to lymphocytes, prolectin expression was also observed in 
spermatogonia (Figure 4.15).  Spermatogonia and germinal centre B cells share the 
unusual property of dividing in normal adult tissue and giving rise to cells with genomic 
DNA that is different from the parent cell (Phillips et al., 2010), suggesting an association 
between prolectin expression and the cell cycle in specialized cell types.  The expression 
pattern of prolectin is therefore very different to other C-type lectins, which are found 
predominantly on myeloid cells (Cambi and Figdor, 2003; Stambach and Taylor, 2003), 
endothelial cells (Fiete et al., 1997; Jung and Ley, 1999; Liu et al., 2004) and hepatocytes 
(Spiess, 1990). 
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General discussion 
 
The work presented in this thesis describes the characterization of two novel human C-
type lectins with potential roles in glycoprotein clearance and cell migration in the immune 
system. 
 
The scavenger receptor C-type lectin in the clearance of Lewisx-tagged neutrophil 
granule glycoproteins 
The scavenger receptor C-type lectin (SRCL) was found to recognize proteins of 
neutrophil secondary granules through binding to Lewisx groups and to mediate cellular 
uptake of the Lewisx-containing neutrophil protein lactoferrin, suggesting a role in the 
clearance of such proteins in inflamed tissues.  Three classes of cytoplasmic granule are 
released by exocytosis from neutrophils in a controlled progression at sites of 
inflammation.  SRCL and the mannose receptor may have complementary roles in 
clearing proteins from different subsets of granules (Figure 5.1).  The targeting of proteins 
to different types of neutrophil granule is directed by the temporal regulation of gene 
expression during myeloid cell maturation (Figure 3.8) (Nauseef, 1999; Faurschou and 
Borregaard, 2003), such that groups of proteins expressed at the same time and co-
localizing in the same granules are likely to be glycosylated in a similar fashion.  Co-
ordinated regulation of the glycosylation machinery with expression of granule proteins 
may therefore enable each group of proteins to be tagged with the same kinds of glycan 
structure.  
Neutrophil primary granules resemble lysosomes in creating a low-pH, degradative 
environment for pathogen elimination, and both lysosomal and primary granule 
glycoproteins carry high-mannose N-linked glycans which facilitate their clearance by the 
macrophage mannose receptor (Olsson et al., 1988; Shepherd and Hoidal, 1990).  Unlike 
lysosomal glycoproteins, which are targeted to lysosomes by tagging with mannose 6-
phosphate (Munier-Lehmann et al., 1996), primary granule proteins are targeted by timing 
of expression (Nauseef, 1999).  This work has shown that secondary granule 
glycoproteins carry entirely different N-glycans, with high-mannose structures being 
replaced by branched and highly-fucosylated complex-type glycans, presumably due to 
initiation of expression of processing glycosidases and glycosyltransferases in the 
endoplasmic reticulum and Golgi apparatus.  Secondary granule glycoproteins thus carry 
terminal galactose and fucose residues and are not recognized by the mannose receptor, 
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but are instead ligands for SRCL, suggesting that the controlled glycosylation of these 
proteins targets them to SRCL for clearance.   
The targeting of proteins from different granules to different clearance receptors is 
consistent with the sequential mobilization of granule types that is employed during 
neutrophil activation to supply appropriate molecules at each stage in the neutrophil 
response (Faurschou and Borregaard, 2003).  Secondary granules are exocytosed during 
extravasation, when metalloproteinases like MMP-9 facilitate penetration of the vessel 
wall by degrading the basement membrane, and in the inflamed tissue following 
extravasation, when the same metalloproteinases facilitate migration and antimicrobial 
proteins such as lactoferrin stall the progress of infection by sequestering iron and 
damaging microbial membranes.  The expression of SRCL on endothelial cells thus 
places the receptor in a good position to mediate local clearance of granule glycoproteins 
released into the bloodstream or into the sub-endothelial tissues.  Primary granules are 
generally fused with phagosomes containing internalized pathogens to mediate 
intracellular killing of pathogens within neutrophils.  Some primary granules are 
exocytosed in inflamed tissues, as a result of inflammatory stimuli resulting from infection, 
and primary granule proteins may also be released following neutrophil death in the 
tissues.  The expression of the mannose receptor on tissue macrophages (Allavena et al., 
2004) places this receptor at the site of primary granule protein release.  Additionally, 
primary granule proteins which diffuse into the circulation could be cleared by the liver 
through the mannose receptor.   
The third class of neutrophil granule, the tertiary granule, contains few soluble 
proteins, its principal function being as a reservoir of cell surface receptors for endothelial 
adhesion and transmigration (Faurschou and Borregaard, 2003).  The main soluble 
constituent is MMP-9, also known as neutrophil gelatinase, such that these granules are 
sometimes referred to as gelatinase granules.  Secondary and tertiary granules are 
formed as a continuum (Nauseef, 1999), so MMP-9 in tertiary granules may carry similar 
glycosylation to MMP-9 in secondary granules and also be a ligand for SRCL.  Since 
exocytosis of tertiary granules occurs following contact with the endothelium but prior to 
extravasation (Faurschou and Borregaard, 2003), SRCL would also be well placed to 
clear tertiary granule proteins. 
The clearance of proteins released from neutrophils is likely to be necessary for 
several reasons relating to the different functions of the various granule components.  
Abrogration of the activity of extracellular matrix-degrading enzymes may prevent 
unnecessary tissue damage and promote healing.  Removal of proteins such as 
lactoferrin, which acts as a signal of infection with wide-ranging effects on cells of innate 
and adaptive immunity and endothelial cells (Legrand and Mazurier, 2010), provides a 
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mechanism to regulate the amplitude of the immune response and restore the normal 
state following resolution of infection.  Efficient clearance of neutrophil-derived proteins 
may also be important in avoiding the emergence of autoreactive antibodies.  Anti-
neutrophil cytoplasmic antibodies reactive with intracellular proteins including lactoferrin 
are observed in a range of autoimmune disorders and are speculated to result from 
association of endogenous proteins with immunostimulatory microbial molecules and 
inefficient clearance of neutrophil debris (Reumaux et al., 2004).   
While the eventual clearance of neutrophil proteins may be necessary to limit 
damaging consequences of inflammation, the released proteins must still be allowed to 
exert their useful effects in facilitating neutrophil migration and attacking invading 
microorganisms.  The expression of SRCL in endothelial cells may be tuned to the low 
level described in Chapter 2 to achieve a balance between allowing time for useful effects 
whilst limiting harmful activity.  It is also possible that SRCL expression may be 
upregulated in acutely-inflamed endothelium to deal with the large numbers of 
degranulating neutrophils.  For protein clearance occurring at a systemic rather than local 
level, even a low-abundance endothelial receptor can provide a high-capacity clearance 
system due to the extensive nature of the vasculature, which in an adult human has been 
estimated to contain up to 6 x 1013 endothelial cells with a total area of endothelium of up 
to 5000 m2 (Davies and Hagen, 1993; Ribatti et al., 2002).  Clearance is also likely to be 
very efficient in small vessels, where SRCL expression was observed (Figures 2.19 and 
2.20), because the ratio of endothelial area to blood volume is inversely proportional to the 
radius of the vessel. 
SRCL is one of a number of glycan-binding proteins with endocytic capability.  For 
some of these receptors, the primary function of endocytosis appears to be the 
internalization of pathogen-associated molecules for antigen presentation.  Functions in 
protein clearance have been ascribed to the mannose receptor and the asialoglycoprotein 
receptor.  The role of the mannose receptor in clearing glycoprotein hormones is now well 
understood (Allavena et al., 2004), but for the asialoglycoprotein receptor, it is only 
recently that physiological ligands have been described (Steirer et al., 2009), despite 
extensive characterization of biochemical and cell biological aspects of endocytosis 
(Spiess, 1990).  SRCL thus represents one of a small number of endocytic lectins for 
which potential endogenous ligands have been identified.  
The identification of granule proteins as the major ligands for SRCL in neutrophils 
suggests that the primary function of the receptor is in protein clearance.  However, an 
additional role in mediating adhesion of neutrophils is not exluded, and neutrophil cell 
surface proteins including CEACAM-1 the two subunits of integrin αMβ2 were also 
identified as ligands for SRCL (Figures 3.6 and 3.9).  Because SRCL appears to be 
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expressed constitutively, rather than only at sites of inflammation as is the case for the 
selectins (Sperandio et al., 2009), the receptor would not be useful in directing neutrophils 
specifically to inflamed endothelium.  However, the highly elongated neck of SRCL would 
project the cluster of CRDs into the vessel lumen, so that circulating neutrophils might be 
captured from beyond the reach of other receptors, from where there may be transferred 
to the selectins, perhaps with the aid of flexing at the hinge region of SRCL, to initiate 
extravasation. 
 
Prolectin in the migration of activated and effector B cells 
Prolectin was found to be expressed in dividing B cells in germinal centres, in non-
proliferating bone marrow cells with the appearance of plasma cells, and in migratory 
intermediates.  The migration of leukocytes is critical for both innate and adaptive immune 
responses, and protein-carbohydrate interactions may underlie multiple aspects of 
immune cell trafficking (Sperandio et al., 2009).  The best characterized examples are the 
roles of the selectins in mediating homing of recirculating lymphocytes to secondary 
lymphoid tissues, and extravasation of neutrophils, through binding to sialyl-Lewisx-
containing glycans (Jung and Ley, 1999; Sperandio et al., 2009).  In addition, the binding 
of CD22 on the surface of B cells to sialylated ligands found specifically on bone marrow 
sinusoidal endothelial cells has been suggested to mediate homing of recirculating B cells, 
and of plasma cells which differentiated outside of germinal centres, to this tissue 
(Nitschke et al., 1999).  In contrast, the interaction of the macrophage galactose lectin 
(MGL) on immature dendritic cells with α-GalNAc-containing glycans of lymph node 
sinusoidal endothelium causes retention of dendritic cells, such that only upon maturation, 
when MGL expression is lost, are the cells free to migrate (van Vliet et al., 2008).  The 
expression of prolectin at the surface of activated and effector B cells, through regulation 
of both gene expression and receptor trafficking, could mediate interaction with fucose-
containing glycan ligands on stromal or endothelial cells to effect B cell shuttling between 
zones of the germinal centre, homing of plasmablasts to the bone marrow, and retention 
of plasma cells within the bone marrow. 
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Prolectin, a previously undescribed glycan-binding receptor,
has been identified by re-screening of the human genome for
genes encoding proteins containing potential C-type carbohy-
drate-recognition domains. Glycan array analysis revealed that
the carbohydrate-recognition domain in the extracellular
domain of the receptor binds glycans with terminal -linked
mannose or fucose residues. Prolectin expressed in fibroblasts is
found at the cell surface, but unlikemany glycan-binding recep-
tors it does notmediate endocytosis of a neoglycoprotein ligand.
However, compared with other known glycan-binding recep-
tors, the receptor contains an unusually large intracellular
domain that consists of multiple sequence motifs, including
phosphorylated tyrosine residues, that allow it to interact with sig-
naling molecules such as Grb2. Immunohistochemistry has been
used to demonstrate that prolectin is expressed on a specialized
population of proliferating B cells in germinal centers. Thus, this
novel receptorhas thepotential to function in carbohydrate-medi-
ated communication between cells in the germinal center.
Membrane-bound mammalian glycan-binding receptors,
often referred to as lectins, are believed to playmultiple distinct
roles in the immune system, decoding information in complex
oligosaccharide structures on cell surfaces and soluble glyco-
proteins (1, 2). A host of glycan-binding receptors on dendritic
cells and macrophages function in pathogen recognition, often
resulting in uptake of microbes through endocytic mecha-
nisms. Examples include the mannose receptor, DC-SIGN,3
langerin, and themacrophage galactose receptor. Glycan-bind-
ing receptors can also recognize glycans found on the surfaces
of mammalian cells. Some of these receptors, such as the selec-
tins, mediate adhesion between leukocytes and endothelia (3,
4). A small number of receptors, notably members of the siglec
family, bind mammalian-type glycans and have been shown to
have potential signaling functions (5). While multiple glycan-
binding receptors have been described on cells of the myeloid
lineage, the complement of such receptors on lymphocytes is
muchmore restricted. The best characterized examples are the
T-cell adhesion molecule L-selectin (4) and the B-cell receptor
CD22, also designated siglec-2 (5).
Genomic screening for potential glycan-binding receptors
has usually been undertaken by initially searching for the pres-
ence of one of the several types of structural domains that are
known to support sugar-binding activity (6). Knowledge of the
structures of multiple families of modular carbohydrate-recog-
nition domains (CRDs) has facilitated identification of proteins
withpotential sugar-binding activity andcan lead topredictionsof
what types of ligands might be bound. Although the human
genome has been extensively screened with profile-recognition
algorithms that identify common sequencemotifs associatedwith
CRDs, refinements to the genome sequence and improvements in
gene-recognition algorithms occasionally result in detection of
novel proteins that contain putative CRDs.
We describe a previously undetected glycan-binding recep-
tor identified by re-screening of the human genome and pro-
vide characterization of its molecular and cellular properties.
Based on its expression in a specialized population of prolifer-
ating B cells in germinal centers, we propose that it be desig-
nated prolectin. Our results suggest that prolectin functions in
carbohydrate-mediated communication between cells in the
germinal center.
EXPERIMENTAL PROCEDURES
ProlectinCloning,Expression,andPurification—The full-length
cDNAwas amplified froma spleen cDNA library (Clontech) using
40 cycles of PCR with Advantage 2 polymerase mix from Takara
and forwardprimerCCCTGGCTGCCACTTGTCAGGTTCand
reverseprimerGGGCTTCAACAGGAACATTTCCGC(Invitro-
gen). The amplified cDNAwas isolated by gel electrophoresis and
cloned into vector pCRII-TOPO (Invitrogen).
The portion of the cDNA encoding the extracellular domain
of prolectin was inserted into the expression vector T5T and
expressed in Escherichia coli strain BL21(DE3) following the
procedure used for DC-SIGN (7). Inclusion bodies isolated by
sonication were dissolved in guanidine hydrochloride in the
presence of a small amount of 2-mercaptoethanol and rena-
tured by dilution into loading buffer (0.5 M NaCl, 25 mM Tris-
Cl, pH 7.8, 25 mM CaCl2) followed by extensive dialysis against
the same buffer. Protein from 6 liters of bacterial culture, in a
final volume of 500ml of loading buffer, was isolated on a 10-ml
column of mannose-Sepharose (8), which was washed with
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loading buffer and eluted with 2-ml fractions of eluting buffer
(0.5 M NaCl, 25 mM Tris-Cl, pH 7.8, 2.5 mM EDTA). Aliquots
(25 l) of fractions were examined by SDS-PAGE (9).
Sugar Binding and Glycan Array Analysis—For glycan array
analysis, modified primers were used to append a biotinylation
tag Gly-Leu-Asn-Asp-Ile-Phe-Glu-Ala-Gln-Lys-Ile-Glu-Trp-
His-Glu after the C-terminal cysteine residue of the CRD. The
modified cDNA was inserted into vector T5T, co-expressed
with plasmid birA, which encodes biotin ligase (Avidity), and
induced in the presence of biotin (10). The monomeric, biotin-
ylated protein, purified on a 10-ml column of mannose-Sepha-
rose as described above for the extracellular domain, was com-
plexed with Alexa-488-labeled streptavidin (Invitrogen) by
incubation overnight at a ratio of 2 mol of CRD to 1 mol of
streptavidin subunit. The complex was isolated on a 1-ml col-
umn of mannose-Sepharose, which was washed with loading
buffer and eluted with 0.5-ml aliquots of elution buffer. The
protein was tested against version 3.1 of the glycan array of the
Consortium for Functional Glycomics using the standard pro-
tocol. The extracellular domain of prolectin was used to coat
polystyrene wells, which were used for solid-phase binding
competition assays with 125I-Man-BSA (E-Y Laboratories) as
the reporter ligand (7). Oligosaccharide ligands were obtained
from Carbosynth Ltd.
Analysis in Transfected Fibroblasts—The full-length cDNA
was cloned into vector pVcos and used to transfect-cre pack-
aging cells (11). The resulting pseudoviruses were harvested
and used to infect Rat-6 fibroblasts, which were subjected to
selection in 400g/mlG418. Analysis of endocytic activity with
125I-Man-BSA was conducted as previously described (11).
Receptor was isolated from cells by solubilization in lysis buffer
(150 mMNaCl, 25 mM Tris-Cl, pH 7.8, 2 mM CaCl2) containing
1% Triton X-100 and protease and phosphatase inhibitors (Set
1 and Set 2 from Calbiochem). After brief sonication and incu-
bation for 30min on ice, debris was removed by centrifugation
for 15 min at 100,000 g, and the supernatant was applied to
a 1-ml column of mannose-Sepharose, which was washed
with lysis buffer containing 0.1% Triton X-100 and eluted in
0.5-ml fractions with elution buffer containing 0.1% Triton
X-100. Fractions were precipitated by addition of trichloro-
acetic acid to 10% for 10 min on ice, and precipitates were
centrifuged for 5 min at 18,000 g, washed twice with 0.5 ml
of ethanol:ether (1:1), and dissolved in sample buffer for gel
electrophoresis.
Rabbit polyclonal antibodies to prolectin were generated
using 1 mg of the bacterially expressed extracellular domain as
antigen following the speedy 28-day rabbit polyclonal antibody
program from Eurogentec. For affinity purification, an affinity
FIGURE 1. Prolectin gene structure and protein organization. A, scale diagram of the prolectin gene. For clarity, exons are shown expanded 3-fold relative
to introns. B, details of unusual GC splice site at the 5 end of the final intron. The predicted GT splice site in the Celera annotation of the genome, GenBankTM
accession EAW84437, leads to an insertion of 12 bases corresponding to insertion of 4 amino acids in the predicted protein sequence, but it leaves the reading
frame intact so that the conserved residues of the CRD are present. C, scale diagram showing the relative positions of glycan-binding receptors containing
C-type CRDs encoded on human chromosome 19. D, distribution of functional domains in prolectin. Predicted N-glycosylation sites are indicated with
hypothetical glycans in stick figures.
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column was constructed with bacterially expressed CRD
immobilized on Affi-Gel 10 (Bio-Rad Laboratories). Mono-
clonal antibodies to phosphotyrosine were obtained from
Amersham Biosciences (4G10) and BIOMOL International
(PY20), and polyclonal antibody to Grb2 was purchased from
Cell Signaling Technology. Alkaline phosphatase-conjugated
protein A (Calbiochem) and goat anti-mouse IgG (Jackson
ImmunoResearch), visualized with 5-bromo-4-chloro-3-indo-
lyl nitroblue tetrazolium phosphatase substrate (Calbiochem),
were used to counterstain blots.
Immunohistochemistry and Immunofluorescence—Formalin-
fixed, paraffin-embedded tissue array slides of human normal
organs were provided by SuperBioChips. The antibodies used
were: mouse anti-Ki67, clone MIB-1 (1:80 dilution), mouse anti-
CD68, clone KP1 (1:40), mouse anti-CD21 (1:33), and negative
controlmouse IgG1 (allDako); affinity-purified rabbit anti-prolec-
tin (10 g/ml); and negative control normal rabbit IgG (gift from
David Guiliano, Imperial College London). Slides were deparaf-
finized in xylene and rehydrated through a graded ethanol series.
Heat-mediated antigen retrieval was
performed using antigen unmasking
solution (Vector Laboratories),
except in the case of anti-CD21,
where retrieval was performed using
trypsin enzymatic antigen retrieval
solution (Abcam). Sections were
blocked with 10% normal goat serum
(Vector Laboratories), and incubated
for 90–120 min with primary anti-
body in 2% serum.
For immunofluorescence, sections
were incubated with Alexa Fluor 488
goat anti-rabbit IgG and Alexa Fluor
594 goat anti-mouse IgG (Invitrogen)
and mounted using Vectashield
mounting medium with 4,6-dia-
midino-2-phenylindole (Vector Lab-
oratories). For immunohistochemis-
try, sections were incubated with
biotinylated goat anti-rabbit IgG or
anti-mouse IgG (Vector Laborato-
ries), followed by quenching of
endogenous peroxidase by 15-min
incubation in 3% H2O2 in phos-
phate-buffered saline. Antigen was
visualized by the peroxidasemethod
using the Vectastain elite ABC and
DAB substrate kits, and counter-
stained with Vector Hematoxylin
QS (Vector Laboratories). Sections
were dehydrated, cleared, and
mounted with VectaMount perma-
nent mounting medium (Vector
Laboratories). Microscopy was per-
formed on a Nikon Eclipse E400
microscope equipped with a
DXM1200 digital camera. Images
were captured with Lucia GF soft-
ware, version 4.60, and were merged in Corel PhotoPaint 12.
RESULTS
The Prolectin Gene Encodes a Novel Receptor Containing a
C-type CRD—A previously undescribed C-type CRD was iden-
tified in an entry denoted FLJ45910 protein (GenBankTM acces-
sion EAW84437) in the human genome annotation submitted
by Celera Genomics. The domain contained key residues that
typically form a Ca2-dependent sugar-binding site in C-type
glycan-binding receptors (12). On further examination, the
genomic region encoding this predicted gene was found to cor-
respond in part to a gene recently given symbol CLEC17A
(GeneID 388512) by the HUGOGene Nomenclature Commit-
tee. The predicted protein from this interpretation of the
genome data (UniProtKB/Swiss-Prot accession number
Q6ZS10) lacks the C-terminal portion of the CRD.
Based on the predicted cDNA sequence from the Celera
annotation, primers were designed for PCR amplification of a
cDNAencoding the putative receptor, and receptormRNAwas
FIGURE 2. Characterization of the CRD in prolectin. A, sequence comparison between the CRDs of DC-SIGN
and prolectin, with cysteine residues highlighted in yellow, ligands for Ca2 1 and 2 highlighted in blue and
green, and other conserved residues shaded orange. Phe325 of DC-SIGN, which forms a critical part of the
secondary binding site, is highlighted in red. B, diagram of the proposed topology of the CRD from prolectin,
based on the structure of the CRD from DC-SIGN (Protein Data Base entry 1K9I). Conserved residues are high-
lighted in the same colors as inA.C, gel showingpurification of the extracellular domain of prolectin expressed
in E. coli. Aliquots of fractions eluted fromamannose-Sepharose affinity columnwithEDTAwere runon thegel,
which was stained with Coomassie Blue. D, examples of solid-phase binding competition assays using mono-
saccharides to inhibit binding of 125I-Man-BSA (radiolabeled, mannose-conjugated bovine serum albumin) to
the extracellular domain of prolectin immobilized in polystyrene wells.
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detected in libraries frommultiple tissues. After this cDNAwas
cloned, the sequence of an IMAGE clone (13) that has an
extended 5 region was deposited in GenBankTM (GenBankTM
accession number BC140848 for the cDNA, and UniProtKB/
Swiss-Prot accession number B2RTX0 for the deduced amino
acid sequence). Cloning with primers in this region confirmed
the presence of a longer transcript which matched exactly the
sequence of the IMAGE clone in the data base. A full-length
cDNA, including this region, was used as a basis for further
experiments.
Using the full-length cDNA as a guide, the complete prolec-
tin gene structure, shown in Fig. 1A, was deduced. Comparison
of the gene and cDNA sequences revealed that theremust be an
unusual GC splice donor site that is utilized instead of the
nearby canonical GT sequence used in the Celera annotation.
This splice results in a deletion of four amino acids in the actual
sequence compared with the predicted sequence (Fig. 1B). The
sequence flanking the GC splice donor site, AGGCAAGT,
exactly matches the ideal sequence for binding to the U2-type
spliceosome,which is believed to compensate for the absence of
the canonical GT donor site (14). The length of the introns near
the 3 and 5 ends of the gene, combinedwith the unusual splice
site, are probably responsible for the fact that the prolectin
cDNAwas not correctly identified by any of the gene prediction
algorithms.
The prolectin gene is located on the long arm of human chro-
mosome 19, which contains a cluster of genes for several other
receptors that utilize C-type CRDs, including the dendritic cell
receptor DC-SIGN (Fig. 1C). However, the new gene is located
roughly 7mega bases away from this gene cluster.
The complete prolectin cDNA sequence encodes a type II
transmembrane protein with an extended intracellular N-ter-
minal domain and a C-terminal extracellular C-type CRD (Fig.
1D). The cytoplasmic domain contains repeated motifs that
match patterns for binding to intracellular signalingmolecules.
There are at least three potential SH2-binding sites and eight
potential SH3-binding sequences (15). Such a large cytoplasmic
domain with so many potential interactions is unprecedented
for a member of the C-type lectin family. These results suggest
that the receptor has novel properties expected for a sugar-
binding receptor with signaling functions.
TheExtracellularDomain of Prolectin BindsTwoClasses of Cell
SurfaceGlycans—Basedonthepresenceofacharacteristicpattern
of amino acids forming the conservedCa2-binding site inC-type
CRDs suchasDC-SIGN, itwaspredicted that theprotein encoded
by this novel gene would bindmannose and related sugars (Fig. 2,
A and B) (12, 16). The extracellular domain was therefore pro-
duced in a bacterial expression sys-
tem and tested for binding to immo-
bilized mannose. The protein was
found to bind tightly to the resin and
was eluted with EDTA (Fig. 2C).
Binding was confirmed in a solid-
phase assay, in which receptor extra-
cellular domain immobilized in
polystyrene wells was probed with
iodinated, mannose-conjugated
serum albumin (125I-Man-BSA).
Competition with monosaccha-
rides revealed similar binding
affinities for mannose, fucose, and
N-acetylglucosamine, with much
weaker binding to galactose (Fig.
2D and Table 1).
FIGURE 3.Probing aglycan arraywith a tetrameric complex of Alexa 488-
labeled streptavidin with biotin-tagged CRD from prolectin. The protein
concentration was 0.45 mg/ml. Glycans that are bound by the probe are col-
ored based on the terminal residues present: red for fucose, green for man-
nose, and blue for N-acetylglucosamine. Structures of the ligands that give
the strongest signals are indicated using symbol nomenclature. A complete
list of all the glycans on the array is provided in supplemental Table S1.
FIGURE 4. Expression of prolectin in fibroblasts. A, immunofluorescence of transfectants and control cells
with anti-prolectin antibodies followed by Alexa 488-labeled secondary antibodies. Nuclei were stained with
4,6-diamidino-2-phenylindole. B, gel electrophoresis of intact prolectin isolated from transfected fibroblasts.
Aliquots of threepeak fractions frommannose-Sepharose affinity columnwere runongels in thepresence and
absence of reducing agent. Protein was detected by blotting the gel and probing with antibodies to prolectin
followed by alkaline phosphatase-labeled protein A.
TABLE 1
Summary of prolectin competition binding data
KI values are shown relative to the value for Me-Man run in parallel in each assay.
The average KI for Me-Man was 9.9 1.2 mM.
Ligand Relative KI
Me-Man 1.0
Me-Glc 3.2 0.1
Me-Gal 30
Man 1.2 0.1
GlcNAc 1.2 0.1
Fuc 1.1 0.1
Lea 0.22 0.01
Lex 0.72 0.08
Man9 0.064 0.04
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A more detailed analysis of sugar-binding specificity was
undertaken by probing a glycan array containingmore than 400
oligosaccharide ligands covalently immobilized on glass. CRD
expressed with a C-terminal biotinylation tag was bound to
fluorescently labeled streptavidin, providing a tetravalent com-
plex that was screened for binding to the array. The ligands
detected on the array fall largely into two groups, displaying
either terminal mannose or terminal fucose residues (Fig. 3).
Closer examination of the mannose-containing ligands indi-
cates that the strongest signals are obtained with structures
containing terminal Man1–2Man1–2Man sequences and
that the fucose-containing ligands include terminal Lewisa,
Lewisx, and Lewisy structures. Probing of the array at lower
FIGURE 5. Trafficking of prolectin expressed in fibroblasts. A, pH depend-
ence of ligand binding. Binding of 125I-Man-BSA to immobilized extracellular
domain of prolectinwas assayed at various pHs in the presence of 2mMCa2.
B, uptake and degradation of 125I-Man-BSA by fibroblasts expressing prolec-
tinorDC-SIGN.Degradationwasmeasuredas acid-soluble fragments appear-
ing in the medium.
FIGURE 6. Potential signaling interactions of prolectin. A, potential bind-
ing motifs for SH2 and SH3 domains in the cytoplasmic domain of prolectin.
B, prolectin phosphorylation. Aliquots of prolectin-containing fractions from
mannose-Sepharose columns of extracts from transfected fibroblasts were
separated on 17.5% SDS-polyacrylamide gels, which were blotted and
probed with antibody to the CRD of prolectin, two different anti-phosphoty-
rosine monoclonal antibodies (left, 4G10; right, PY20) and a control mouse
IgG2b antibody. C, cytoplasmic tail interactions. Aliquots of elution fractions
from mannose-Sepharose columns of extracts from fibroblasts transfected
with empty vector (N) andwith vector containing theprolectin cDNA (P) were
separated on 17.5% SDS-polyacrylamide gels, which were blotted and
probed with antibody to the CRD of prolectin, anti-phosphotyrosine (mono-
clonal antibody 4G10), and affinity-purified polyclonal antibody to Grb2.
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protein concentration resulted in reduction of all the signals,
indicating that no one of these categories of ligand binds with
dramatically higher affinity than others. The observed binding
to both high mannose and Lewis-type structures was also con-
firmed in competition assays (Table 1). These assays indicate
that the Lewisa trisaccharide is a better ligand for prolectin
than is Lewisx, suggesting that the apparent preference for
Lewisx-containing structures on the array is a result of the
Prolectin Ki67 CD21 CD68
Prolectin Rabbit IgG Ki67 CD21 CD68
Prolectin Ki67 Prolectin Ki67
Stomach Tonsil
Lymph Node
Tonsil
FIGURE 7. Immunohistochemical localization of prolectin. Germinal centers from multiple tissues were probed with polyclonal antibodies to prolectin,
control rabbit IgG, ormonoclonal antibodies specific for dividing cell nuclear antigenKi67, dendritic cellmarkerCD21, andmacrophagemarkerCD68.Antigens
were visualized with peroxidase immunochemistry. Scale bars, 100 m.
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disposition of these structures, often in multiple copies, on
larger oligosaccharides.
The profile of results is similar to that obtained for the den-
dritic cell receptor DC-SIGN, but there are significant differ-
ences between the preferred ligands for the two proteins (16).
Binding of oligosaccharides to C-type CRDs usually involves
docking of a monosaccharide into the primary binding site at a
conserved Ca2, with enhanced affinity for the oligosaccharide
resulting from secondary contacts between other sugars in the
oligosaccharide and residues nearby on the protein surface (12,
16). A phenylalanine residue in DC-SIGN that makes key con-
tacts with portions of high mannose oligosaccharides and a
valine residue that contributes to the specificity of DC-SIGN
for Lewisx and Lewisa structures are not conserved in prolectin,
suggesting that the secondary binding sites in the two receptors
must be different. This conclusion is consistent with the
observed differences in selectivity for different ligands within
broadly similar classes.
Prolectin Is Expressed at the Cell Surface—The properties of
prolectin were examined by stable expression of a full-length
cDNA in Rat-6 fibroblasts, cells that display no detectable sur-
face glycan-binding receptors but which have been shown to
support activity of multiple exogenous receptors containing
C-type CRDs (11, 16, 17). Immunofluorescence staining
revealed that prolectin appears on the cell surface of the trans-
fectants (Fig. 4A), and receptor isolated from the fibroblastswas
found to form disulfide-linked oligomers with molecular mass
in excess of 175 kDa (Fig. 4B). Based on the previously charac-
terized pattern of disulfide bonds within C-type CRDs (18, 19),
a single free cysteine residue would be present in the CRD (Fig.
2B). Interchain disulfide bonding of this cysteine could lead to
dimer formation, but the larger size of the oligomers observed
would require formation of additional interchain disulfide
bonds involving one of the cysteine residues in the transmem-
brane domain of the receptor. Dimerization of dimers brought
about in this way would lead to tetramer formation, which
would be consistent with the observed size of the disulfide-
linked oligomer observed on gels.
Oligomer formation is a common feature of glycan-binding
receptors and can be an important determinant of the way that
they interact with glycans on cell surfaces (12, 20, 21). Many
receptors form dimers, and DC-SIGN forms tetramers, but
they are noncovalent and the neck sequence that supports oli-
gomer formation in DC-SIGN is
unrelated to the sequence of the
neck in prolectin (22).
Because many oligomeric type II
receptors that contain C-type CRDs
mediate endocytosis (11, 16, 17), it
was of interest to see if prolectin
supports endocytic activity. The pH
profile of ligand binding in the solid-
phase assay showed that ligand
release occurred at low pH, but that
half-maximal release occurred at
pH 5.2 (Fig. 5A). This value is sub-
stantially lower than the typical
value for recycling endocytic recep-
tors such as DC-SIGN and the hepatic asialoglycoprotein
receptor (16, 23). When 125I-Man-BSA was incubated with the
transfected fibroblasts, no uptake and processing of ligand was
observed, providing a sharp contrast with DC-SIGN transfec-
tants assayed in parallel (Fig. 5B).
The Cytoplasmic Domain of Prolectin Communicates with
Signaling Molecules—Although prolectin does not support
endocytosis, examination of the cytoplasmic domain suggested
the alternative possibility that it has signaling capacity, because
of the presence of numerous sequences predicted to bind SH2
and SH3 domains (Fig. 6A). In the oligomeric protein, these
sequences would form large clusters of potential binding sites
for adapter molecules that could link the receptor to intracel-
lular signaling pathways. The SH2-binding sequences contain
tyrosine residues that would be expected to be targets for tyro-
sine kinases and antibody probing of blots of prolectin purified
from the fibroblasts confirmed the presence of phosphoty-
rosine (Fig. 6B).
The sequence context of the phosphorylated tyrosine resi-
dues suggests potential interactions with specific classes of
cytoplasmic signaling molecules (24). In particular, the ubiqui-
tous adapter protein Grb2 contains an SH2 domain that binds
the target sequence YXNX (25). Interestingly, Grb2 also con-
tains class I SH3 domains that interact with the target SH3-
binding motifs identified in prolectin. Consistent with these
predictions, antibody blotting of the receptor-containing frac-
tions from the mannose-Sepharose affinity column demon-
strated that Grb2 co-purifies with prolectin (Fig. 6C), confirm-
ing that prolectin interacts with intracellular signaling
machinery either directly or indirectly.
Prolectin Is Expressed onDividingBCells ofGerminalCenters—
Immunohistochemistry using the affinity-purified polyclonal
rabbit antibodies was used to screen an array of human tissues
to define sites of expression. The results revealed a very
restricted pattern of staining, with the major site of expression
being germinal centers in various tissues, including lymph
nodes, tonsils, stomach, intestine, appendix, and spleen (Fig. 7).
Antibodies selective for follicular dendritic cells or tingible
body macrophages found in the light zone of the germinal cen-
ters do not co-localizewith prolectin. Thus, unlike otherC-type
lectins such as DC-SIGN and the mannose receptor, prolectin
is not found on dendritic cells or macrophages. In contrast,
Ki67 antigen found in nuclei of dividing B cells shows extensive
FIGURE 8. Comparison of prolectin and Ki67 antigen distribution. Germinal centers were stained with
antibody to prolectin and counterstained with Alexa 488 secondary antibody (green). In the three images on
the right, sectionswere also stainedwithKi67 antibody and counterstainedwithAlexa 594 secondary antibody
(red). Scale bar, 100 m.
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overlap with the prolectin staining, suggesting a novel localiza-
tion of this receptor in B cells.
Co-localization of prolectin with the dividing B cell marker
Ki67 was confirmed using immunofluorescence (Fig. 8). In ger-
minal centers from multiple tissues, essentially all prolectin-
expressing cells are also Ki67-positive. Based on their location
and reaction with the anti-Ki67 antibody, the clustered, doubly
stained cells in the dark zone appear to be centroblasts. Prolec-
tin expression thus defines a sub-population of dividing B cells
of the dark zone. In the surrounding mantle zone, the occa-
sional Ki67-positive cells have a similar morphology to the pro-
lectin-positive cells in the dark zone and all of these cells co-
express prolectin.
DISCUSSION
Although prolectin has some similarity to other glycan-binding
receptors containing C-type CRDs, it has several properties that
distinguish it from other known members of this group. Impor-
tantly, the fact that prolectin does not display endocytic activity is
consistent with its expression in B cells rather than macrophages
or dendritic cells. This pattern of expression and lack of endocytic
activitymakes it unlikely that prolectin functions as a primary rec-
ognition receptor in the innate immune response, a role that is
commonly ascribed toDC-SIGN, langerin, themannose receptor,
and other receptors that contain C-type CRDs (1, 26–28). Simi-
larly, in contrast to the selectin cell adhesion molecules, prolectin
bearsmultiple signalingmotifs in the cytoplasmic domain, so that
it can interact directly with signaling pathways within lympho-
cytes, although it may also have a role in cell adhesion. Thus, pro-
lectin does not readily fall into any of the previously described
categories ofC-type lectins, and it does not have anyobvious para-
logs in mammalian genomes.
Despite these differences, the glycan array results suggest
that that there is likely to be overlap in potential ligands for
prolectin and DC-SIGN, because both receptors display a dual
specificity for mannose- and fucose-terminated glycans. Com-
mon types of ligands would include surface glycans on other
cells bearing Lewisa, Lewisx, and Lewisy epitopes (16, 29). It has
been proposed that these structures are presented to DC-SIGN
on intercellular adhesionmolecule 3 (ICAM-3) on T cells, lead-
ing to adhesion between the T cells and dendritic cells (30). By
analogy, one function of prolectin may be to participate in
interaction of the B cells on which it is expressed with T cells or
other cells in the germinal center.However, the potential ability
of prolectin to initiate signaling in response to a glycan ligand
indicates that it probably has additional roles in communica-
tion between B cells and other cells in germinal centers.
The pattern of expression of prolectin within the germinal cen-
ters may provide some additional clues about its potential func-
tions. Following somatic mutation of antibody genes in centro-
blasts of the dark zone, centrocytes are known to migrate to the
light zone where selection of cells with enhanced affinity for anti-
gen occurs and cells with dysfunctional immunoglobulin genes
undergo apoptosis (31). The disposition of clusters containing
many of the prolectin-positive cells near the edge of the dark zone,
and the presence of individual cells in the adjacent regions of the
mantle zone suggests that cells expressing prolectin might be in
transit intooroutof thegerminal center and that the receptormay
play a role inmigration of cells between these compartments dur-
ing antibody affinity maturation.
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